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INTRODUCTION 
Congenital diseases 
4 - 6% of the liveborns are affected with some form of congenital disease 
(Warkany, 1971; Trimble & Doughty, 1974). Accordingly, in The Netherlands 
each year 8000- 12.000 children are born with a more or less severe handi-
cap. In some cases morphological and/or functional abnormalities are apparent 
shortly after birth, as is the case in anencephaly, meningomyelocele, conge-
nital heart defects, several chromosomal aberrations and inborn errors of meta-
bolism. In other congenital diseases the onset of clinical manifestations occurs 
in early or late childhood and some sex-chromosomal aberrations will not be 
detected before puberty. 
Finally, a number of these diseases is not manifest before adulthood, like 
Huntington 1s chorea and a number of variants of inherited metabolic disorders. 
The three main categories of congenital diseases are: 
1. Chromosomal aberrations, with an incidence of 1 · 200 !iveborns (Jacobs 
et al., 1974); about 1000 patients per year in The Netherlands. 
2. Gene mutations, resulting in metabolic diseases, incidence 1 : 100 live-
barns and accordingly 2000 patients per year. 
3. Disturbances during embryonic development, 2 - 4 100 liveborns, and 
4000 - 8000 patients per year. 
Most numerical chromosomal aberrations are caused by nondisjunctions during 
gametogenesis or during the first divisions of the fertilized ovum. The most 
frequent examples are trisomy 21 (Down's syndrome), Klinefelter's syndrome 
(47 XXY), Turner's syndrome (45 XO) and 47 XYY. In some of these syn-
dromes the risk of non-disiunction increases with maternal age, as in trisomy 
21. This has an incidence of 1 : 3000 newborns from mothers younger than 30 
years; the incidence rises to 1 : 280 in mothers of 35-39 years and to 1 : 40 in 
mothers older than 45 years. A minority of chromosomal disorders is caused by 
structural abnormalities of the chromosomes, like translocations, inversions, 
etc. Part of these are inherited from one of the parents, who is a phenotypic-
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ally normal carrier of the balanced form of the rearrangement. The risk for 
affected offspring in carriers of balanced translocations is dependent on the 
type of translocation and the sex of the carrier-parent and may vary from 10-
100%. 
In McKusick 1s catalogue (1971) nearly 2000 different gene mutations of Men-
delian inheritance are listed. Many of these result in metabolic disorders, 
but only in 10% of these the exact nature of the biochemical defect has been 
characterised (Stanbury et al. 1 1972). In about 50 severe inborn errors of me-
tabolism the enzymatic defect or the storage of a specific metabolite can be 
demonstrated in in vitro cultured skin fibroblasts from the patient (for reviews: 
see Milunsky et al., 1970; Milunsky and Littlefield, 1972). If the genetic 
trait shows recessive inheritance 1 both parents are heterozygous carriers and 
asymptomatic; the (recurrence) risk for an affected child is 25%. A son of a 
mother, who is heterozygous for an X-linked disease 1 has a chance of 50% to 
be affected. Most of these genetic metabolic diseases are relatively infrequent 
(varying from about 1 : 1500 to 1 : 100.000), but as a total group they are 
twice as frequent as chromosomal aberrations. 
The major category of congenital diseases are the disturbances in embryonic 
development which may be the result of environmental and/or genetic factors. 
The most common types are congenital heart defects (=!::_ l : 100 live barns), 
neural tube defects ~ 1 : 500) 1 cleft lip and/or palate 1 club foot and seve-
ral hundred other congenital deformities. The risk for such an anomaly in-
creases in some types after the birth of an affected child; in other types this 
is possibly not the case. 
The knowledge about the etiology is very incomplete in most cases of conge-
nital disease. As a result causal prevention is nearly impossible, except for 
the avoidance of well-known teratogenic factors like ionizing radiation 1 cer-
tain viral infections and certain toxic drugs. Therapeutic methods are not a-
vailable for chromosomal aberrations and most of the inherited metabolic di-
10 
::;eases. Improved surgical techniques contributed to the management of many 
congenital malformations like cleft lip and palate, cardiac malformations, 
skeletal deformities, etc. 
Genetic counseling and prenatal diagnosis of congenital diseases 
Many of the congenital diseases from the three categories are associated with 
severe physical and/or mental abnormalities and most patients require intensive 
medical and psychosocial care, often during several decades. Besides the pro-
blems caused by a handicapped life, parents - and sometimes patients - are 
confronted with the fear of recurrence of the disease in their future offspring. 
The organization of genetic advice required in these situations received in-
creasing attention during the last decade. An increasing number of couples, 
having a (distant) relative affected with some type of congenital disease, also 
ask for such an advice about their own risks and the methods for prevention. 
Genetic counseling will primarily be based upon the availability of a precise 
diagnosis and on information about the mode of inheritance of the disease in-
volved. The physician giving genetic counseling should have sufficient know-
ledge of the principles of genetics, embryonic development, recent diagnostic 
methods for congenital diseases and of therapeutic and preventive means. He 
needs time to explain the risks (which may vary from negligeable to 100%) 
and to help the counselees to reach a decision which is appropiate in their 
individual situation. These decisions are often very difficult1 since they may 
involve the acceptance of a high risk of another affected child or the deci-
sion to refrain from reproduction .. In other cases artificial insemination, adop-
tion, or abortion may be considered. 
The interpretation of the risk-figures and the decision reached by the coun-
selees will be determined by many factors, like the composition of their fa-
mily, their age, the severity of the disease involved, their psychological 
tolerance and the opinions and attitudes in the society. 
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The development of methods enabling prenatal diagnosis of a number of con-
genital diseases offers new perspectives to many couples at risk. The first re-
ports of succesfull analyses of the fetal karyotype in cultured amniotic fluid 
cells were published nearly 10 years ago (Steele & Breg, 1966; Jacobson & 
Barter, 1967). The first genetic metabolic disorders were detected soon after-
wards by biochemical assays of amniotic fluid supernatant and cultured amnio-
tic fluid cells (Nadler, 1968; Fupmoto et al., 1968). During the last five 
years more and more experience has been gained with transabdominal amnio-
centesis in the 14th - 16th week of pregnancy, the subseguent in vitro culti-
vation of fetal cells from the amniotic fluid and the karyotyping and biochemi-
cal analysis of these cells.An increasing number of parents at risk for a chromoso-
mal aberration or a genetic metabolic disorder asked for prenatal diagnosis and 
several centers described the results on their first series of hundreds of cases 
(Nadler, 1972; Milunsky & Atkins, 1974; Philip et al., 1974; Hsu & Hirsch-
horn, 1974i Golbus et al., 1974i Wahlstrtsm et al., l974i Niermeijer et al. 
1975). It appears, that amniocentesis in early pregnancy is a relatively safe 
procedure and that ~he analytical results are very reliable. 
It may be of great advantage for parents at risk to have certainty about the 
status of the fetus. Prenatal diagnosis will show in many cases that the fetus 
is not affected by the disease tested for and the parents can be reassured. On 
the detection of a fetal abnormality the parents may ask for interruption of 
the pregnancy, thus preventing the birth of a severely affected child. 
The possibilities for prenatal detection were recently extended by the finding 
of Brock & Sutcliffe (1972) that closure defects of the neural tube (anencepha-
ly and meningomyeloc~le) are detectable in early pregnancy by elevated con-
centrations of alpha-fetoprotein in the amniotic fluid supernatant. 
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INDICATIONS FOR PRENATAL DIAGNOSIS 
The main indications for prenatal diagnosis used at the moment are: 
- mothers aged 38 years or over. 
- mothers who previously gave birth to a child with a chromosomal aberration. 
- pregnancies, where on of the parents is a balanced carrier of a chromosomal 
rearrangement (translocation, inversion). 
- pregnancies at risk for one of those 50 inborn errors of metabolism, that can 
be detected in cultured amniotic fluid cells. 
- pregnancies at risk for an open neural tube defect. 
The indications will be briefly discussed below. 
1. RISK FOR A NUMERICAL CHROMOSOMAL ABERRATION 
The most frequent examples are the recurrence risk of trisomy 21 (Down 1s syn-
drome) and the risk for chromosomal aneuploidies at advanced maternal age 
(38 years and older). 
The recurrence risk for trisomy 21 is l o/o as calculated either from retrospective 
data (Pfeiffer et al., 1973) or from prospective series of prenatal diagnoses for 
this indication (Milunsky, 1973). The recurrence risk of other numerical aberra-
tions is less well known. This is related to the question of the presence in man of a 
familia~ tendency to non-disiunction. Two types of evidence for this phenomenon 
are present: 
a. A number of sibships have been described with aneuploidies for different chro-
mosomes (Girardet et al., 1972; Bell & Cripps, 1974; Holmgren & t!.nsehn, 1971; 
Hamer ton, 1971). 
b. Chromosomal studies on subsequent spontaneous abortions in the same family in-
dicate that if the first abortion showed a chromosomal aberration, the following 
was likely to be caused by a chromosomal aberration, not necessarily being of 
the same type (Boue & Boue, 1973). 
These factors are to be considered when giving recurrence risks for a trisomy others 
than trisomy 21. Bell & Cripps (1974) advise prenatal monitoring in 
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every pregnancy in families where a child with an aneuploidy has been born. 
Chromosomal mosaicism in one of the parents might give a considerably higher 
risk for recurrence of the same aneuploidy than in the previous group and se-
veral of these families were described (Beratis et al. 1972; Hsu et al., 1971). 
The recurrence risk of chromosomal mosaicism is probably in the order of 1% 
but cases of familial mosaicism were described, where higher risk figures are 
involved (Hsu eta!. 1970; Shih et al., 1974). 
Down•s syndrome is not the only trisomy with an increased frequency at ad-
vanced maternal age; other autosomal trisomies tend to be more common as 
well. However, these will be found relatively rarely since there is a high 
a 
early abortion rate in these cases (Laurence et al., 1974 ). The risks for a 
chromosomal aberration in the maternal age-groups of 35-39 years and over 
40 years were found to be 1.5% and 3o/o, respectively in a collected series 
of prenatal diagnoses (Hsu & Hirschhorn, 1974). 
2. RISK FOR A STRUCTURAL CHROMOSOMAL ABNORMALITY 
The risk for the carrier of a balanced chromosomal translocation for offspring 
with an unbalanced karyotype depends on the type of translocation and the 
sex of the carrier-parent. Hsu & Hirschhorn (1974) find a risk of 20% in 93 
pregnancies monitored for this indication. Individuals carrying inversions in 
one of their chromosomes are also at an elevated risk for children with un-
balanced karyotypes. In each patient with clinical symptoms suggestive for a 
chromosomal aberration karyotyping should be carried out to establish the 
exact nature of the aberration and its mode of inheritance. The birth of a 
child with an unbalanced karyotype may be prevented in time by family stu-
dies, identification of carriers, followed by genetic counseling and prenatal 
diagnosis. The birth of affected children in families of (distant) relatives and 
a high frequency of spontaneous abortions may be the indicators for the pre-
sence of such an inherited chromosomal translocation. 
14 
The recurrence risk of a de novo translocation is probably very small (Gard-
ner & Veale, 1974) and at the moment this seems no indication for amniocen-
tesis. 
3. RISK FOR AN X-LINKED DISEASE 
When the mother is a carrier of an X-linked disease, there is a 50% chance 
for her son to be affected. Prenatal sex determination by chromosome analysis 
may help these parents to limit their families to unaffected daughters (who 
will be carriers in 50% of the cases). The limitations of this approach are ob-
vious, but it is the only possibility for these parents to have their own child-
ren, without being forced to accept a high risk for a severely affected child. 
This approach applies to those X-I inked disorders where the basic defect is un-
known. (e.g. Duchenne•s muscular dystrophy, X-linked mental retardation, 
etc.) or is not yet detectable in amniotic fluid or cultured amniotic fluid 
cells (e.g. hemophilia). In a few X-linked diseases the biochemical defect is 
expressed in cultured amniotic fluid cells and this allows prenatal identifica-
tion of an affected male fetus {Fabry's disease; Hunter•s disease; the Lesch-
Nyhan syndrome; for references: see Burton et al., 1974). 
4. RISK FOR A METABOLIC DISEASE 
About 50 severe recessive autosomal or X-linked diseases can now be detected 
in utero by biochemical assays of cultured amniotic fluid cells (for reviews, 
see: Milunsky et al., 1970; Milunsky & Littlefield, 1972; Burton et al., 1974). 
In autosomal recessive diseases the diagnosis of a first affected child usually 
is the first indication that both parents are carriers of the same gene mutation. 
The recurrence risk is 25%. Prenatal diagnosis in future pregnancies of these 
parents will only be reliable if cultured cells of the affected child are a-
vailable. The prenatal diagnosis will be based on a comparison of the bio-
chemical assays on amniotic fluid cells from the pregnancy at risk, control 
cells from a normal pregnancy cultured under identical conditions and fibro-
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blasts from the patient with the metabolic defect. 
The birth of a first affected child can be prevented only in those circumstan-
ces where the carriership of the parents has been identified before their first 
pregnancy. This is sometimes possible in X-linked diseasesi for autosomal dis-
orders this is generally not the case. Large-scale carrier testing for these di-
seases will only be useful in populations with a high frequency for certain 
gene mutations. The only example of such a program is the carrier-testing for 
Tay-Sachs 1 disease in certain Ashkenazi-Jew population groups in the United 
States, where prenatal diagnosis can be offered to couples identified as hete-
rozygotes (Kaback et al., 1974). 
5. RISK FOR AN OPEN NEURAL TUBE DEFECT 
Open defects of the neural tube (anencephaly and meningomyelocele) are re-
latively frequent congenital malformations of multifactorial origin. The recur-
rence risk after one affected child is about 5% and after two affected child-
ren it increases to~ 10% (Bonaiti-Pellie & Smith, 1974). The malformation 
in the subsequent child may be either identical or of a different type. An 
affected parent has a 3 - 4% risk for an affected child (Carter, 1974). 
Prenatal detection of open neural tube defects is possible by analysis of the 
concentration of alpha-fetoprotein in the amniotic fluid (Brock & Sutcliffe, 
1972i Allan et al.., 1973)i closed defects, some of which may have milder 
clinical manifestations, cannot be detected with this method (Laurence et al., 
1973) and the parents should be informed accordingly. 
This recent development will be a quite common indication for prenatal moni-
toring, and in most cases this will be for parents with an affected child. 
Elevated levels of amniotic fluid alpha-fetoprotein can in some cases also be 
detected in maternal serum (Brocket al., 1973). In a number of studies the 
value of this maternal indicator for fetal neural tube defects was explored 
(Harris et al., 1974; Seller et al., 1974; Wald et al., 1974). The possibili-
ties for lar.ge-scale screening so far ore not very promising. 
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Future developments in prenatal diagnosis 
The actual techniques of prenatal diagnosis by amniocentesis and analysis of 
amniotic fluid and cultured amniotic fluid cells seem to be preferable over 
proposed other approaches to fetal specimens for diagnosis. Recently, the use 
of placental biopsies (Kullander & Sandahl, 1973; Ogita et al., 1974) was 
advocated as a source for material for prenatal cytogenetic diagnosis. Valenti 
(1973) proposed intrauterine blood sampling by puncture of fetal blood vessels 
with an endamnioscope, which could enable intrauterine detection of hemoglo-
binopathies. 
Preliminary results of techniques for fetal observation and biopsy through am-
nioscopes (Scrimgeour, 1974i Wheeless, 1974i Levine et al., 1974i Laurence 
et al., 1974b) warrant the conclusion, that as yet this procedure is too 
dangerous for clinical application. 
Safe techniques for fetal observation and blood sampling might be a signifi-
cant contribution to prenatal detection of some congenital malformations, fetal 
hemoglobinopathies and possibly in the future hemophilia, when analytical me-
thods are available. Methods for the detection of hemoglobinopathies in small 
samples of blood have been described (Cividalli et al., 1974; Chang et al., 
1974; Hobbins et al., 1974). Attempts are being made to detect HbS on indi-
vidual erythrocytes occuring in the amnioting fluid (Boyer et al., 1974; Hea-
dings et al., 1974). In contrast to earlier reports (Fortune & Fox, 1973), the 
activity of factor VIII is present in fetal blood in early pregnancy and if ap-
propiate sampling techniques become available, prenatal diagnosis of hemophi-
lia could become possible (Holmberg et al., 1974). 
The extension of possibilities for prenatal diagnosis in the near future will be 
mainly dependent on the further clarification of biochemical defects in gene-
tic diseases. The recent finding of adenosine deaminase deficiency in cultured 
amniotic fluid cells from a fetus, postnatally shown to be affected with severe 
combined immonodeficiency disease (Hirschhorn et al., 1975) is an example of 
this rapidly expanding field. 
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Another important contribution would be the development of methods for the 
induction of the expression of genes normally not expressed in cultured cells. 
The present state of prenatal diagnosis leaves much to be done. Although ma-
ny papers appeared about this method, still too many people involved in me-
dical care are unaware of its possibilities. Information about prenatal diagno-
sis, as well as on principles of genetics, recurrence risks and on modern me-
thods for the diagnosis of chromosomal disorders and inborn errors of metabo-
lism, should be incorporated into (postgraduate) medical education. 
At this moment, genetic counseling is the most effective way for prevention 
of congenital diseases •. For those parents at risk for a chromosomal aberration, 
one of some fifty metabolic diseases, a severe X-linked disease or 
a neural tube defect, prenatal monitoring may be of great help in the diffi-
cult choice between the acceptance of a (high) risk for an affected child or 
the impossibility of having their own healthy children. The discrepancy be-
tween the number of prenatal analyses made and the number of pregnancies 
that are at risk according to the present categories of indications shows that 
much improvement is possible in diagnosis and genetic counseling of conge-
nital diseases. 
The decisions by parents or patients at risk for affected offspring should not be 
influenced by fears for future generations. Several population geneticists (Mo-
tulsky et al., 1971; Fraser, 1972; Fraser and Mayo, 1974) calculated that 
even extensive use of prenatal diagnosis and selective abortion only have a 
minor effect on the gene frequencies of autosomal recessive diseases. For X-
linked recessive diseases there may be an increase of female heterozygotes but 
not of an extend to cause any concern. 
Prenatal diagnosis may therefore be considered as a useful means to prevent 
the birth of affected children in individual families and in this way if offers 
the possibility for parents at risk to extend their families with unaffected 
children. 
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INTRODUCTION TO THE PAPERS 
This thesis deals with several methodological and practical aspects of prenatal 
diagnosis. 
A genetic metabolic disease can only be detected in utero if the enzymatic 
defect or storage of a specific metabolite is expressed in cultured cells from 
an affected individual. This should be demonstrated for each separate disease. 
An' example of such a study is presented in appendix paper I. The data in-
dicate, that the enzymatic defect in the haemolytic anaemia caused by pyru-
vate kinase deficiency (an autosomal recessive disease) is not detectable in 
fibroblasts and cultured amniotic fluid cells, since these only produce the 
M-type of this enzyme, whereas the anaemia is related to a deficient activi-
ty of the L-type. As a consequence, prenatal diagnosis of this disease is not 
possible. 
The prenatal diagnosis of enzymatic defects requires analysis of a sufficient 
number of amniotic fluid cell cultures cultivated under identical conditions 
and for a comparable period as the diagnostic sample. Sufficient amniotic 
fluid samples from normal pregnancies will generally not be available at the 
very moment these are required. To solve this problem a method was develop-
ped to store uncultured amniotic fluid cells without loss of cell viability. This 
method is described in appendix paper ,II and has enabled us to collect suffi-
cient control material for later use in prenatal diagnosis of enzymatic defects. 
The possible detrimental effects of transport periods of up to a few days on 
the viability of amniotic fluid cells was tested simultaneously and the results 
indicate that transport during periods of up to seven days did not interfere 
with succesfull cell cultivation. This means that prenatal diagnosis can be 
offered to people living at long distances from the center performing the ana-
lysis. 
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The prenatal diagnosis of metabolic disorders usually required the biochemical a-
nalysis of a few million cells and accordingly the time to obtain these cells during 
cultivation varied from 4- 8 weeks after amniocentesis. Such a long waiting pe-
riod is a serious psychological disadvantage and also interruption of the pregnancy 
should for medical and ethical reasons- when needed- be carried out as early as 
possible. This problem was experienced in a number of groups (Littlefield, 1971; 
Galjaard et al., 1972; Milunsky et al., 1972; Epstein et al., 1972; Golbus et 
al., 1974). To reduce this waiting period the sensitivity of the analytical 
techniques had to be increased to enable the investigation of small numbers 
of cultured amniotic fluid cells. Our group has developped such methods for 
the microchemical analysis of several enzymes involved in genetic diseases 
(Galjaard, 1972; Galjaard et al., 1974°; 1974~. The methodology for one 
of these enzymes (acid a-1 ,4-glucosidase, deficient in Pompe's disease) is 
described in appendix paper Ill. Mi cromethods for incubation of small numbers 
of ce lis and small volumes of reagents were tested as well as different substra-
tes either for spectrophotometric or fluorometric assays. Significant reductions 
in the number of cultured cells required for a diagnosis could be achieved by 
using microvolumes of the substrate 4-Methylumbelliferyl a-D-glucopyranoside. 
Analysis could be performed on homogenates containing the equivalent of 
about 1000 cultured amniotic fluid cells for each incubation; the total cell 
number for a prenatal diagnosis, including a protein assay, could be estimated 
as the equivalent of 4000 homogenised cultured cells. A further reduction 
could be realised by adaptation of preparation techniques developed for tissue 
sections by Lowry (Lowry, 1953; Lowry & Possoneau, 1972). Small groups 
(about 100) of freeze dried amniotic fluid cells are dissected under microsco-
pic control from a culture grown on a thin transparent plastic foil. 
The increasing use of cultured cells for diagnostic and genetic studies on 
human metabolic diseases warrants the study of a number of factors influencing 
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the expression of enzymatic activities in in vitro cultivated cells. Appendix 
paper IV reports a number of such studies on the causes of variation of lyso-
somal enzymatic activities. Wide variations in the activities of acid a-1,4-
glucosidase in fibroblasts and cultured amniotic fluid cells from controls and 
heterozygotes for type II glycogenesis were observed. Part of these were cau-
sed by differences in cultivation conditions. It became apparent, that for a 
number of lysosomal hydrolases a proportional relation exists between the du-
ration of the culture phase (passage) and the enzymatic specific activity. Va-
riations of a-1,4-glucosidase residual activities observed in fibroblasts from 
different patients with Pompe•s disease might be related to a genetic hetero-
geneity, i.e. different mutant genes causeating identical diseases. Levels of 
acid a-1,4-glucosidase in primary and later subcultures of control amniotic 
fluid cell cultures show considerable variations and this should be considered 
in comparative studies in actual prenatal diagnosis. Microassays of enzymatic 
activity in small cell numbers from the same culture show considerable vari-
ation of activities among individual cells and these might be caused by locqt 
differences in in vitro cell proliferation or differences in the cell cycle. 
Studies on genetic heterogeneity are possible by fusing (appendix paper IV) 
cellstrains from patients with apparently identical metabolic diseases and stu-
dying the occurrence of complementation, i.e. the restoration of enzymatic 
activity in hybrid cells. If the latter phenomenon occurs, this is an indication 
that the disease is caused by different gene mutations in the two patients. 
p-Galactosidase assays in individual binuclear hybrid cells were carried out 
to study the genetic background of different clinical variants of GM1-ganglio-
sidosis. 
In appendix paper V the practical application is described of microchemical 
enzymatic analysis in 6 pregnancies at risk for Pompe's disease. Another 
example of application in prenatal diagnosis is described in appendix paper 
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~in a pregnancy at risk for X-linked Fabry's disease. Microchemical analy-
sis showed normal a-galactosidase activities in groups of l 00-200 freeze-dried 
cultured amniotic fluid cells and this enabled a diagnosis 11 days after amnio-
centesis. At the same time fetal karyotyping of a replicate culture indicated 
the presence of a male fetus. The enzyme analysis was confirmed by a study 
on homogenates of larger numbers of cui tured cells from the same pregnancy 
in two independent laboratories. This is an example of a prenatal diagnosis 
for a metabolic disease completed in a period comparable (or even shorter) to 
that for prenatal chromosome analysis. 
Results of prenatal diagnoses in pregnancies at risk for different lysosomal 
storage diseases, including metachromatic leukodystrophy and Hunter's disease, 
are presented in appendix paper VII. Arylsulfatase A assays on homogenates 
of cultured amniotic fluid cells were completed in 16 and 18 days after am-
niocentesis, respectively. Studies of 35so 4 incorporation and release in cells 
from 2 pregnancies at risk for Hunter's disease {mucopolysaccharidosis type II) 
were combined with cytogenetic analysis and could be completed within 4 
weeks after amniocentesis. 
A survey of prenatal monitoring of 350 pregnancies at risk for a chromosomal 
aberration, a sex-linked disease, a metabolic defect or a neural tube defect 
is presented in appendix paper VIII. The clinical and laboratory methods used 
are described. Amniocentesis was found to be a safe procedure both for the 
mother and the fetus. Prenatal chromosome analysis has now become a routine 
method and the use of banding techniques is essential for karyotyping. 
Four chromosomal non-disjunctions were found in 87 pregnancies tested because 
of advanced maternal age. In 101 pregnancies with a recurrence risk of 
Down's syndrome, 2 fetuses with an abnormal karyotype were detected. In 11 
cases, in which one parent was a carrier of a balanced translocation, 2 un-
22 
balanced fetal karyotypes were found. 
Fetal chromosome studies in 43 pregnancies at risk for an X-linked disease 
indicated the presence of a male fetus in 21 cases. 
47 Analyses of alpha-fetoprotein in amniotic fluid from pregnancies at risk for 
a neural tube defect indicated the presence of 3 affected fetuses in the se-
cond half of pregnancy; these last fetuses were found to be anencephalic on ultra-
sound. In 34 pregnancies prenatal monitoring was carried out for 11 different me-
tabolic diseaSes and 3 affected fetuses were detected. This type of investigation 
requires specific experience in the microchemical analysis of cultured amnio-
tic fluid cells. As most of these diseases are infrequent, cooperation between 
different European centers to this purpose is needed; in the present study 40% 
of the samples for metabolic d-iseases was referred by different European cen-
ters. 
The detection of a fetal abnormality or a male sex (in cases of X-linked dis-
orders) was the indication for selective abortion in 36 of 350 pregnancies tes-
ted. However, in 909'o of the pregnancies the result of prenatal testing ex-
cluded that the fetus was affected by the disease involved and as a result 
these pregnancies could be continued without further anxiety for the parents. 
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SUMMARY 
Prenatal diagnosis of a number of congenital diseases is possible by amniocen-
tesis in the 14th - 16th week of pregnancy and subsequent analysis of cultured 
amniotic fluid cells or amniotic fluid supernatant. Parents at risk for a child 
with a chromosomal disorder, an X-linked disease, a neural tube defect or a 
metabolic disease may use this new tool in genetic counseling to limit their 
further offspring to unaffected children by requesting termination of a pregnan-
cy when a fetal abnormality has been detected. 
The present thesis describes methodological studies in the field of prenatal di-
agnosis of metabolic diseases and clinical applications of prenatal monitoring 
in a series of 350 pregnancies with an elevated risk for a chromosomal aber-
ration, an X-linked disease, a metabolic genetic disorder or a neural tube 
defect. 
One prerequisite for the prenatal diagnosis of a genetic metabolic disease is, 
that the enzymatic defect or metabolite specific for this disorder is detectable 
in cultured cells from an affected individual, since cultured (amniotic fluid) 
cells will be used in prenatal monitoring. This should be demonstrated for each 
separate disease. An example of such a study is presented in appendix paper I. 
The data indicate, that the enzymatic defect in the haemolytic anaemia caused 
by pyruvate kinase deficiency (an autosomal recessive disease) is not detecta-
ble in fibroblasts and cultured amniotic fluid cells, since these only produce 
the M-type of this enzyme, whereas the anemia is caused by a deficient ac-
tivity of the L-type. 
The availability of control amniotic fluid- cell samples is important whenever 
a prenatal diagnosis of a metabolic disorder in cultured amniotic fluid cells 
is to be made: enzymatic data from the case at risk must be compared with those 
from amniotic fluid cells grown under identical conditions and for the same period 
of time. A method enabling the storage of control amniotic fluid cells with main-
tenance of cell viability is described in appendix paper II. Concurrently, a delay 
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of several days between amniocentesis and starting the cell culture of amnio-
tic fluid samples showed to be not deleterious to the subsequent culturing of 
the cells. This makes prenatal diagnosis available to parents living at long 
distances from centers, where the analysis is carried out. 
The detection of biochemical defects (enzyme activities or metabolites) in cul-
tured amniotic fluid cells required relatively large numbers of cells (mil-
lions) in the earlier year5 of prenatal diagnosis and this prolonged the period 
between amniocentesis and completion of the diagnosis to 4 - 8 weeks in 
most instances. The application of microtechniques enables a significant re-
duction in the number of cells required for the prenatal diagnosis of a number 
of enzymatic defects. Appendix paper II! describes the development of such 
techniques for the assay of acid a-1 ,4-glucosidase, the enzyme deficient in 
Pompe's disease. The use of homogenates of cultured cells enables diagnostic 
assays on ~ 10.000 cells with maltose or p. nitrophenyl-a-D-glucopyranoside 
as the substrate; with 4 methylumbelliferyl-a~D-glucopyranoside this number 
could be reduced to ~ l 000 cells. The use of groups of freeze dried cultured 
cells isolated from a culture grown on a thin transparent plastic film permits 
the analysis of 100 - 200 cells. These methods allow completion of a prena-
tal diagnosis in ~ 2 weeks after amniocentesis. 
Many factors, including genetic heterogeneity, may affect the level of en-
zymatic activities in cultured fibroblasts and amniotic fluid cells. Several of 
these were studied in appendix paper IV. A marked effect was found of the 
period of time in culture on lysosomal enzymatic activities in fibroblasts. In 
analyses on single or small groups of cultured cells variations were found 
which might be caused by local differences in cell proliferation of the culture 
or differences in the phase in the cell cycle of the cells used for analysis. 
p-Galactosidase assays in individual binuclear hybrid cells were carried out 
to study the genetic background of different clinical variants of GM 1-ganglio-
sidosis. 
30 
The application of microchemical analyses in pregnancies at risk for Pompe 1s 
disease and Fabris disease is presented in appendix papers V and VI. Prena-
tal monitoring for Pompe 1s disease was completed in 12 - 22 days in 6 cases. 
Differences were found in acid a-1,4-glucosidase activities between primary 
amniotic fluid cell cultures and later subcultures. Fabry 1s disease was exclu-
ded in a pregnancy at risk 11 days after amniocentesis by microchemical ana-
lysis of a,...galactosidase activity in groups of 100 - 200 freeze dried cells. 
Analyses on homogenates of larger numbers of cultured cells, studied at a 
later moment after amniocentesis, confirmed these results. 
These techniques allow a prenatal diagnosis of a number of lysosomal enzyme 
deficiencies in a period of about two weeks after amniocentesis, which is 
comparable to the time required for a prenatal chromosome analysis. 
A summary of results on prenatal diagnosis of a number of lysosomal storage 
diseases in appendix paper VII indicates that monitoring for metachromatic 
leukodystrophy could be completed in 16- 18 days and for some of the muco-
polysaccharidoses (studied by metabolism of radioactive labelled sulphate in 
cultured cells) within 4 weeks after amniocentesis. 
The results of prenatal monitoring in 350 pregnancies for a variety of genetic 
disorders are described in appendix paper VIII. Amniocentesis carries no appre-
ciable risk to the mother and the risk to the fetus for a spontaneous abortion seems 
not to be elevated over the natural risk in this period of pregnancy. Prenatal 
diagnosis of chromosomal aberrations may be considered as a routine and the 
use of banding techniques is essential for a reliable analysis. This applies to 
mothers at advanced maternal age (38 years and older) who have an increased 
risk for non-disjunction. In a group of 87 pregnancies studied 4 non-disjunct-
ions were detected. 
The recurrence risk of trisomy 21 (Down 1s syndrome) may be estimated as 1%. 
In 101 pregnancies tested for this indication one trisomy 21 was found. 
In 43 pregnancies at risk for an X-linked disease (haemophilia, Duchenne's 
muscular dystrophy, etc.) prenatal chromosome analysis was used to limit the 
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families of female carriers to unaffected daughters. 
In 34 pregnancies prenatal monitoring was carried out for 11 different metabo-
lic diseases; 3 abnormal fetuses were detected. 
The detection of neural tube defects {anencephaly and meningomyelocele) by 
elevated levels of alpha-fetoprotein in the amniotic fluid is a recent extension 
of the indications for prenatal diagnosis and it is the first congenital malfor-
mation of multifactorial inheritance that can be detected prenatally. This test 
was introduced in the present study in 1974 and besides pregnancies with a 
recurrence risk for a neural tube defect all amniotic fluids studied for other 
indications were tested as well. In 47 pregnancies at risk for an open defect 
of the neural tube three anencephalic fetuses were detected in the second 
half of pregnancy. 
The results of prenatal diagnosis were the basis for selective tennination in 
36 of the 350 pregnancies tested. The value of this diagnostic approach was 
equally important for those parents, who obtained the reassurance that the 
genetic disorder tested for had been excluded. 
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SAMENVATTING 
Prenatale diagnostiek van een aantal aangeboren ziekten is mogelijk door am-
niocentese (vruchtwaterpunctie) in de 14e - 16e week van de zwangerschap, 
gevolgd door onderzoek van gekweekte vruchtwatercellen of van het vrucht-
water zelf. Het onderzoek stelt ouders met een verhoogd risico op een kind 
met een chromosoomafwijking, een sluitingsdefect van de neuraalbuis of een er-
felijke stofwisselingsziekte in stoat eigen kinderen te krijgen, die niet aan de be-
trokken ofwijking lijden: wordt bij prenatale diagnostiek een afwijking vastge-
steld, of een mannelijke foetus gevonden bij risico op een geslachtsgebonden er-
felijke ziekte, dan kunnen zij om be~indiging van de zwangerschap vragen. 
Dit proefschrift beschrijft een aantal methodologische onderzoeken op het ge-
bied van de prenatale diagnostiek van erfelijke stofwisse!ingsziekten en de 
klinische toepassing van prenatale diagnostiek in 350 zwangerschappen, waar-
in een verhoogd risico bestond op een kind met een chromosoomafwijking, een 
geslachtsgebonden ziekte, een erfelijke stofwisselingsstoornis of een sluitings-
defect van de neuraalbuis (anencephalie of spina bifida aperta). 
Er zijn thans ~ 50 ernstige erfelijke stofwisselingsziekten, die prenataal 
zijn vast te stellen. Een voorwaarde daartoe is, dot het voor die ziekte spe-
cifieke enzymdefect of stapelingsproduct aangetoond kan worden in gekweekte 
cellen van een patis:nt met de betrokken ziekte: bij prenatale diagnostiek 
zullen gekweekte (vruchtwater-) cellen worden gebruikt als bron van infor-
matie over de foetus. 
In artikel I van de appendix wordt aangetoond, dat deze voorwaarde niet 
vervuld kan worden bii de haemolytische anaemie ten gevolge van pyruvaat 
kinase deficil:!ntie, een autosomaal recessief erfelijke ziekte. De anaemie 
wordt veroorzaakt door een deficil:!ntie van het L-type van het enzym, terwijl 
in fibroblasten en in gekweekte vruchtwatercellen aileen het M-type van dit 
enzym wordt gemaakt. 
Voor prenatale diagnostiek van erfelijke stofwisselingsstoornissen is steeds no-
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dig een gelijktijdige analyse van vruchtwatercellen van de betrokken zwanger-
schappen en eel len van normale zwangerschappen (verkregen bij abortus). Daar 
deze laatste slechts incidenteel beschikbaar zijn, werd een methode ontwik-
keld (artikel II van de appendix) om vruchtwatercellen ongekweekt in te vrie-
zen met behoud van levensvatbaarheid voor een latere celkweek. Tevens werd 
gevonden, dot transport van vruchtwatermonsters gedurende enkele dagen na 
amniocentese geen nadelige gevolgen behoeft te hebben voor de kweek van de 
cell en. Dit maakt prenatale diagnostiek bereikbaar voor ouders, die op grotere 
afstand wonen van centra, waar deze diagnostiek wordt uitgevoerd. 
Bij de prenatale diagnostiek van erfelijke stofwisselingsziekten waren oorspron-
kelijk enkele mi/ioenen gekweekte vruchtwatercellen nodig voor de bioche-
mische analyse. 
Voor het verkrijgen van deze hoeveelheid cellen waren kweektijden nodig 
van 6 - 8 weken. Dergelijke lange wachttijden hebben niet aileen psycholo-
gische nadelen, maar maken het oak onmogelijk een eventuele zwangerschapson-
derbreking zo vroeg mogelijk uit te voeren. 
Een verkorting van deze wachttijd kon worden verkregen door gebruik te rna-
ken van gevoeliger meetmethodieken, die onderzoek van kleinere aantallen 
vruchtwatercellen mogelijk maken. De methodologie van de microchemische 
analyse van de activiteit van het enzym zure a-1 ,4-giucosidase, dot defici~nt 
is bij de ziekte van Pompe (glycogenose type II), wordt beschreven in artikel 
!.!.!_ van de appendix. Met 4-Methylumbelliferylglucopyranoside als substraat is 
analyse mogelijk van een homogenaat van ~ 1000 gekweekte cellen. Een ver-
dere reductie van dit celaantal is mogelijk door analyse van groepen van 100 
- 200 gevriesdroogde eel/en, die onder microscopische controle gersoleerd zijn 
uit een celkweek die groeide- op een dunne transparante plastic film. Met 
deze methoden is een prenatale diagnose van de ziekte van Pompe mogelijk 
in ongeveer 2 weken na amniocenteses. 
Vele factoren kunnen van invloed zijn op de enzymactiviteiten in gekweekte 
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cellen. In artikel IV van de appendix werd een aantal daarvan onderzocht. Er. 
blijkt een duidelqke relatie te bestaan tussen de kweekduur en de enzymactiviteit 
van lysosomale enzymen. Bij analyse van k/eine groepen cellen werden varieties 
gevonden, die te verklaren zijn uit locale verschillen in celproliferatie in een 
kweek of uit verschillen in fase in de celcyclus van de onderzochte cellen. De 
genetische achtergrond van klinisch verschillende typen van GM
1
-gangliosidose 
werd bestudeerd door celfusie, gevolgd door analyse van de p-galactosidase ac-
tiviteit in afzonderlijke binucleaire hybride cellen. 
De toepassing van microchemische analysemethoden in prenatale diagnostiek van 
de ziekten van Pompe en Fabry wordt beschreven in artikel V en VI van de appen-
dix. Bii 6 prenatale diagnosen voor de ziekte van Pompe werd het resultaat be-
kend in 12- 22 dagen na amniocentese; de ziekte van Fabry kon worden uitgeslo-
ten 11 dagen na amniocentese door microchemische analyse van a-galactosidase 
activiteit in kleine groepen gevriesdroogde vruchtwatercellen. Deze resultaten 
werden bevestigd door onderzoek van homogenaten van gekweekte eel len op een 
later tijdstip. 
Een samenvatting van prenatale diagnostiek voor een aantal lysosomale stapelings-
ziekten is beschreven in artikel VII van de appendix. Prenataal onderzoek voor 
metachromatische leukodystrofie (arylsulfatase A deficil:!ntie) werd voltooid in 16-
18 dagen en voor de mucopolysaccharidose type II (ziekte van Hunter) (onderzocht 
door meting van metabolisme van radioactief gemerkt sulfaat in vruchtwatercellen) 
binnen 4 weken na amniocentese. De toepassing van microchemische analyse-
methoden heeft bijgedragen om de lange wachttiiden bij prenatale diagnostiek van 
erfelijke stofwisselingsziekten te verkorten. 
Artikel VIII van de appendix beschriift de toepassing van prenatale diagnostiek in 
350 zwangerschappen, waarin een verhoogd risico bestond op een in vruchtwater 
of vruchtwatercellen aantoonbare afwijking. Het risico van amniocentese voor de 
moeder is verwaarloosbaar klein, voor de foetus liikt het risico op een spontane 
35 
abortus na amniocentese niet duidelijk verhoogd t.o.v. het normale risico op een 
mi skraam in de betreffende zwangerschapsperi ode. 
Prenataal chromosomenonderzoek is een routine geworden voor zwangeren van 38 
jaar en ouder 1 die een verhoogd risico hebben op een kind met een chromosoom-
afwijking (1 ,5-3%); in 87 van de onderzochte gevallen werd 4 maal een chromo-
soomafwijking vastgesteld. Hetzelfde geldt voor moeders, die reeds een kind met 
een trisomie 21 (Down•s syndroom) kregen. Het herhalingsrisico van deze afwij-
king bedraagt 1%. In 101 onderzochte zwangerschappen we.-d eenmaal een foetus 
met een trisomie 21 gevonden. 
In 43 zwangerschappen bestond een risico op een geslachtsgebonden erfelijke 
ziekte bij een mannelijke foetus (spierdystrofie van Duchenne, haemofilie, etc.). 
Via prenataal chromosomenonderzoek konden deze draagster-moeders hun gezin 
beperken tot meisjes, die niet aan de betreffende ziekte zullen lijden. In 34 ge-
vallen werd prenataal onderzoek gedaan naar een van ll verschillende stofwisse-
lingsziekten; drie maal wer-d een afwijkende foetus gevonden. 
Sluitingsdefecten van de neuraalbuis (anencephalie en spina bifida aperta) zijn de 
eerste aangeboren afwijkingen met multifactori~le erfelijkheid, die prenataal zijn 
aan te tonen door een verhoging van het gehalte van het foetale eiwita-foetopro-
teine in het vruchtwater. Deze test werd in 1974 ingevoerd in dit onderzoek en 
sedertdien wordt het onderzoek gedaan niet aileen in zwangerschappen met een 
herhalingsrisico voor een defect van de neuraalbuis, maar ook in alte andere 
vruchtwatermonsters van zwangeren, die om andere indi cati es worden onderzocht. 
In 47 gevallen, waarin een verhoogd risico bestond, werd 3 maal in de tweede 
helft van de zwangerschap een sterk verhoogd a-foetoprotein gehalte gevonden. 
In deze laatste gevallen werd bij ultrasonografisch onderzoek een foetus met anen-
cephalie aangetoond. 
Op grand van de resultaten van prenatale diagnostiek werd in 36 gevallen door de 
ouders be~indiging van de zwangerschap gevraagd. De waarde van deze diagnos-
tische mogelijkheid was even duidelijk voor de overige ouders, die de zekerheid 
kregen, dat in de onderzochte zwangerschap het verhoogde risico was uitgesloten. 
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NAWOORD 
Curriculum vitae: eindexamen gymnasium 1958. Studie geneeskunde te Leiden 
(doctoraal exam en 1967; semi -arts examen 1969) en te Rotterdam (arts-examen 
1972). Van 1960- 1965 student-assistent op de afdeling Sociale Hygi~ne van 
het Nederlands lnstituut voor Praeventieve Geneeskunde te Lei den. Vanaf mei 
1968 verbonden aan de afdeling Celbiologie en Genetica van de Erasmus Uni-
versiteit te Rotterdam, wear eind 1969 begonnen werd met het in dit proef-
schrift beschreven onderzoek. 
De prenatale diagnostiek kon i.n Rotterdam tot stand komen door de nauwe 
samenwerking tussen de afdelingen Celbiologie en Genetica, Verloskunde-Gy-
naecologie, Biochemie I, Kindergeneeskunde en Neurologie. Deze samenwer-
king en die met vele andere collega•s in Nederland en daarbUiten is essenti-
eel om prenqtale diagnostiek in het bereik te brengen van die zwangeren, bij 
wie daartoe een indicatie bestaat. 
Prof. Dr. H. Gafiaard heeft zich als promotor ten zeerste ingezet voor de 
introductie van prenatale diagnostiek in Nederland. lk ben hem erkentelijk 
voor zijn grote betrokkenheid bij dit onderzoek en zijn aandacht bij de tot-
standkoming van de publicaties. 
Prof. Dr. D. Bootsma ben ik erkentelijk voor zijn belangstelling en steun tij-
dens de voortgang van di t onderzoek. 
Prof. Dr. A.L.C. Schmidt ben ik erkentelijk voor de wijze, waarop hij col-
lega Jahodova in stoat stelde om op zqn afdeling amniocentese in de vroege 
zwangerschap te ontwikkelen en voor zijn betrokkenheid bij de beginfase van 
di t onderzoek. 
In de dagel i jkse samenwerking met mevr. M. Jahodova, gynaecologe, mevr. 
Dr. E.S. Sachs en Dr. W.J. Kleijer ontstond een hecht team, waarin de 
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voortgang van het onderzoek mogel i jk werd. 
Daarnaast is dit onderzoek verOOnden met het enthousiasme van de mede-au-
te~rs, werkzaam op verschillende afdelingen, waarvoor ik hen dankbaar ben. 
Dr. A.M. Hagemeijer-Hausman en hoar medewerksters op de afdeling Cytoge-
netica verrichtten een jaarlijks toenemend aantal chromosoomonderzoeken nood-
zakelijk voor een juiste indicatiestelling Voor prenatale diagnostiek. 
Dr. J.F. Koster, afdeling Biochemie I, volgde de ontwikkeling. van dit onder-
zoek met vele adviezen en verrichtte enzymatische diagnostiek bij index-pa-
ti~nten uit de onderzochte families. Dr. J. Fernandes, afdeling Kindergenees-
kunde, was betrokken bij de indicatiestelling tot prenatale diagnostiek, i.h.b. 
bij de glycogeenstapelingsziekten. Dr. H.F.M. Busch, afdeling Neurologie, 
verrichtte het draagsterschap-onderzoek voor de spierdystrofie type Duchenne; 
Dr. J.J. Veltkamp, afdeling Haemostase, Academisch Ziekenhuis te Leiden, 
en Dr. J. Stibbe, afdeling Haematologie, verrichtten draagsterschap-onder-
zoek van Hemofilie A. Dr. J.L.J. Gaillard, afdeling Pathologische Anatomie 
I, verrichtte het morfologisch bevestigingsonderzoek na selectieve abortus. 
Vele medewerkers van de afdeling Celbiologie en Genetica gaven met grate 
inzet hun medewerking aan di t onderzoek: mevr. C. Tichelaar-Kiepper; mevr. 
G. Olyhoek-Griffioen; mevr. A.M. Zandvoord-Waayers; A. Hammer; mej. L 
Wolffers, A. Hoogeveen, mevr. H.A. de Wit-Verbeek; mevr. M.J.C. van 
Gent-van Breda; mej .. H. Verschuur. Voorts: J.G.H. Fengler en T.M .. van 
Os (fotografie); mevr .. A.M. Godijn en mej. J.A. Solman (sterilisatie); mej. 
M. van Duuren(grafieken); mej. M. H.J. van Rijn (secretariaat). Afdeling 
Biochemie 1: mej. R.G. Slee. 
Het manuscript werd persklaar gemaakt door mevr. G. M. Schreuders-Hender-
son, J.G.H. Fengler en H.E. Vijvers. 
Dr. K.L. Garver, Magee Women•s Hospital Pittsburg (U.S.A.) assisted in this 
study by supplying us with amniotic fluid samples from control pregnancies. 
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Pyruvate kinase in cultivated amniotic fluid cells 
After glucose-6-phosphate dehydrogenase deficiency L-type pyruvate kinase 
deficiency is the most common erythrocyte metabolic error. Although the clinical 
pattern is reported to be quite variable, a rather high rate of mortality in early life 
has been found1 • Recently, pyruvate kinase was purified from human erythrocytes2 
and it was found that the enzyme exhibits allosteric properties. These properties were 
compared with the partially purified enzyme from pyruvate kinase-deficient patients. 
In three of four unrelated patients the mutant enzyme did not show allosteric 
properties, while in a.ll patients an increased thermolability was found3 • 
The properties of red hlood cell pyruvate kina'" is very much like the (liver) 
L-type pyruvate kinase. Besides the L-type the liver also contains the (muscle) M-type 
pyruvate kinase which in deficient patients remains unchanged. It has been shown 
that in pyruvate kinase deficiency there is also a decrease of total liver pyruvate 
kinase activity'. However, to perform antenatal diagnosis of this deficiency it is 
necessary to establish which type (L- or M-type) of pyruvate kinase is present in 
human cultured fibroblasts and amniotic fluid cells. 
Pyruvate kinase act-ivity was measured according to the method of Bi.icher and 
Pfleiderer5. Starch gel electrophoresis was performed with the method of Bigley et al. 6 , 
the pynlVate kinase activity was detected with the fluorescent technique'. 
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Fig. r shows the saturation curve for phosphoenolpyruvate (PEP) of fibroblast 
pyruvate kinase with [ADPJ = 2 mM. The curve is hyperbolic and fructose-r,6-di-
phosphate (Fru-r,6-P2) does not stinmlate the enzymatic reaction. The same result 
was obtained with cultivated amniotic fluid cells. It is known that the L-type pyru-
vate k.inase of liver and erythrocyte exhibits an S-shaped saturation curve, while the 
M-type does not. Furthermore, Fru-r,6-P2 stimulates the L-type and transforms the 
-;igmoidal curve into a hyperbolic one. The enzymatic activity of the M-type is not 
influenced by Fru-I,6-P2• 
-
control 
-
[Fru-1.6-P2}~o.s mM 
6Efml 
(ADP] = 2mM 
0.15 • ( • • 0.10 
005 
0 
0 ,. 2.0 lO 
[PEPjtmMJ 
Fig. I. PEP saturation curve for :fibroblast pyruvate kinase in the absence and presence of Fru-r,6-
P2. Buffer 0.1 M Tris-HCl (pH 7.6), [ADP] = 2 mM, reaction medium contains o.o8 mg protein. 
e-e, control; x-x, in the presence of Fru-r,6-Pe (o.5 mM). 
Table I summarizes the apparent Km values for PEP at fixed ADP concentra-
tion. It shows that the apparent Km values obtained for pyruvate kinase in fibroblasts 
Clin. Chim. Acta, 36 (1972) 572-573 
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and cultivated amniotic fluid cells are in the same order as those for theM-type from 
various origins. 
TABLE I 
THE APPARENT Km VALUES FOR THE SUBSTRATE PHOSPHOENOLPYRUVATE AT [ADP) = 2 mM 
FOR RAT LIVER (L-AND M-TYPE), HUMAN ERYTHROCYTE, HUMAN FIBROBLAST, HUMAN AMNIOTIC 
FLUID CELLS, AND HUMAN LEUCOCYTES PYRUVATE KINASE 
Liver (rat)* 
Erythrocyte (human) 
Muscle (human) 
Leucocytes (human) 
Cultured amniotic fluid cells (human) 
Cultured fibroblast.'> (human) 
Type Km (mM) 
L 
M 
L 
M 
M 
M 
M 
o.8o 
0.075 
0-4-5 
0.02 
0.05 
0.10 
0.10 
*Obtained from Tanaka et al., ]. Biockem. (Tokyo), 62 (1967) 71. 
Furthermore, electrophoresis showed that the mobility of fibroblast pyruvate 
kinase is the same as that of the M-type, but quite different from the erythrocyte 
L-type pyruvate kinase. 
From these data, it can be concluded that cultivated fibroblasts and amniotic 
fluid cells contain the M-type pyruvate kinase. As the diagnosis pyruvate kinase 
deficiency is based on a decreased activity of the L-type, fibroblasts nor amniotic 
fluid cell cultures can be used in diagnosis of this disease. Therefore, antenatal diag-
nosis of this disease by using cultured amniotic fluid cells is impossible. 
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Summary. 1. A method for freezing uncultured amniotic fluid ceHs is presented, which 
allows their use· as pregnancy-age matched controls in prenatal diagnosis of metabolic diseases. 
2. Amniotic fluid cells were successfully cultured after up to 7 days in transport, which makes 
prenatal diagnosis available to parents living a long way from specialized centers. 
Zusammenfassung. 1. Eine Einfriermethode fiir nichtkultivierte Fruchtwasserzellen wird 
beschrieben, wodurch-man diese wie Kontrollmuster an wenden kann bei pri:inataler Diagnostik 
von Stoffwechselkrankheiten. 2. Fruchtwasserzellen wurden erfolgreich kultiviert nach lang-
zeitigem Transport (7 Tage); dieser Befund bringt eine pranat.ale Diagnostik im Bereich ent-
fernt von spezia!isierten Zentren lebender Eltern. 
An increasing number of inborn errors of metabolism can be detected in early 
pregnancy (IV!ilunsky et al., 1970; IV!ilunsky and Littlefield, 1972). Until now 
metabolic defects have been· determined by biochemical analysis of cell homo-
genates obtained from large numbers (millions) of cultured amniotic-fluid cells. 
As a consequence the period of time required for prenatal diagnosis in most in-
stances has been very long (4--10 weeks) (Brady et al., 1971; Fratantoni et al., 
1969; Epstei.n et al., 1972; Cox et al., 1970). 
This period can be substantially reduced for a number of metabolic diseases by 
using microchemical techniques allowing the analysis o{ enzyme activities in 
clones of a few hundred cells (Galjaard et al., 1972). Knowledge of the variation 
in enzyme activity among heterozygotes for the disease concerned and also a 
proper selection of control material is of great importance fOr a reliable prenatal 
diagnosis, as there is increasing evidence that the "biochemical behavior" of 
cultured cells can be influenced by the 9-uration of. cell culture (Robbins et al., 
1970), the phase in the growth curve (DeMar3, 1964) and the conditions of cell 
culture (Ceccarini and Eagle, ~9~1; Lie et al., 1973). It therefore seems preferable 
to compare analytical data from the pregnancy at risk with those from control 
amniotic fluid samples at the same stage of pregnancy and grown in identical 
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conditions at the same time. This can only be realized when control amniotic 
fluid is available at any moment when a pregnancy at risk is to be monitored, 
which will rarely occur. In this communication the transport of amniotic fluid 
samples is discussed and a method is presented for long-term storage of these 
samples with preservation of cell viability. 
Samples of amniotic fluid are centrifuged for 5 min at 80 X g and the cell pellets 
(0.2- 1.4 x 106 cells) are resuspended in 1 ml cell culture medium (Ham's F 10) supple-
mented with 15% fetal calf serum, 4% dimethyl sulfoxyde (as cryoprotective agent) and 
antibiotics. Cell suspensions are transferred into ampoules which, after sealing, are frozen at 
a rate of 1 degCjmin over liquid nitrogen vapor down to -70°C and subsequently stored 
under liquid nitrogen. To test the viability of the cells ampoules are taken after 7-22 days 
and rapidly thawed (under running tapwater). The cell suspensions are then washed by 
resuspending in 5 ml of serum-free medium, centrifuged for 5 min at SO X g, and resuspended 
Table 1. Amniot,ic fluid cell culture: Direct culture versus culture after freezing of uncultured 
cells a 
Sample Pregnancy Direct culture: Frozen cells: 
(weeks) First dividing cells First dividing cells 
(days) + typeb (days) + typeb 
20 5 10 
2 17 10 (E, F) 4 (F) 
3 18 4 6 
4 17 4 
5 13 6 5 
6 16 6 (E, I, F) 7 (E, I, F) 
7' 18 4 (E, I, F) 6 (I) 
8' 19 3 (E, I, F) 7 (E, F) 
a Suspensions of uncultured amniotic fluid cells (0.2- 1.4 x 106 cellsjml). 
b F = Fibroblast-like, E = Epitheloid, I = Intermediate. 
c Samples in transport for 7 days. 
Table 2. Amniotic fluid ceil culture: Culture of samples after 5-7 days in tra.nsfera 
Sample Pregnancy Days in Cell Primary Cell Karyo-
(weeks) transport count.jml growth typeb typing 
(days) 
1 13 7 76500 6 F 
2 14 5 26100 6 E/I 
4 21 5 55600 4 F 
5 16 5 36500 7 
6 5 121000 3 E+F 
7 18 5 69000 4 F 
9 18 21000 7 E+I 
a Transport by air mail in siliconised glass tubes at ambient temperature. 
b E = Epitheloid, F = Fibroblast-like, I = Intermediate type. 
(days)' 
20 
17 
6 
12 
6 
11 
10 
c Interval (days between initiating culture and obtaining sufficient cells for chromosome 
analysis. 
Transport and Storage of Amniotic Fluid Samples 
in F 10 supplemented with 25% fetal calf serum and antibiotics. Aliquots (0.75 ml) of cell 
suspensions are carefully pipetted onto 22 X 22 mm coverslips in 35 mm Falcon Petri dishes. 
After 12~24 hrs for cell attachment additional medium is added. A fully humidified incubator 
with 5% C02 in the gaseous phase is used. 
The results of culturing of the stored samples were compared with those of 
aliquots from the same sample cultured immediately (Table 1). No difference was 
observed in the time interval for the appearance of dividing cells or the type of 
proliferating amniotic fluid cells. It may be concluded that samples of uncultured 
amniotic fluid cells treated according to the method described can serve as reliable 
controls in prenatal diagnosis of metabolic disorders. 
Two of the samples (Nos. 7 and 8, Table 1) had even been in transport for 7 
days without d~trimental effects on in-vitro cell growth afterwards. This finding 
is also illustrated by results of cell cultures of amniotic fluid samples from various 
periods of gestation air-mailed from the USA to Europe during different transfer 
times (Table 2). First mitoses were observed after 3-7 days and sufficient cells 
for karyotyping were obtained after 6-20 days of in-vitro growth. These results 
indicate that a transport time of up to 7 days does not affect the possibility for 
prenatal karyotyping. 
The main conclusions from these results are: 
1. Storage of unprocessed amniotic fluid cell samples is possible with preser-
vation of cell viability, thus allowing the use of optimal control material in the 
prenatal analysis of a pregnancy at risk for a metabolic disease. 
2. Even a few days of transportation have no detrimental effect on in-vitro cell 
growth, offering the possibility of prenatal diagnosis for parents at risk for a genetic 
disease living a long way from specialized centers. 
Acknowledgem.ent. This work was supported in part by a grant from Preventie Fonds. 
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A METHOD FOR RAPID PRENATAL DIAGNOSIS OF GLYCOGENOSIS II 
(POMPE'S DISEASE) 
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SUMMARY 
A method is described enabling prenatal diagnosis of glycogenesis II (Pompe's 
disease) within 7-10 days after amniocentesis in the 14th-r6th week of pregnancy. 
The procedurE' is based on amniotic fluid cell cultivation on thin plastic foil, freezing 
and freeze-drying of the cells and subsequent microdissection of pieces of plastic foil 
each containing 70-250 lyophilized cells. These are incubated in microliter volumes 
of substrate. The extinction or fluorescence values are measured in microcuvettes 
adapted to a normal spectrofluorometer or in microcapillaries using a microscope 
s.pectrofluorometer design. The methods developed are compared with conventional 
biochemical analyses. 
INTRODUCTION 
Hers1 delineated the basic defect in type II glycogenesis (Pompe's disease) as a 
deficient activity of the lysosomal acid a-1,4-glucosidase. In patients with Pompe's 
disease this enzyme deficiency has been demonstrated in various tissues and organs2 •3 • 
Nitowsky and Grunfeld4 showed that the acid a-glucosidase deficiency is also ex-
pressed in leucocytes and in cultivated skin fibroblasts. This not only facilitated the 
diagnosis of patients and heterozygous carriers but also formed the basis for prenatal 
detection of this autosomal recessive disease. The first examples of prenatal diag-
nosis of Pompe's disease were based on a deficiency of a-glucosidase in amniotic 
fluid, in uncultivated and cultivated fluid cells5 •6 • Later, it became apparent that the 
use of amniotic fluid and uncultivated cells could result in erroneous interpretations 
(refs. 7, 8), because of the possibility of contamination with maternal components and 
because of the presence in amniotic fiuid of an a-glucosidase with different properties 
than the lysosomal acid gll;lcosidase which is deficient in Pompe's disease7· 9 • 
The necessity to use cultivated amniotic fluid cells for a reliable prenatal diag-
nosis implied a long waiting period. So far 4~6 weeks of in vitro cultivation (after 
amniocentesis in the 14th-18th week of pregnancy) was necessary to obtain sufficient 
cell material for a-glucosidase analysis5 •6 •10 • Such long waiting periods not only mean 
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a psychological stress for the parents concerned but also in the case of an abnormal 
fetus interruption of a pregnancy at later stages may result in more obstetrical 
difficulties. The use of microchemical techniques8 •11- 15 enables a reduction of the 
number of cultured cells required for analysis and preliminary data on the application 
of such microtechniques in the prenatal analysis, of a number of lysosomal enzymes 
in cultured amniotic fluid cells have been presented8 , 16 • 
In this paper a micromethod is presented which allows prenatal diagnosis of 
Pompe's disease within 7-14 days after amniocentesis in the r4th-r6th week of 
pregnancy. The method developed has been compared with other assay procedures 
and some problems encountered in the practical use of the various methods will be 
discussed. The application of this micromethod in the prenatal monitoring of several 
pregnancies at risk for Pompe's disease will be described separately17 • 
MATERIAL AND METHODS 
In vitro cultivation and preparation of cell material 
Control amniotic fluid was obtained by transabdominal amniocentesis between 
the r4th-r6th week of pregnancy after ultrasound localization of placenta and fetus. 
S-IS ml amniotic fluid was centrifuged in siliconised glass tubes and the cell pellet was 
resuspended in Ham's Fro medium supplemented with 20% fetal calf serum. When 
microchemical studies were to be performed on dissected small clones of freeze-dried 
cells, in vitro cultivation was carried out on "mylar dishes" consisting of a 5 em 
diameter glass ring and a bottom of thin plastic (Melinex polyester film type o, I. C. I. 
Holland). For (micro)biochemical studies on cell homogenates cultivation was per-
formed in 35 mm falcon dishes. Established fibroblast strains from control individuals, 
patients with Pompe's disease and heterozygous carriers were cultured under similar 
conditions, using Ham's Fro supplemented with rs% fetal calf serum. 
Amniotic fluid cells were either directly used for cell cultivation and subsequent 
analysis or were cultivated after storage of the unprocessed cells, using a new method 
(ref. r8). Cell homogenates were prepared by trypsinization with 0.25% trypsin 
solution and washing of the cells which were then suspended in 0.001% bovine 
albumin. After counting the cell number in a hemocytometer, homogenization was 
carried out by sonic vibration (2 X30 sec) or by repeated freezing and thawing. In 
most experiments a concentration of about ro6 cells per ml was used (corresponding 
to a protein concentration of about 0.3 mg/ml). Analysis of cell homogenates was 
either performed directly or after storage of the cell sonicate at -70". Depending on 
the type of experiments r-ro pJ aliquots of cell homogenate were used for a-lA-
glucosidase and protein analyses. 
For direct assays on freeze-dried cells (Fig. 4), the "mylar" dishes containing 
groups of cultured amniotic fluid cells or fibroblasts were frozen in C02-acetone 
( -70°) or in isopentane-liquid N2 ( -IJ0°) after removing the medium by three times 
rinsing in isotonic salt solution. The dishes were then transferred to a freeze-drying 
apparature (W.K,F., type 05, Wetzlar Instr.) while kept at low temperature. Lyo-
philization of the cultured cells was carried out in vacuo (ro-~mm Hg) at -45o during 
about 15 hours and the vacuum was released after the dishes were allowed to warm to 
20°. Freeze-drying of the cells not only allows storage for long periods (at -70°) but 
it also enables isolation of cells voithout any loss of enzyme activity. 
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In a conditioned foom (20° ± o.s and relativ~ humidity <4o%) pieces of 
plastic foil containing small numbers (tenths~hundreds) of freeze-dried cells were iso-
lated using free hand microdissection under a stereomicroscope (zoomobjective, total 
magnification 6o-r2ox). The number of cells on each dissected piece of plastic was 
counted using a raster specially designed for this purpose (Micropure, Arnhem, 
Holland) which is placed under the culture dish during microdissection. The dissected 
pieces of foil, containing a known number of cells (7o-2so) were used for further 
microchemical analyses. 
(Micro)biochernical assays 
Protein analysis. The method described by Lowry et al.U was adapted to a 
smaller final volume to decrease the amount of cell material required for analysis. To 
s ttl of cell homogenate so p:l copper sulphate is added and after ro min s p:l of Falin 
reagent is added. After 4S min in the dark the extinction at 7SO nm is read in ultra-
microcuvettes (volume of about 20 p:l with an optical path of ro rum) adapted to a 
Zeiss PMQ 2 spectrophotometer. Different concentrations of bovine albumin in dis-
tilled water served as standards. 
a-I,4-glttcosidase assays 
(I) .'Maltose as a substrate. The procedure described by Nitowsky and Grunfeld4 
was adapted for use in small final volumes to reduce the number of cells required for 
analysis. ro p:l cell homogenate was incubated with IO p:l substrate (S mg maltose per 
ml in o.os M acetate buffer pH 4.0) during 30 min, I and 2 hours at 37°- After heating 
2 min at I00°, cooling in ice and S min centrifugation at 3000 rev./ min Io ftl of the 
incubation mixture was added to so ftl glucose oxidase reagent and incubated at 37o 
during I hour. The extinction was read at 440 nm in Zeiss ultramicrocuvettes. Con-
centrations up to 200 f.lg fml glucose \Vere used as standards. 
( 2) p-Nitrophenyl ct-D-glucopyranoside was also used as a substrate using various 
final volumes depending on the amount of cell material to be analyzed. S pl cell 
homogenate has been incubated with 2S p:l4 mM p-nitrophenyl a-n-glucopyranoside 
in o.r M citrate buffer, pH 4-0. Incubation times varied from 0.5-6 hours at 37o and 
the reaction was stopped with 30 ftl 0.2 M NaOH in ice. Extinction at 40S nm was 
read in different ways depending on the final volume. Down to 6o ttl extinctions were 
recorded in microcuvettes adapted to a Zeiss spectrophotometer. Extinction measure-
ments in final volumes of I ttl were carried out in glass microcapillaries (Drummond 
microcaps of r mm diameter) using a Leitz micrcspectrophotometer type MPV obj. 
2.5 X Pl. and an E.M.I., type: 9558 QA photomultiplier with a Knott power supply. 
(3) 4-Methylurnbellijeryl a-D-glucopyranoside was used as a substrate in a con-
centration of 2.2 mM acetate buffer, pH 4.0. To obtain maximal sensitivity of the 
a-glucosidase analysis incubation was carried out in microliter volumes8 • In most 
experiments incubation of cell homogenate (o.r-I ,ul) or of di<>sected pieces of plastic 
foil containing a small number of lyophilized cultured cells was carried out in 0.3-2 ,ul 
of substrate during I-2 hours at 37°. To prevent evaporation incubation in such small 
volumes was performed under paraffin oil using teflon rack with small wells (oil well 
technique) according to principles described by Matchinsky20 and Lowry12 (Fig. 4). 
Cell samples and microdroplets of reagents were introduced into the "oil well" under 
microscopic control using quartz constriction pipettes which were kindly made for us 
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by Dr. 0. H. Lowry. After incubation the reaction volume was pipetted into soo p:l 
o.s M carbonate buffer (pH ro.7) and the fluorescence of methylumbelliferone was 
measured in a Perkin-Elmer fluorometer (extinction 365 nm. fluorescence 448 nm). 
The fluorescence of smaller volumes was measured in capillaries using the same micro-
spectrofinorometer as descr~bed, but with a Ploem Opak illuminator21 • 
All experiments on cell homogen<ites were performed in triplo and in the micro-
assays on freeze-dried cells at least IOpiece-s of plastic containing a varying number 
of cells (70-250) were dissected. In the latter experiments empty pieces of pla.::tic 
dissected adjacent to the lyophillized cells were incubated as blanks. V\rhen low cell 
concentrations are incubated addition of bovine albumin (o.2 mgjml) is requirrd. 
RESULTS 
(I) Microchemical analyses on cell homogenates 
(a) 111 altose as substrate. When the analysis of IX-I ,4-glucosidase activity is 
carried out according to the original procedure of Nitowsky and Grunfeld4 about roG 
cultivated control fibroblasts are required to yield accurate extinction values. For a 
reliable diagnosis sufficient cell material must be available for triplo measurements, a 
protein assay and also the sensitivity of the assay should enable a clear distinction 
between low enzyme activities in cells from heterozygous carriers and deficient cells 
from patients with Pompe's disease. This means that at least I0 7 cultured amniotic 
fluid cells must be available for a prenatal diagnosis when conventional procedures 
are used. 
In this assay, like in each spectrophotometric analysjs, the amount of cell 
material required, decreases proportionally when the fmal volume of the assay is 
reduced. We have combined such a reduction -·:'If the incubation and measuring volume 
with a simpliiication of the procedure. IO p:l of several dilutions from a homogenate 
prepared from cultured amniotic fluid cells has been incubated for 2 hours at 37° in 
IO p:l maltose substrate. After 2 min heating to I00° ro pl of the incubation mixture 
was pipetted into 50 p:l glucose oxidase reagent and kept for I hour at 37°. The ex-
Exfmcf1on 
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Fig. I. a:-1,4-Glucosidase activity in cultured amniotic fluid cells (A) and fibroblasts {B) using 
maltose as a substrate (6o t-tl final volume). 
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tinction at 440 nm was read in 20 p;l microcuvettes fitting to a specially designed cuvet 
housing for a Zeiss spectrophotometer. Several steps of the original procedure 
(addition of water, centrifugation, addition of strong acid in the glucose assay step) 
could be omitted thus enabling more easy analysis in microvolumes. 
The results illustrated in Fig. rA show that under those conditions a minimum 
of about ro ooo normal amniotic fluid cells is required for one single measurement. 
Incubation of less cells results in unreliable extinction values. As mentioned earlier in 
prenatal diagnosis sufficient cell material must be available for triplo measurements 
and a Lowry protein assay which requires a few thousand cells even when performed 
with a 6o fll final volume. Furthermore low a-glucosidase activities as present in cells 
from heterozygotes should be detectable and results in Fig. rB illustrate that this will 
require more than twice the amount of cell material compared to normal controls. 
The a-glucosidase activity in normal cultured fibroblasts is in the order of 6 ·ro-9 
mole ·min-1 mg-1 protein or I-2 ·ro-13 mole · h-1 per cell. As a result of these factors at 
least 70 ooo cultured amniotic fluid cells must be available for prenatal diagnosis of 
Pompe's disease when maltose is used as a substrate even when the assay is carried 
out in the smallest final volume that can be measured with microcuvettes adapted to 
commercially available spectrophotometer. 
Theoretically, further reduction in the number of cells required for analysis 
could be accomplished by combining longer incubation periods with a further de-
crease of the final volume using microscopic spectrophotometry to measure the ex-
tinction in submicroliter volumes. As is shown in Fig. rB the enzyme reaction already 
shows some deviation from linearity during the first 2 hours of incubation and after 
longer incubation periods no reliable results were obtained. A further reduction in the 
incubation volume and final volume (down to 1 ftl) implicate the necessity of in-
cubation unde1 paraffin oil to prevent evaporation and of extinction measurements in 
microcapillaries using a microspectrophotometer. It was found that the various steps 
required in the a-glucosidase assay when maltose is used as a substrate, could not 
easily be ccmbined with the manipulation of submicroliter volumes. For this purpose 
single step enzyme assays should be preferred. 
(b) P-Nitrophenyl-cx.-n-glucopyranoside as substrate. The a-glucosidase assay 
using p-nitrophenyl-glucoside as a substrate has several advantages when the analysis 
A B 
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0 
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Fig. 2. o::-1,4·Glucosidase activity in cultured fibroblasts using p-nitrophenyl-o:-o-glucoside as a 
substrate (6o ,ul final volume). 
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is to be carried out on little cell mat:erial. Linearity of the enzyme reaction with this 
artificial substrate was observed even during very long incubation periods {Fig. zB). 
Again for this spectrophotometric assay a reduction of the incubation and final volume 
will enable extinction measurements with less cell material. In Fig. zA results are 
illustrated 0f incubations of decreasing numbers of cultured control fibroblasts using 
a 6o pl final volume and all incubation time of 6 hours. A minimum of about 4000 
cells is required to yield extinction values of about o.I. The activity in normal cultured 
fibroblasts was found to be about 3-4 X less than "'Nith maltose as a substrate. In order 
to be able to perform triplo measurements, a protein assay and to detect low enzyme 
activities in cells from heterozygous carriers at least 30 ooo cultured amniotic fluid 
cells shoul_dbe available for a prenatal diagnosis of Pompe's disease when p-nitro-
phenyl-glucoside is used as a substrate in a final volume of 6o pl. 
Compared to the assay with maltose as a substrate the single step reaction with 
p-nitrophenyl-glucoside will more easily enable a further reduction of the final 
volume. When incubation is performed in microliter volumes the reaction should be 
performed under paraffin oil to prevent evaporation. The extinction measurements 
of the p-nitrophenol formed can be carried out with a microscope spectrophotometer 
design. To investigate the reliability of such measurements various dilutions of p-
nitrophenol in o.I N NaOH were measured in a nonnal 3 ml cuvet {Io mm optical 
path) in a Zeiss spectrophotometer and the results were compared with those of I ,ul 
samples measured in niicrocapillaries using a Leitz microspectrophotometer. From 
each dilution IO samples were measured and the results are shown in Table I. A re-
markable agreement is observed over the whole range of extinction values. The fact 
that the 1 pl samples show ten fold lower extinction values is the result of the ten fold 
smaller optical path in the microcapillaries. The results also show that in micro-
spectrophotometry much lower extinction values (about IO X} can still be measured 
accurately compared with a nonr.al spectrophotometer. The standard deviation of the 
measurements is quite small over the whole extinction range. These results indicate 
that the use of I ,ul final volume enables the analysis of 3o--60 fold less cell material 
than is possible with the smallest microcuvettes adapted to normalspectrophotometers. 
TABLE I 
ACCURACY OF EXTINCTION MEASUREMENTS OF p-NITROPHENOL IN I ,ul VOLUMES USING MICRO-
SPECTROPHOTOMETRY 
Extinction in normal 
spectrophotometer 
( 3 ml cuvet, Io mm 
optical pathway) 
o.63o 
0-535 
0-448 
o.350 
0.26! 
O.OJll-
0.064 
0.044 
0.030 
Mean extinction in 
microspectrophotometer* 
(I pl capillary, I mm 
optical pathway) 
X S.D. 
0.0621 
0.0531 
0.0446 
0.0346 
0.0255 
0.0075 
0.0064 
0.0044 
O.OOJO 
o.ooo3 (o.5%) 
0.0004 (O.J%) 
o.ooo6 (r.2%) 
0.0005 (r.4%) 
o.ooor (o.5%) 
0.0004 (5%) 
o.ooo1 (2%) 
o.ooo1 (2%) 
0.0002 (7%) 
*. Measuring~mes up to 30 min did n~t influence the extinction v.ilues, indicating that no evapora-
tion of the nncrodroplets covered with paraffin oil in the microcapillaries occurred. 
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For the prenatal diagnosis of Pompe's disease this means that a few hundred-
thousand cultured cells would be sufficient for a-glucosidase analysb if a final volume 
of 1 .ul is used. However, a protein determination in triplo microvolumes requires at 
least 3000 cells and hence a total of about 4000 amniotic fluid cells must be available. 
(c) J11ethylumbelliferyla-D-glucopyranoside as substrate. Incubations with this 
substrate have been carried out at 37o and a substrate concentration of 2.2 mM which 
is about the maximal solubility. The Km for cultured fibroblasts was found to be 
3.6 mM. Methylumbelliferyl-glucopyranoside yields a fluorescent product which can 
be measured with greater sensitivity than a coloured substance. The minimum amount 
of methylumbelliferone which could be measured in a 500 .ui final volume under ex-
perimental conditions is about ro-12 mole. However, this does not necessarily mean 
that this amount of product can be accurately determined in an enzyme assay on 
cultured cells. Like in-any other fluorometric reaction, the sensitivity which can be 
attained for a given final volume and fluorometer design mainly depends on the blank 
value. This latter can be reduced by decreasing the incubation volume as this results 
in less nonspecific fluorescent material as well as less fluorescence from spontaneously 
hydrolysed substrate. The iilflue:r:ce of a decrease in incubation volume and final 
volume on the minimum amount of methylumbelliferone that can be detected has been 
investigated in the following way. Different amounts of methylumbelliferone were 
dissolved in varying volumes of 2.2 mM methylumbelliferyl-o::-D-glucopyranoside and 
incubated during r hour at 37o. Subsequently the samples were diluted with 0.5 M 
carbonate buffer to different final volumes. In 5 ml and 500 pi volumes the fluores-
cence at 448 nm was measured with a conventional fluorometer and in volumes of 50, 
TABLE II 
~NFLUENCE OF INCUBATION VOLUME AND FINAL VOLUME ON THE SENSITIVITY OF THE FLUORO-
METRIC ASSAY OF METHYLUMBELLlFERYL SUBSTRATES 
Amount of methyl- Incubation Final Blank Measurement 
umbelliferone in 2.2 M volume volume % transm. % transm. 
M. U.-glucoside 
"' "' 
Conventional 750 ro-u mol. 30 5000 '5 37 
fluorometry 750 Io-13 mol. 30 soo U7 353 
75 Io-13 mol. 30 soo U7 4' 
75 Io-13 mol. 3 soo '5 37 
7-5 Io-13 mol. 0.3 soo 3 4 
Microscope 7-5 I0-13 mol. 0.3 so 
'' 
42 
fluorometry z Io-13 mol. 0.3 w 83 z6 
z ro-13 mol. 0.05 5 33 s6 
ro and 5 ,u:l by microfluorometry. The results in Table II indicate that for measure-
ments with a conventional fluorometer the incubation volume must be reduced to 
0.3-3 pi in order to be able to detect ro-11-ro-12 mole of methylumbelliferone. Even 
then the difference between the measurement and the blank value is very small. 
Greater sensitivity can be obtained by also reducing the final volume and thus in-
creasing the concentration of the fluorescent product. As shown in Table II the 
ratio between measurement and blank value improves when the reduction in final 
volume is combiRed with a further decrease in incubation volume. By combining in-
cubation b 0.05 ,t.d of substrate under paraffin oil and measurement of the fluorescent 
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product in a 5 ,ul final volume using microfiuorometry less than ro-13 mole methyl-
umbelliferone can be detected. 
As the a-glucosidase activity in normal cultured fibroblasts is in the order of 
ro-u mole· hour1 per cell it can be predicted that only a few tenths-hundreds cul-
tured cells are sufficient for a reliable assay provided that the incubation volume is 
kept small. In Fig. 3 the relation between the amount of methylumbelliferone formed, 
and the number of cultivated amniotic fluid cells is illustrated. In agreement with the 
expectation based on the model experiments from Table II the a-glucosidase activity 
could be detected in as little as zoo-300 cells when r pl cell homogenate was incubated 
in 2 ,ul substrate. After incubation during r hour measurement of methylumbelliferone 
was performed after dilution to a final volume of 500 pl. The activity found for normal 
cultured amniotic fluid cells was about ro fold less than with maltose as a substrate. 
Fluorescence 
300 (%Tr:-448nm) 
'" 
""' 
oo 
bla~·""c._-,,;i;,;;----;,~ooo---,wO:o>ioc--->.,ooo~----,,,;ooooo. 
Cell number 
Fig. 3· IX·I,4-Glucosidase activity in cultured amniotic fluid cells using methylumbelliferyl-ll:-D-
glucoside as a substrate (3 p:l inc. vol., 500 p:l final volume). 
Again, for a reliable prenatal diagnosis more cell material will be required to 
enable triplo measurements and to make a proper distinction between an enzyme 
deficiency and a decreased a-glucosidase activity as present in cells from heterozygous 
carriers. As a consequence, using methylumbelliferyl substrate about rooo amniotic 
fluid cells are required for a prenatal analysis using microliter volumes for incubation 
and 500 ,ul final volume. For a parallel protein assay another 3000 cells must be avail-
able. 
Further increase in the sensitivity of the methylumbelliferyl assay can be 
obtained by longer incubation periods as it was found that the reaction is linear up 
to over 8 hours. Another possibility is a further reduction of the incubation volume 
(down to 0.05 pl} and measurement of the fluorescence in small final volumes (about 
ro-50 pl} using microcapillaries and a microjfuorometer design. According to the 
model experiments in Table II this procedure nearly allows a-glucosidase analysis 
down to the single cell level. However, in prenatal diagnosis based on studies of cell 
hornogenates such extreme sensitivity of the enzyme assay is irrelevant, because of the 
necessity of a parallel protein determination which requires at least a few thousand 
cells. To ·avoid this disadvantage a method has been developed for a direct a-gluco-
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sidase analysis on isolated groups of freeze-dried cells thus enabling the expression of 
the enzyme activity per cell instead of per unit weight protein. 
( z) Microchemical analysis on microdissected clones of freeze-dried cells 
(a) Preparation and microchemical analysis of normal freeze-dried cultured cells. 
For those enzyme assays with a sufficient sensitivity to allow the analysis of a few 
tenths~ hundreds cells the enzymatic acitvity can in principle be expressed per single 
cell. This requires th.e isolation of a counted number of cultivated cells without any 
detrimental effect on the activity of the enz:yn1e to be analyzed. Methods originally 
described by Lowry11 for the isolation and microanalysis of tissue structures have 
bee:h adapted for the ilivestigation of small groups of cultured cells. The procedures 
followed are described in the paragraph MATERIAL AND METHODS and Fig. 4 illustrates 
the main steps·. 
In vitro cultivation of established amniotic fluid cell strains or :fibroblasts used 
as controls in prenatal diagnosis should be done in such a way that the cell density is 
not too large to avoid erroneous cell counting. On the other hand the cell density should 
not be too small because the minimum number of cells (about 70-r2o cells) required 
for a reliable a-glucosidase assay must be present on an area of about 0.2-r mm2 of 
plastic foil on which the cells have grown. A piece of plastic foil with larger dimensions 
does not :fit into the incubation volume of 0.3-r 1-tl, which is necessary for a reliable 
fluorometric assay. In our hands seeding of about 100 ooo cells in 4 ml per "mylar 
in yitro cultivation 
on plastic foil 
quick freezing 
freeze -drying 
(12 h. at-45"C; 10-3mm.Hg.) 
microdissection of 
plastic toil with 
counted number of cells 
incubation in small volumes 
(0.3-3.0 JJO under paraffin oil and 
microscopic control 
introduction of incub. volume in 
capillaries or dilutiQn in buffer · 
reading extinction or 
fluorescence in 
(micro) spectra-fluorometer 
Fig. 4· Methods for microchemical analysis of small numbers of freeze-dried cells. 
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dish" and grown for 2-3 days usually gave the right cell density. In primary cultures 
of amniotic fluid cells as used in prenatal diagnosis the situation is more favorable as 
the first clones (after about 7-10 days cultivation) usual consist of closely packed 
epithelial like and for fibroblast like cells, which are still sufficiently separated to allow 
accurate counting. 
After freeze-drying the morphology of the cultured cells was found to be well 
preserved and under a stereomicroscope certain differences in structure, like different 
cell types within the same culture may well be detected. Free-hand microdissection 
of ro-rs groups of roo-200 cells can be carried out within an hoUr and during this 
period and even up to 2 days there are no changes in a-glucosidase activity in the 
lyophillized cultured cells. 
To investigate if the lysosomal enzyme a-glucosidase is sufficiently liberated 
into solution and accessible for the substrate, when a piece of foil containing freeze-
dried cells is directly incubated without previous homogenization, the following 
In vitro cultivation of amniotic fluid cells 
l 
I 
I 
Cell homogenate 
(sooooo cellsfml) 
I 
I 
5 ~tl for 
protein anal. 
(2500 cells) 
10 ,ul for 
enzyme assay 
(sooo cells) 
I I 
12.1 x lo-7 gm 
L1E in 6o ,ul 
(2 hr inc.) 
o.o8o 
a-1,4-glucosidase activity 
per min fmg protein 
3.0 x w-9 mole. 
Freeze-dried on plastic 
foil (so.ooo cells) 
I 
Incubation in 200 ,ul buffer, 30 min 20°C 
5 ,ul for 
protein anal. 
(1250 cells) 
I 
10 ,ul for 
enzyme assay 
(2500 cells) 
I 
L1E in 6o ,ul 
(2 hr inc.) 
0.041 
a,1,4 glucosidase activity 
per min/mg protein 
3.1 x lo-9 mole. 
Fig. 5· Determination of a-1-4 glucosidase activity in small numbers of cultivated amniotic 
fluid cells. 
experiment was designed (Fig. 5). Control amniotic fluid cells were cultivated on 
plastic foil (for tills purpose a culture dish was used, designed by Dr. P. HCsli) and 
after freezing and freeze-drying a strip of foil containing a known n11Ihber of cells was 
transferred into zoo ~1 acetate buffer. After 30 min at 20° a ro p;l aliquot of the buffer 
was used for an a-glucosidase assay (using maltose as a substrate) and a 5 ,.ul sample 
for detennination of the protein content. From the two values obtained the specific 
a-glucosidase activity in the buffer solution was found to be 3.1 X ro-9 molesjrninfmg 
protein (Fig. 5). This value corresponds remarkably well with the a-glucosidase 
activity determined in a . cell homogenate prepared from the same cell strain at the 
same time (3.0 x ro-9 molesjminjmg protein)·. These data indicate that the interaction 
between a-glucosidase and substrate after direct incubation of a piece of plastic foil 
containing freeze-dried cells is comparable to that in a conventional assay on cell 
homogenate. 
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TABLE III 
IX-GLUCOSIDASE ACTIVITY IN DISSECTED CLONES OF FREEZE-DRIED CULTURED FIBROBLASTS 
Number of Cells 
Control Pompe 
wo no 
So >70 
65 ws 
75 >50 
>OO 12"0 
gs go 
65 70 
70 70 
So So 
So So 
ss ss 
70 go 
Fluorescence a-Glucosidase activity 
(% transm.-blank value*) (xro- 14 mole M.U. h-1 per cell) 
Control Pompe 
20 2 
'7 0 
'3 0 
•6 2 
30 g 
24 25 
20 
u 0 
'5 0 
'7 0 
32 0 
'5 0 
Control 
2.6 
2.6 
2.6 
2.7 
3-g 
3·3 
4·0 
2.2 
2.5 
2.6 
4·7 
2.8 
g = 3·0 
S.D.= 0.7 
Pompe 
o.g 
3-4 
no detectable activity 
in >So% of the samples 
*.Fluorescence values of ro empty pieces of plastic ranged from 2-5 with a mean of 3% transmis-
swn. 
(b) a-Glucosidase activity in dissected freeze-dried cells and comparison with cell 
homogenates from controls, patients with Pompe's disease and heterozygote carriers. 
Fibroblasts from a normal control and a patient with Pompe's disease were cultivated 
on mylar dishes. The a-glucosidase activity was determined by microchemical 
analyses of 10-12 pieces of plastic foil containing a counted number (65-170) of cells 
using methylumbelliferyl-glucoside as a substrate. The results in Table III show that a 
clear distinction between these two categories of cells is possible using the micro-
TABLE IV 
IX-GLUCOSIDASE ACTIVITY IN CULTURED CELLS FROM CONTROLS, PATIENTS WITH l'OMPE'S DISEASE 
AND HETEROZYGOTES 
Control fibroblasts 
Control amniotic 
fluid cells 
Heterozygous 
:fibroblasts 
Pompe fibroblasts 
Dissected groups of freeze-dried 
cells from one cell strain 
(3 exp.) *Mean activity 
x ro-14 mole· h-1 per cell 
4.0 ± I. I 
4·7 ± 2.0 
3·0 ± 0.7 
2.1 ± 0.9 
2.8 ± I.O 
r.s ± o.6 
2.0 ± I.6 
r.o ± o.8 
2.> ± 1.8 
< o.s 
< o.s 
<o.s 
Cell komogenaies from 
different cell strains** 
Mean activity Activity range 
X ro-14 mole·h-1 X ro-n mole·min-1 
per cell per mg protein 
4·0 8oo-34oo (n = 5) 
2.0 j9o--rno (n = 5) 
2.2 414-2120 (n = 5) 
0.04 w- so (n = 4) 
* From each cell strain 3 independent experiments were carried out, each consisting of a-glucosid-
ase analysis in 8-18 pieces of plastic foil containing 7o-26o cells each. 
* * The mean a-glucosidase activity has been determined from analyses in triplo on cell homo-
genates from 4-5 different individuals; the range of the values is presented in the right column. 
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techniques described. For the ~solated groups of nmmal fibroblasts consistently 
higher fluorescence values than the blanks (empty pieces of plastic dissected adjacent 
to the cells) were ·observed and a mean activity of 3 X ro~umole · h-1 per cell was 
found. In 10 out of 12 groups of cells from the patient with Pompe's disease no 
a-glucosidase activity coUlO- be detected which means an activity of less than 
0.5 x Io-14 mole · h-1 per celL 
In Table IV the a-glucosidase activity in dissected groups of freeze-dried cells is 
compared with that in cell homogenates from corresponding cell strains. From 
fibroblasts of controls, patients with Pompe's disease and heterozygote carriers and 
from control amniotic fluid cells one strain was used for microanalysis of freeze-dried 
cells in three independent experiments. The results were compared with ana1ytico.l 
data from cell homogenates obtained from 4-5 individuals in each category. The 
results in the first column of Table IV show that there is quite a variation between the 
experiments within one cell strain and also between the a-glucosidase activity in 
different groups of cells. It is, however, possible to distinguish the enzyme activities in 
control fibroblasts and deficient cells whereas fibroblasts from a heterozygote give 
intermediate values comparable to those in normal amniotic fluid cells. Similar 
differences are observed in the studies on cell homogenates, shown in the last column 
of Table IV. For each category of cells, except those from patients with Pompe's 
disease there is a wide range in the enzyme activity between different individuals. 
The analytical data obtained by microchemical analysis of small groups of 
freeze-dried cells correspond very· well with those obtained on cell homogenates when 
the latter are expressed per celL This latter value is calculated by supposing that I mg 
protein corresponds to 3 ·I06 cells. This supposition is based on eXperiments where the 
cell number after trypsinization has been related to the- protein content after homo-
genization and also on direct microinterferometric measurements of the dry mass of 
single cells22 • The level of detection in the microchemical analysis of a few hundred 
freeze-dried cells under the experimental conditions of the experiment in Table IV 
only allows the conclusion that in cells from patients with Pom:Pe's disease the a-glu-
cosidase activity is less than 5 ·ro-15 mole· h-1 per cell. In studies on cell homogenates 
the exact value of the deficient activity was found to be in the order of 4 -I0-16 mole · h-1 
per celL 
The experimental data obtained indicate that the microchemical analysis of 
a-glucosidase activity in small groups of freeze-dried cultured cells gives reliable 
results compared with conventional analytical prOcedures. The method developed 
thus offers the possibility of rapid prenatal diagnosis of Pompe's disease because the 
small number of amniotic fluid cells now required for analysis will be available within 
7-ro days after amniocentesis. 
DISCUSSION 
Methods for prenatal diagnosis of chromosomal aberrations and about 30 inborn 
errors of metabolism have been developed (see for reviews:>-3-25). The application of 
these methods gains increasing interest of centers involved in the genetic counseling 
of families with a high genetic risk. It has been established that the most suitable 
period for transabdominal amniocentesis is between the 14th-r6th_ week of pregnancy 
because at this stage sufficient amniotic fluid is available and the number of viable 
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fetal cells present in most cases allOw a successful in vitro cultivation24 •26 • The pre-
natal diagnosis of metabolic disorders requires biochemical analysis of the speci~c 
enzyme defect or the. detection of specific accumqlated metabolites. Using conven-
tional analytical techniques rocro8 cultured amniotic fluid cells corresponding to 
about 0.3-30 rng protein must be available. As a result the cultivation period and 
hence the waiting period for the parents involved has been 4-6 weeks for most pre-
natal diagnoses and in some instances, like in the analysis of cystinosis and muco-
polysaCcharidoses even uP to 8-ro weeks 27 ·28 • Prenatal diagnosis of glycogenesis type 
II (Pompe's disease) required about 5 weeks5 •6 . AlthOugh parents with a high risk for 
an affected child are usuallY strongly motivated to have a prenatal diagnosis, in our 
opinion it is advantageous to accomplish the analysis before the mother has felt child 
movements, i.e. before the r8th week of pregnancy. 
By adapting prepa1ation procedures and microchemical analytical techniques 
which have mainly been developed for histochemical investigation on tissUe sections 
(refs. II, !2, 14, 20), a considerable reduction in the number of cultured amniotic fluid 
cells required for prenatal analysis can be obtained8 • 15 • 16 . 
The use ·of freeze-dried cultured cells for direct microchemical analysis was 
found to give results comparable to those from conventional studies on cell homo-
genates (Fig. 5 and Table IV). As a consequence a protein determination can be 
avoided in the prenatal diagnosis of those enzyme defects which can be analyzed in a 
few hundreds of cultured cells. To obtain such sensitivity both in spectrophotometric 
and :fiuoromehic reaCtions a reduction of the incubation volume is required. In spectro-
photometry also the final volume has to be reduced and depending on the enzyme 
activity and the assay used, extinction measurements in volumes of less than 20-
50 pl may be required. In such instances microcuvettes adapted to commercialspectro-
. photometers can no longer be used and a microscope spectrophotometer design has to be 
applied. Our analyses of p-nitrophenol using microspectrophotometry have shown 
that a 30-60 fold increase in sensitivity can be reached compared with a 6o J.ll volume 
using normal spectrophotometry when measurements are cmried out in I J.ll (Fig. 2 
and Table I). In this way a sensitivity could be reached which is comparable to that 
of a :fluorometric assay using a metl,1ylumbelliferyl substrate. 
Generally fluor ometric procedures will be preferred because in many instances 
the final measurement can be performed in a normal fluorometer. As far as the use of 
methylumbelliferyl substrates is concerned the minimum amount of fluorescent 
product detectable with a normal fluorometer is in the order of IO·-u-1o-12 moles, 
provided that small incubation volumes (0.5-1 pl) are used (see Table II). If the ac-
tivity of the enzyme to be analyzed is in the order of ro-12 to Io-14 mole·h-1 per cell a 
direct analysis of a few hundred isolated freeze-dried cells according to the procedure 
described can easily be performed. This was so far found to be the case for about 
6 l)rsosomal storage diseases which can be analysed with methjlurnbelliferyl sub-
strates8. For these diseases and for some defects that can only be detected by a 
(micro)spectrophotometric assay prenatal diagnosis can be accomplished within 
7-20 days, depending on the enzyme defect. 
However, one of the main problems in prenatal diagnosis of metabolic disorders 
with an autosomal recessive inheritance is the difficulty of a clear distinction between 
cultured amniotic fluid cells with an enzyme deficiency and those with a decreased 
activity from a heterozygous carrier. The few examples presented for Pornpe's disease 
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(Table IV) show that clear distinction between these two categories of cells is possible 
when the mean activities are compared. But within the wide range of activities for 
each cell type, very low values may be encountered in cells from a heterozygous 
carrier. The sensitivity of the assay must therefore be sufficient to detect such low 
values to avoid erroneous interpretations. The results of the model experiments using 
microfluorometry (Table II) indicate a possibility to obtain further increase in sen-
sitivity of the detection of methylumbelliferone. 
By using these micr-ofiuorometric techniques, certain lysosomal enzyme activi-
ties can even be measured quantitatively in one single cultured cell. This will provide 
new possibilities for more fundamental studies on metabolic cooperation and genetic 
complementation at the single celllevel2- 31• 
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1. Summary 
A better understanding of the variation in lysosomal enzyme activities (2 - 7 fold 
differences) in cultured cells from controls, heterozy.gotes and affected patients, is impor-
tant both in (prenatal} diagnosis of metabolic diseases and in fundamental studies on ·somatic 
cell genetics and metabolic interaction. 5 - 10 fold variations in the activity of acid 
o(-1.4-glucosidase and ,8-galoctosidase were observed in relation to the growth curve of 
the culture (2 - 30 days after lost subculture), Considerable differences in lysosomal 
enzyme activity were also found between various cell groups and between individual cells, 
using microchemical techniques. These differences are probably related to proliferative 
activity and phase in cell cycle, Experiments on co-cultivation (2 - 12 days) of normal 
and enzyme deficient cells showed no indication of metabolic co!jperation for o(-glucosi-
dase and ,4-galactosidase. In the analysis of two cell populations within the some culture 
it must be realized that selection at the advantage of both normal and enzyme deficient 
cells may occur as was shown by model experiments on G6PD activity in single cells from 
subcultures of a heterozygote for the X-linked G6PD deficiency. Finally, the role of 
genetic heterogeneity was studied in fibroblasts from patients with various types of GM1-
gangliosidosis using complementation analysis in individual binuclear heterokaryons after 
cell hYbridization, 
2. Introduction 
During the last few years the genetic defect for an increasing number of lysosomal 
storage diseases has been demonstrated in cultured skin fibroblasts. Cultured cells have 
become an important tool in the postnatal and prenatal diagnosis of patients with inborn 
errors of metabolism and in the detection of heterozygous carriers 1 Furthermore they 
provide a useful model in basic studies on the capacity of uptake of specific enzymes by 
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mutant cells2- 7• Also, the use of cell hybridization of cultured fibroblasts from patients 
with an apparent similar enzyme defect may contribute to a better understanding of the 
. h . . b 1· d" S-l O genetrc eterogenerty rn meta o rc t~eases • 
For a correct interpretation of the analytical data both in (prenatal) diagnosis and 
in fundamental studies, exact knowledge is reguired about the background of the variations 
observed in most enzyme assays on culture·d human cells 11 - 19 • The present communication 
deals with studies on the variation of lysosomal enzyme activities in cultured human cells 
under different experimental conditions. The effect of different in vitro growth conditions 
. 20-22 
was shJdied and microchemical technrques enabled us to investigate at the single cell 
levelr the effect of co-cultivation of normal and enzyme deficient cells and the behaviour 
of two cell populations within the same culture from a heterozygous carrier for an X-
linked metabolic disease. When combined with somati·:: cell hybridization techniques the 
microchemical assay procedures also allowed complementation studies on individual 
binuclear heterokaryonsr which provides more information about the 
f I f 23, 24 h . I d b or a particu or enzyme de ect . T e expenmenta ata to e 
genetic heterogeneity 
presented here will 
mainly be restricted to the lysosomal enzymes acid o{-1.4-glucosidase and f)-galactosi-
dase. 
3. Materials and Methods 
Fibroblasts derived from skin biopsies from controlsr heterozygous carriers for 
glycogenesis II (Pompe's disease) and glucose-6-phosphate dehydrogenase (G6PD) deficiency 
and from patients with Pompe's disease and patients with GM ]-gangliosidosis type 1 and 2 
were cultured according to procedures describe~ earlier 19 ' 21 r 22 . Amniotic fluid cell 
cultures from normal pregnancies and pregnancies at risk for Pompe's disease were initiated 
from 5 - 10 mi. samples of amniotic fluid obtained by transabdominal amniocentesis at the 
19, 21 14 - 16th week of pregnancy 
Studies on the effect of different in vitro growth conditions on the activity of 
lysosomal enzymes were performed by seeding a!iquots of about 105 human fibroblasts from 
early passages into 35 mm Falcon petri dishes and cultivation in Ham's FlO mediumr 
supplemented with 15% fetal calf serum which was replaced three times o week. After 
2r 4r lr lOr 14, 22 and 30 days replicate cultures were harvested and the protein 
content and the lysosomal enzyme activities were determined. The procedures of cell 
homogenate preparation and of the microchemical assays for protein and for .c/...-1.4-
g[ucosidase and ;.J-galactosidase activity using methylumbelliferyl substrates have been 
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describ~d previously 21 ' 22' 24 The activity of the same enzymes has been determined at 
various time intervals (16 - 55 days) after primary culturing of normal amniotic fluid cells. 
The 'tariation of c(-1.4-glucosidase and ;d-galactosidase activity in individual fibro-
blasts within the same culture dish has been analyzed by microdissection of single freeze-
dried cells which had been grown on the thin plastic foil which formed the bottom of the 
culture dish. Details of this isolation procedure, the incubation of single cells into micro-
droplets of substrate under paraffin oil and the subsequent measurement of the fluorescence 
intensity of the methylumbelliferone formed, by using microcapillaries and a microspectro-
fluorometer design hove been described elsewhere20 - 22 
As a model for the behaviour of two cell populations (with normal and deficient 
enzyme activity) within the some fibroblast culture of a heterozygous carrier of an X-
I inked disease, the distribution of G6PD activity in single cells was analyzed in successive 
subcultures of a cell strain from a heterozygote for G6PD deficiency. About 6-104 cells 
from each subculture were seeded into a "5 em p5 myla.r dish" with a thin plastic bottom 
and after two days in vitro growth the G6PD activity in randomly dissected individual 
. 23 24 25 
cells was analyzed using a NADP(H) cycl1ng method ' ' 
The occurrence of metabolic cotlperation between normal and enzyme deficient cells 
was studied by co-cultivation of equal numbers of control fibroblasts with fibroblasts from 
patients with Pompe's disease (o(-glucosidase deficient) and with type 1 GM-1 gangliosi-
dosis. Co-cultivation of 8.105 cells from a subculture of both cell strains was 
carried out in Falcon flasks during 2 - 12 days, At various time intervals cells were 
harvested and the protein content and the activity of 4 -galactosidase and o(-glucosidase 
were determined. About 3 - 6. 104 cells of the mixed population after different time 
intervals of co-cultivation were seeded into a "mylar dish" and the 0\.-glucosidase or j3-
galactosidase activity was analyzed in randomly isolated freeze-dried cells after two days 
further in vitro growth. The enzyme activities of cells in the mixed cell population were 
compared with those of both original cell strains, 
The genetic heterogeneity of jl-galactosidase deficiency in patients with different 
clinical forms of GM1 ganglisosidosis was tested by complementation studies in individual 
binuclear heterokaryons. Cell hybridization with Sendai virus waS- carried out V·'ith 106 cells 
of both parental cell strains according to procedures described earlier9 ' 24 • Subcultures of 
(J -galactosidase deficient fibroblasts from patients with GM 1-gangl iosidosis type 1 and 2 
were fused and 3 - 4. 104 cells of the hybridized population were seeded into a "mylar 
dish" and grown for two days. Subsequently the medium was washed off the dishes were 
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freeze-dried and 40- 80 binuclear heterokaryons were randomly dissected. Their/)-
galactosidase activity was determined with a microassoy using 1 mM methylumbelliferyl-
t1 D I "d H 4 2 b 22, 24 Th . " II fV- -go actopyranos1 e at p . as a su strate . e actiVIty per ce was 
compared with that of mononuclear and binuclear cells from normal and hybridized cells 
of control cell strains. 
4. Results 
a. Variation in lysosomal enzyme activity in homogenates of fibroblast and amniotic 
fluid cell c,dtures from controls, heterozygotes and affected patients 
In table 1 the results are presented of a large number of assays for acid o(-1.4 glucosi-
dase activity in fi.~roblasts from various controls, heterozygotes and patients with glyco-
genesis II and in cultured amniotic fluid cells. Cell cultivation was carried out under 
identical conditions but they were harvested and analyzed at different time intervals after 
the last subculture. 
Table l 
d.....-1.4-Giucosidase activity in cultured amniotic fluid cells and in fibroblasts from controls 
heterozygotes and patients with glycogenesis II (Pompe's disease)* 
o<.-Giucosidase activity (x T0- 12mole/min/mg.protein) 
Control fibroblasts 3900 2645 956 1440 
Heterozygou~ fibroblasts 353 480 1654 169 215 158 
Pompe's fibroblasts 25 18 26 38 10 
Control amniotic fluid 603 1227 642 714 1770 
cells, later subculture 
Control amniotic fluid 261 479 414 121 754 
cells, primary culture 
*Each value represents the mean enzyme activity obtained from 2 - 5 analyses of one cell 
strain. Activities for different cell strains within each category are presented. The lowest 
and highest activities for each category of cells are underlined. 
The data show that for each category of cells there is considerable variation among the 
mean enzyme activities in cell strains from different individuals. The extreme values 
within each category may differ 300 - 500%. The greatest variation seems to exist in 
cells obtained from various heterazygotes (not belonging to the some family). However, 
in table 1 the data for each cell strain represent the mean of 2 - 5 independent analyses 
and as is shown in table 2 there may also be considerable variation among analyses on 
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different cultures of the same cell strain. 
Table 2 
Variation in eX-glucosidase activity in various analyses on the same cell strains 
r:/....-Giucosidase activity* (xlo-1 2mole/min/mg.prot.) 
Control amniotic fluid cells 370 - 1049; 659 - 765; 548- 763 
Control fibroblasts 2240 - 5326; 1010 - 1598; 2010 - 3280 
Heterozygous fibroblasts 142 - 475i 131 - 291; 420 - 541 
Pompe's fibroblasts 5 - 29; 22 - 29; 21 - 29; 3 - 24 
*Figures are the extremes 2 - 5 analyses on the same cell strain; results for 
3 - 4 cell strains in each category ore presented. 
As a conseguence, correct interpretation in (prenatal) diagnosis may be difficult i+" this 
must be based on comparison of single enzyme assays on one cell strain from each category. 
This is expecially the case for the detection of heterozygous carriers because the 
enzyme activities in this group may overlap control values (table 1). In prenatal diagnosis 
the distinction between heterozygous carriers and affected patients may cause problems. 
As is shown in table 1 the d.-glucosidase activity in later subcultures of control amniotic 
fluid cells is about three times lower than in control fibroblasts. In primary cultures of 
amniotic fluid cells the enzyme activity may again be 2 - 3 fold lower than in later sub-
cultures and if the same ratio's hold for cells from heterozygotes the enzyme activity in 
primary cultures of amniotic fluid cells may be very low (TO - 15% of fibroblast values) 
when the fetus is a heterozygous carrier. 
The variation in enzyme activity as described above has also been observed for a 
number of other lysosomal enzymes. The effect of the cell population growth curve on the 
activity of fJ -N-ocetylglucosominidase, arylsulphatase A, o/.-galoctosidase, ,~(}-glucosidase, 
;{J-galactosidase and cX_-glucosidose has been investigated by one of us (M.H.-D). 
Detailed results will be published elsewhere but as the data obtained were guite similar for 
all lysosomal enzymes investigated we will only present those for C>(-glucosidase and fJ-
galactosidase. Fig. 1 shows the results for the specific (.!-galactosidase activity in a 
normal fibroblast strain. The protein content per dish as well as the specific jJ -galactosi-
dase activity continue to increase up to the end (30 days) of the observation period. There 
is on 8 fold! increase in enzyme activity between day 2 and 30 after the lost subculture. 
In other experiments with a higher initial cell density the increase in protein content came 
to a stop earlier but the (J -galactosidase specific activity continued to increase. Primary 
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amniotic fluid cell cultures do not show a correlation between specific lysosomal enzyme 
activity and culture time. 
I• l ,., 
IJ-Galactos,daSl' Total protl'in 
activoly pt>r dish 
0.9 
500 08 
0.7 
375 0.6 
05 
250 0., 
OJ 
"5 02 
o.• 
• 
• 
days alter subcultovatian 
j}-goloctosidase activity 
• is expressed as ]Q-Bmoles/ 
hour/mg protein. 
Protei~ content is expressed 
as 1 o- g per dish 
Fig. 1 Increase in ;J-galactosidase activity during the growth of normal fibroblasts, 
Fig. 2 shows similar results for the activity of acid c(-1.4-glucosidase which more 
or less linearly increases with a factor 10 from 2 to 30 days after subcultivation. Also 
in cells from heterozygous carriers there is an increase in enzyme activity during the 
growth curver although when investigated for several cell strains, the increase stOems to 
be less steep than in controls. The c<-glucosidase activity in fibroblasts from patients with 
Pompe's disease remains low during the whole observation period. From these results it may 
be concluded that in comparative studies of lysosomal enzyme activities standardization of 
the cell density and the time between seeding and harvesting of a culture is very 
important. 
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n-glucos•das .. 
aclnnly 
" 
D(-glucosidase a9tivity is 
expressed as 10- moles/min/ 
mg protein, 
• " conlrols 
• o ~,..l,.rozygotes 
.,. ,. pompe pall<'nls 
>----<r-
IO 1.1. 22 30 
days after subcull•vot•on 
Fig. 2. Increase in acid 0\-1.4-glucosidase activity during the growth of fibroblasts 
derived from controls, heterozygous carriers and patients with glycogenesis II. 
b. Variation in lysosomal enzyme activity in single and small numbers of cultured 
cells. 
Small groups (100 - 300) of freeze-dried cultured cells can be isolated and analyzed 
and the enzyme activity can be expressed per cell without the need of parallel protein 
assays. This method allows enzyme assays on various groups cells within the same culture 
dish. An example of such analysis for acid c<.-7.4-glucosidase activity in groups of 110-
260 cells from a primary culture of amniotic fluid in the same dish is illustrated in table 3. 
Table 3 
Acid cl.._-1.4-glucosidase activity* in small groups (100 - 300) of freeze-dried amniotic 
fluid cells isolated from one culture dish 
Number of cells per isolated group 
r::J...-1.4-Giucosidase activity per cell 
(x 10-14 mole;hour) 
170 190 110 170 160 140 260 170 160 
3.2 2.4 4.2 2.1 1.5 2.4 1.1 1.7 1.6 
*Er.zyme activity has been detennined by incubation during l hour at 3T>C in 3 )-l-1 
2.2 mM 4-Methylumbelliferyl-o<..-D-glucopyranoside pH4.0. 
The results indicate that even within one culture dish there is considerable variation in 
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o( -glucosidase activity when different cell groups are compared. Similar observations have 
been made for other lyso~omal enzymes (o<'.-galactosidase, iJ -galactosidase). The errors in-
volved in the microchemical assay have been determined to be less than 10% 22 and the 
error in cell counting is 10 - 15%. Apart from these factors the variation in enzyme 
activity might be related to local differences in proliferative activity and unbalanced 
growth within one culture dish. 
The activity of a number of lysosomal enz)'TT1es can also be determined in individual 
~c~u~lt~u~c~e~dc.::c~e~llo;:s. With the microtechniques mentioned this applies to 
per cell -14 exceeds 10 moles methylumbelliferone formed per hour. 
enzymes which activity 
Fig. 3 and 4 illustrate 
respectively the .,.a-galactosidase and c(-1.4-glucosidase activities in single cells randomly 
dissected from one dish at two days after seeding of about 4.104 cells of an early passage 
of normal human fibroblasts. The results indicate that 'also among individual cells there is 
considerable variation in enzyme activity. Both for c(-1.4-glucosidase and ;6-galactosidase 
the difference between the lowest and highest activity is a factor of 5 - 7 and in other 
(non-lysosomal) enzymes tested we have even observed greater variation. These differences 
might be related in part to differences in the phase of the cell cycle of the analyzed 
cells. Within one culture dish there exists also a considerable variation in the total 
cellular dry mass of individual celli2 r 26 and the differences in enzyme activity might 
he less if they were expressed on the basis of the cellular dry mass of each particular 
cell. 
Frequency 
- Frequency 
" 
!0 -
n:41 
i"' 2.6x1 o-13 mole/hr./cell 
-
s d:l.fo 
n:48 
-
-
i .. 9.9mole/hrlcell 
I-- - Sd:4.5 
-
I-- - ,--
--,---- -
-
0 
0 07 1_4 21 2_8 JS 4.2 4.9 5.6x10 13 mole 
! h 
-
0 
18 xiO 14 mole 0 8 !0 !1 4 6 !4 !6 
!1-Galactosidase activity oc-1.4.Glucos'tdase acttv•ly 
Fig. 3, Variation in ~-galactosidase activity of single cells from a normal fibroblast culture. 
Fig. 4. Variation in acid o(-1.4-glucosidase activity of single cells from a normal fibroblast 
culture. 
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c. Behaviour of two cell populations with different enzyme activities within one culture. 
The study of the behaviour of two cell populations within one culture is of practical 
importance in (prenatal) diagnosis of heterozygotes for X-linked metabolic diseases. Also 
in more fundamental studies of metabolic cooperation and genetic complementation, the 
analysis of enzyme activities in individual cultured cells from two populations is of interest. 
Examples of each aspect will be presented. 
Equal numbers of subcultures of fibroblasts from a patient with Pompe's disease and 
from a normal control were co-cultivated during 2 - 12 days. Similar experiments were 
carried out with normal fibroblasts and ,;.3-galactosidase deficient cells from a patient with 
GM ]-gangliosidosis. As is shown in table 4 neither for the 0(-glucosidase nor for the 
(<3-galactosidase deficient cell strains any residuai activity could be detected. After 
various periods of co-cultivation with equal numbers of normal fibroblasts no indication was 
obtained for metabolic co~peration. The specific activity of both lysosomal enzymes in the 
mixed population was found to be about half of that of the normal control fibroblasts 
grown under similar conditions. However, in this type of experiment differences in protein 
content of both co-cultivated cell strains might complicate a correct interpretation of the 
data on enzyme activity. 
Table 4 
Specific activity of lysosomal enzymes in cell homogenates after co-cultivation of nonnal 
and enzyme deficient human fibroblasts 
('-Galactosidase activity ci._-Giucosidase activity 
Norma I fibroblasts 
Enzyme deficient fibrobl. 
After 2-4 clays co-cultivation 
After 7-9 days co-cultivation 
After 12 days co-cultivation 
-9 (x 10 mole/hour/mg. protein) 
270** 
not detectable 
102 (41%) 
141 (52%) 
44, 248* 
not detectable 
19 (43%) 
80 
116 (47%) 
*Data obtained 2 and 12 days after subcultivation of the same cell strain. 
**Grown for 4 days. 
Similar experiments on co-cultivation were carried out but foliowed by enzyme 
analyses on individual cells which were randomly selected from the mixed cell population. 
In the case of ;{J-galoctosidase such as~ays were performed two days after seeding of 
equal numbers of normal and enzyme deficient cells in a "mylar dish". The results in 
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Fig. 5 illustrate the presence of a considerable number of enzyme deficient cells between 
cells with a normal ;J-galactosidase activity. The distribution of enzyme activity per cell 
in the latter resembles that in a normal cell strain. In the case of c(-glucosidase analysis 
co-c~ltivation of equal numbers of normal and enzyme deficient cells was carried out in 
a Falcon flask and after 4 and 12 days cells were trypsinized and about 4.104 cells of the 
mixed ce.ll population were seeded on a "mylar dish". After two days further cultivation, 
individual freeze-dried cells were randomly dissected and their o(-glucosidase activity was 
determined. The results in Fig. 6 indicate that even after 12 days co-cultivation a 
population of enzyme deficient cells remained present among normal fibroblasts. 
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Fig. 5. _,8-Galactosidase activity of single cells isolated from a mixed culture after 2 days co-
cultivation of enzyme deficient fibroblasts from a patient with GMl-gangliosidosis 
(type 1) and of normal fibrol:..lasts. 
Fig. 6. Acid 1:{-1.4-glucosidase activity of single cells isolated from a mixed culture after 12 
days co-cultivation of enzyme deficient fibroblasts from a patient with glycogE;nosis II 
and of normal fibroblasts, 
Another situation where two cell populations are present within the same culture dish 
is in a fibroblast culture from a heterozygous carrier for an X-linked enzyme deficiency. 
As a result of random inactivation of one of the X-chromosomes one may expect 50% of 
cells with a normal activity of the particular enzyme and 50% of enzyme deficient cells. 
We have tested the distribution of normal and enzyme deficient cells in successive sub-
culture fibroblasts from a heterozygous carrier for G6PD deficiency. In table 5 the percen-
tages of cells With normal G6PD activity and of enzyme deficient cells are illustrated in 
successive subcultures of the same cell strain. For each subculture about 4.104 cells were 
seeded in a "mylar dish" and the G6PD activity was analyzed in randomly dissected cells 
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from the same dish after two days cultivation. 
Table 5 
Single cell analysis of G6PD activity in cultured fibroblasts from a heterozygous carrier 
for G6PD deficiency 
G6PD activity (x l0- 12moles;hour/cell) 
Experiment I Experiment II 
- -Subculture G6PD+ cells G6PD cells Subculture G6PD+ cells G6PD cells 
lOth X= 4.0 6th (A) X= 5.6 
n= 28 (37%) n~~ 47 (63%) n= 36 (75%) n= 
12th X= 4.8 9th (A) X= 4.6 
n= 24 (32%) n= 53 (68%) n= 30 (91%) n= 
13th X= 2.0 6th (B) X= 3.1 
n= 20 (25%) n= 60 (75%) n= 36 (75%) n= 
17th x= 2.1 9th (B) X= 3.6 
n= 9 (18%) n= 41 (82%) n= 53 (98%) n= 
*A and Bare cells from different frozen subcultures from the same cell strain. X= 
enzyme activity of G6PD+ cells. n= number of cells analyzed. 
12 (25%) 
3 (9%) 
ll (25%) 
(2%) 
mean 
The results in the left column show that in successive subcultures (from lOth to 17th) the 
percentage of G6PD deficient cells increases at the expense of cells with normal enzyme 
activity. The results of On independent experiment on the same cell strain show that during 
successive subculture also the percentage of G6PD deficient cells may decrease. Selection 
during in vitro cultivation may thus occur at the advantage of both enzyme deficient cells 
and cells with normal activity. This fact is of importance in the interpretation of enzyme 
activity in cultured cells from heterozygotes for X-li nked diseases. 
d. Oenetic heterogeneity studied by complementation analysis in single binuclear 
hybrid cells. 
Apart from the variations in lysosomal enzyme activity resulting from the factors 
mentioned there are genetic factors which determine the clinical and pathological mani-
festations arising from a specific enzyme deficiency and also the (residual) activity of the 
defective enzyme. This genetic background of clinical and enzyme heterogeneity can be 
investigated by complementation analysis in hybridized cultures of fibroblasts from two 
patients with "the some" enzyme deficiency but different clinical manifestations. The 
following experiments illustrate the feasibility of microchemical enzyme assays in individual 
binuclear hybrid cells randomly selected from a culture, two days after fusion of sub-
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cultures of fibroblasts derived from patients with type 1 and type 2 GMl-gangliosidosis. 
In cell homogenates and in individual freeze-dried cultured fibroblasts from both 
types of patients no activity of jJ -galactosidase could be demonstrated with methylumbelli-
feryl substrate, compared with a,n activity of 1 - 2.10- 13 mole/hour/cell in normal 
cultured fibroblasts. Cell hybridization with Sendai virus was carried out between fibre-
blasts from a normal control, between cells from the same patient and between cells from 
the two different patients, Two days after cultivation of the hybridized cell population 
in a "mylar dish" individual binuclear heterokaryons were analyzed for !) -galactosidase 
activity and the results were compared with those of normal mononuclear fibroblasts. In 
table 6 and Fig. 7 and 8 the experimental data are summarized. The t>-galactosidase 
activity in binuclear heterokaryons after fusion of cells from a nolTllol fibroblast culture 
was found to be higher than in mononuclear cells from the same culture (Fig. 7). The 
latter values correspond to those found in a normal, non-hybridized culture, After fusion 
of fJ -galactosidase deficient cells with normal fibroblasts types of binuclear heterokaryons 
were obseiVed which is in agreement with the theoretical expectation (Fig. 8). 
Fr"'qu"'ncy 0 binucl"'ar hybrids x~3.3~1.2 
~ mononucl"'or C€'115 iC: 1 9!09 
11-Golactosodose activity 
' 1 
fl-Gal- hybridS n= 27 
11-Gal' ., n:25(~8'/,) 
X= v:.x10-13 mol€'/hr 
s d=o 1 5 
11-GolactosldosP act•v•ly 
Fig. 7. Gene dossage effect for (<3-galactosidase activity demonstrated by comparing enzyme 
assays on single mononuclear cells and binuclear heterokaryons after cell hybridization 
of normal fibroblasts. 
Fig. 8. Distinction of single binuclear heterokoryons with different levels of ,d-golactosidose 
activity as demonstrated after cell hybridization of normal fibroblasts with fibroblasts 
from a patient with GM 1-gongliosidosis type 1. 
A number of hybrid cells had no ;(3-galactosidase activity, other binuclear cells showed 
an enzyme activity comparable to that in normal mononuclear cells (probably fusions of 
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normal and deficient cells) and the remaining cells hod a high activity (probably the 
result of fusion of two normal cells), These results clearly indicate the possibility of 
detecting within one ceU population binuclear heterokaryons with different levels of lyso-
somal enzyme activity, 
Table 6 
Genetic complementation studies in individual binuclear hybrids after fusion of 
(J-galactosidose deficient fibroblasts from patients with GMl-gangliosidosis 
t pe 1 and t pe 2 
Type of cell fusion 
Control x control 
GMl gangliosidosis 
Type 1 (GM) x type 1 (GM) 
Type 2 (Garr) x type 2 (Garr) 
Type 1 (GM) x type 2 (Gacc) 
,l.l-Galatosidase activity 
-13 (xlO mole/hour ceiO 
;1-Gal- cells ;?-Gal+ cells 
n= 21 
n= 42 
n"" 53 
n= 67 
:x~ 3.3 ;.d. 1.3 
X mean enzyme activity in c\.-ga[+ cells and s.d, is the standard deviation, 
n= number or cells with either a deficient or a normal ;::3-ga lactosidase activity, 
Complementation studi·es carried out between fibroblasts from patients with different 
types of GM1-gangliosidosis have so for not provided any indication for genetic comple-
mentation. In table 6 an example of such experiments illustrate that after fusion of two 
different enzyme deficient cell strains only binuclear heterokaryons were observed with a 
deficient ,J -galactosidase activity, 
5, Discussion 
The large variation observed for d..-1.4-glucosidase activity in different cell strains 
of the same category (controls, heterozygotes or affected patients) is in agreement with 
data on other lysosomal enzymes in cultured fibroblasts and amniotic fluid cells 13 • 14• 17• 
18
, Part of these variations may be explained by the marked effect of the cultivation 
period and the degree of confluency on the activity of several enzymes 11 • 12• 15• 16 
but even when cells are cultured under standardized conditions some of the variation 
remains 14• This variation and the differences in lysosomal enzyme activity between 
cultured fibroblasts, later subcultures of amniotic fluid cells and primary cultures of 
amniotic fluid cells indicate the necessity of using contrd material grown under 
stnndardized conditions when reliable prenatal diagnosis of metabolic disorders is attempted, 
Microchemical assays on groups of 100 - 300 freeze-dried cultured amniotic fluid cells or 
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control fibroblasts show that even within the same culture dish there is an 
. . I I . . be . II 19, 27 venation m ysosoma enzyme activity tween var1ous ce groups , 
appreciable 
Enzyme analyses 
on individual cells (Figs. 3 and 4) also showed considerable variations in activity of o\-
glucosidase and ;3-galactosidase. It seems that these variations in enzyme activity are 
22 28 
related to differences in proliferative activity and in phase of the cell cycle 1 • When 
the enzyme activities as measured in single cells will be related to the total cellular dry 
weighl2' 26 the variation at this level might be reduced, 
In the interpretation of enzyme assays on cultured cells from a heterozygous carrier 
for an X-linked metabolic disease and also on studies of metabolic cotsperation between 
two cell populations precise knowledge about the behaviour of both cell types during 
prolonged cultivation is required. In fibroblast cultures of heterozygotes for various X-
linked metabolic diseases the presence of both enzyme deficient and nonnal cells have 
b d d b I . h . 29 - 31 h . h . I f een emonstrate y c on1ng tee n1ques . T e m1croc em1ca assay o enzyme 
activities in individual cells enabled us to study the behaviour of two ·cell populations 
within the some culture dish. The results obtained for successive subcultures of the same 
fibroblast strain from a heterozygote for G6PD deficiency revealed that selection may 
occur in the direction of both enzyme deficient cells and cells with nonnal activity 
(table 5). Similar experiments on heterozygotes for X-linked lysosomal storage diseases 
may provide further insight in this aspect and also in the occurence of metabolic 
cotsperation between nonnal and enzyme deficient cells27• So far we have not been able 
to show metabolic cooperation for acid oZ-1.4-glucosidase and /)-galactosidase after co-
cultivation of nonnal fibroblasts with cells from patients with Pompe's disease and with 
GMl-gangliosidosis (table 4 and Figs. 5 and 6). These results are in contrast with the 
experimental evidence for metabolic cotsperation between cell strains from patients with 
• f I h 'd . 32 h " d" h I I I vanous types o mucopo ysacc on os1s T e nn 1ng t at severo ysosomo enzymes ore 
d.l t k f h I d" b d r· . II 2 - 6 · d" h rea 1 y a en up rom t e cu ture me 1um y enzyme e 1c1ent ce s 1n •cates t at 
the absence of metabolic cotsperation should be explained by differences in enzyme 
secretion rather than by different behaviour in enzyme uptake. Further infonnotion on the 
possibility of a different behaviour in intercellular transport of different lysosomal enzymes 
4
' 
7 
should be obtained. Attention should also be given to differences in the amounts of 
enzyme added in model experiments and the amounts of lysosomal enzymes secreted by 
normal cultured cells. 
Port of the variation in lysosomal enzyme activity as well as in the clinical and 
pathological manifestations resulting for "the some'' enzyme deficiency seems to be 
genetically detennined. For a number of metabolic disorders the use of cell hybridization 
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techniques followed by complementation analysis for the particular metabolic defect have 
• f . • h . S-lO F d fi . h provided 1n ormation about genetic eterogene1ty • or most enzyme e 1c1ent uman 
somatic cell hybrids there is no selective system and complementation studies must there-
fore be performed on isolated hybrid cells. The applicability of enzyme assays on indivi-
dual binuclear heterokaryons isolated after fusion of two human cell strains with "a similar" 
enzyme deficie-ncy is illustrated by complementation studies on d-galactosidase activity 
after hybridization of fibroblasts from patient with different types of GMl-gangliosidosis 
33 
-
36
. So far no genetic complementation has been observed in binuclear hybrid cells 
after fusion of cells from patients with GMl-gangliosidosis type 1 and type 2. If different 
mutations were present in the same polypeptide chain of the deficient enzyme complement-
ation will not easily be detected. Another unanswered question is whether complementation 
for lysosomal enzymes con be demonstrated in binuclear heterokaryons since we do not 
exactly know how the synthesis and coupling of various subunits of a lysosomal enzyme 
occurs. For a better understanding of the genetic heterogeneity in lysosomal storage 
diseases more information about these fundamental processes is required and also about the 
molecular properties and functions of the normal and deficient (iso)enzymes in different 
33-37 
organs 
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PAPER V 
PRENATAL DIAGNOSIS OF TYPE II GLYCOGENOSIS (POMPE'S DISEASE) 
USING MICROCHEMICAL ANALYSES 
M.F. Niermeijer (54), J.F. Koster*, M. Jahodova**, J. Fernandes***, 
M.J. Heukels-Dully, and H. Galjaard 
Department of Cell Biology and Genetics, Department of Biochemistry*, 
Department of Obstetrics and Gynecology**, and Department of Pediatrics***, 
Medical Faculty, Erasmus University, Rotterdam, The Netherlands 
EXTRACT 
The number of cultured amniotic fluid cells required for the prenatal diagnosis 
of metabolic defects can be reduced by using microchemical techniques. Six 
cases are presented of prenatal monitoring for glycogenesis type II (Pompe 1s 
disease), in which a-glucosidase assays were performed in (sub)microliter 
volumes with 4-methylumbelliferyl- a-D-glucopyranoside as a substrate. Using 
cell homogenates, the period of time between amniocentesis (performed in the 
14th-15th week of pregnancy) and the diagnosis varied from 12-22 days. This 
could further be reduced to about 10 days when microchemical enzyme ana-
lyses were performed on dissected groups of small numbers (100-300) of freeze-
dried cultured cells. The a-glucosidase activities (expressed per cell) obtained 
by these microtechniques were found to be in good agreement with data from 
conventional biochemical assays. Furthermore, it was observed that the acid 
a -glucosidase activity is much lower in primary cultures of amniotic fluid 
cells, approximately 105-200 pmol/min/mg protein than in cells from later 
subcultures, which had activities up to 700-1.600 pmol/min/mg 2-3 weeks 
after the last subcultivation. Primary cultures of normal amniotic fluid cells 
should therefore be used as a control in prenatal diagnosisi this is especially 
important when microtechniques are used to enable an early prenatal diagnosis. 
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SPECULATION 
In prenatal diagnosis of at least seven lysosomal storage diseases the time 
interval between amniocentesis and the diagnosis can be reduced by using 
microchemical assays on dissected groups of 100 - 300 freeze-dried cui tured 
amniotic fluid cells. Correct interpretation of the analytical data requires the 
use of primary cultures of normal amniotic fluid cells as controls. If enzymatic 
activities in various strains of fibroblasts and amniotic fluid cells are to be 
compared, cell cultivation conditions should be strictly controlled. 
INTRODUCTION 
The presence of lysosomal a -1,4-glucosidase activity in leucocytes (18) has 
facilitated the diagnosis of glycogenesis type II (Pompe1s disease). The finding 
that acid a -1 ,4-glucosidase activity was also d-eficient in cultured skin fibro-
blasts from pqtients with Pompe's disease {34) suggested the possibility of pre-
natal detection (6, 30, 31). When parents at risk for an affected child ask 
for prenatal monitoring the_ time interval between amniocentesis and the diag-
nosis should be kept as short as possible. Unfortunately a direct assay of 
enzymatic activities in uncultured amniotic fluid cells or in amniotic fluid 
supernatant is unreliable (6, 30). However, when cultured amniotic fluid cells 
were used for biochemical analysis, 4 - 6 weeks were required to obtain 
sufficient cell material (6, 24, 30, 31) and even longer periods (2, 10) have 
been described for other metabolic diseases. 
The number of cells required and the time needed for the diagnosis can be 
reduced if microchemical techniques are used. These methods were originally 
developed for histochemical studies on tissue sections (16, 25, 26, 28) and 
have been adapted for the analysis of small numbers of cultured amniotic 
fluid cells (12, 13). The first examples of their application for prenatal diag-
nosis have been reported (11, 14). 
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The present paper describes six prenatal analyses for Pompe's disease using 
microchemical techniques. Some problems in the interpretation of the analy-
tical data are discussed in relation to the clinical and biochemical diagnosis 
of affected siblings, the use of proper control material, and the influenCe of 
cell culture conditions on enzymatic activity. 
MATERIAL AND METHODS 
Acid and neutral a -1 ,4-glucosidase assays on tissues and leucocytes of 
affected patients and heterozygous carriers were performed as described pre-
viously (21). In pregnancies at risk for Pompe's disease 10- 20 ml of amnio-
tic fluid was obtained by transabdominal amniocentesis in the 14 - 16th week 
of pregnancy (calculated from the last menstrual period) after ultrasound 
localization of the placenta. 
Preparation of cell material 
The amniotic fluid sample .i-S- centrifuged in siliconized glass tubes for 5 min. 
at 80 xgand the supernatant is centrifuged for another 10 min.at 1,500 x gand 
stored at -70°C until analysis. The cell pellet is resuspended in Ham's FlO 
medium (44) supplemented with 20% fetal calf serum (45), penicillin 
(100 U/ml), and streptomycin (50 fig/ml). Cell cultivation is carried out in a 
fully humidified atmosphere with 5% C02 in air. For microbiochemical analyses 
on cell homogenates cell cultivation is performed in 35 mm plastic Petri 
dishes (46) and cell counting and homogenization is carried out as described 
earlier (13). When microchemical assays are to be performed on dissected 
groups of freeze-dried cells an aliquot of the cell suspension is cultured on 
a 11 mylar dish 11 consisting of a glass ring of 5 em outside diameter with a bottom 
of thin plastic film (47). When sufficient cell growth has occurred, the dish is 
quickly frozen and freeze-dried overnight at -45~C in vacuo. Subsequently a 
measured number of cells (100-300) are dissected under a stereomicroscope as des-
cribed earlier (13) .In each prenatal diagnosis confluent subcultures of amniotic 
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fluid cells from a normal pregnancy(l4-17th week),fibroblasts from a previous 
affected sibling, or a nonrelated patient with Pompe's disease, and fibroblasts 
from the heterozygous parents and from normal individuals were used as 
controls. Cells were grown in Ham's FlO medium supplemented with 15% fetal 
calf serum and antibiotics. In one case (V Co. 2) a primary culture of normal 
amniotic fluid cells was used as a control (48). 
Microchemical analysis 
Either 0.3 1 JJI of cell homogenate or dissected pieces of plastic film 
containing a small number of lyophilized cells were incubated under micros-
copic control in small volumes (0.6 - 2 Jll) of substrate covered by paraffin 
oil, using the 11oil well technique,. (28). 
Incubation in 2.2 mM 4-methylumbelliferyl- u-D-glucopyronoside (49) in 
0.2 M acetate buffer at pH 4.0 was carried out for 1-2 hr at 37°. The reac-
tion mixture was then diluted with 500 ~I 0.5 M carbonate buffer (pH 10.7) and 
the fluorescense was read in a fluorometer (50)(exdtation 365 nm; 
emission 448 nm). The enzymatic activity was expressed per cell when dis-
sected groups of freeze-dried cells were analysed. In the analysis of cell 
homogenates the protein content was determined according to the method of 
Lowry (27) in a final volume of 60 jll. The enzymatic activity was expressed as 
moles of methylumbelliferone liberated per minute per milligram of protein.For 
comparative studies with the assays on dissected groups of cells, the analytical 
data on cell homogenates were also expressed per cell as calculated from the cell 
counts after trypsinization. The enzymatic analyses of amniotic fluid supernatant 
for acid and neutral a-1 ,4-glucosidase were performed as described previously 
(21) and expressed per milligram of protein. Neutral a-glucosidase assays 
were performed as a reference enzyme; assay conditions were the same as for 
acid glucosidase except that incubation was carried out in 0.1 M fumarate 
buffer at pH 6.5. 
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RESULTS 
1. PRENATAL DIAGNOSIS USING MICROCHEMICAL ANALYSIS OF CELL 
HOMOGENATES 
F9mily 1 Bi h9d one healthy boy and two children who died at 6 and 5 
months of cardiopulmonary failure; in the youngest child (!_!U) Pompe 1s 
disease was diagnosed by the demonstration of a deficient acid a-1 ,4-gluco-
sidase activity in leucocytes and muscle (Table 1). In the fourth pregnancy 
amniocentesis had to be repeated because of insufficient amniotic fluid cell 
growth. The results of enzyme assays on cultured cells from the second sample 
(obtained in the 19th week) are given in Table 2 (~). The acid a-gluco-
sidase activity was found to be about 1% of the value in control fibroblasts, 
and it was less than 10% of the values found in fibroblast cultures from the 
heterozygous parents. 
TABLE 1 
ACID AND NEUTRAL a-1)4-GLUCOSIDASE ACTIVITIES* OF VARIOUS 
CEll TYPES IN PATIENTS WITH GLYCOGENOSIS II 
Patient Code Leucocytes Muscle 
odd neutral ratio acid neutral ratio 
I Bi 3 4.2 7.1 0.60 1.26 2.54 0.46 
II No1 0.17 0.65 0.26 
Ill Nie 
IV Vo 3 6.0 11.0 0.54 
Controls (rF34) 5.6-16.3 5.0-17.9 0.8-1.3 4.1-21.4 1.4-2.7 3.4-7.9(~9) 
V Co , .. 0.0 0.19 0 
Controls** (rF 16) 0.39-0.89 0.21-0.69 1.1-1.8 
Enzyme activities were measured with maltose as substrate at pH 4.0 and 6.5 and 
expressed in 1Q-9 mol glucose formed/min/mg protein. 
In these analyses enzyme activities were measured wit!) glycogen as substrate at 
pH 4.0 and 6.5 and expressed in the some units. 
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PRENATAL DIAGNOSIS OF pOMPE'S DISEASE USING HOMOGENATES 
OF CULTURED AMNIOTIC FLUID CELLS 
a-1,4-GLUCOSIDASE ACTIVITY* (x 10-! 2 mole/min/mg. protein) 
Patient code and 
cultivation period 
Pregnancy 
at risk** 
Control 
amniotic fluid cells0 
Control 
fibroblasts 
Heterozygous 
fibroblasts 
Pompe's 
fibroblasts 
81 4 (20 days) 26 381 2760 353 ~ 
3280 480 ,J 
II No 4 (17 ") 501 1049 4130 1654 ~ 
Ill Nie 3 (22 ") 680 1227 1598 2120 ~ 
715 5326 822 " 
IV Vo 4 (14 ") 112 614 1010 475 ~ 
v Co 2 (12 ") 104** and 261 ** 372 ~ 
391 *** 
Enzyme activity was determined with rnethylumbelliferyl substrate and in microvolumes. 
Analyses in primary cultures and *** after two subcultivotions of the same cell strain. 
0 All control samples were later passages except for ** which was a primary culture, 
28 
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Assays on neutral glucosidase as a reference showed activities in the control 
range. The parents were informed of the presence of an affected fetus and 
they requested interruption of the pregnancy. Analyses on fetal tissues after 
induced abortion with hypertonic saline showed a deficiency of acid gluco-
sidase activity (Table 3 ) which confirmed the prenatal diagnosis of Pompe 1s 
disease. 
In family II No the first child (II No 1) died ot the age of 2 months with 
symptoms of generalized muscle hypotonia, cardiorespiratory insufficiency and 
hepatosplenomegaly. A deficient acid a-glucosidase activity was found in a 
muscle biopsy. In a second pregnancy in 1969 amniocentesis was performed 
but enzyme assays could only be performed on the amniotic fluid supernatant; 
a normal value wos observed and fortunately a healthy girl was bom (Table 3, 
II No 2). In the third pregnancy amniocentesis was carried out in the 15th 
week but the mother came into spontaneous labour in the 19th week. A defi-
cient acid a-glucosidase activity was observed in various fetal tissues 
(II No 3, Table 3 ). In the fourth pregnancy enzyme assays in cultured 
amniotic fluid cells were performed 17 days after amniocentesis (Table 2, 
II No 4). The activity was about half of the value in control amniotic fluid 
cells and about 30% of that in fibroblasts from the heterozygous mother, As 
the activity was about l 0 fold higher than that in fibroblasts from an affected 
sibling (Table 2) we decided that the fetus could be a carrier or normal. 
After the birth of a healthy girl enzyme analyses on leucocytes of umbilical 
cord blood showed a ratio of acid to neutral a-glucosidase activity which was 
intermediate between the heterozygote and control range when maltose was 
used as a substrate (Table 3 ) • With glycogen as substrate enzyme levels were 
found in the range of heterozygotes (22). 
In family ill Nie the first male child died at 6 months of shock and cardio-
pulmonary failure. Microscopic examination at autopsy showed vacuolization 
and glycogen accumulation in heart muscle fibers; no abnormalities were found 
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CONFIRMATION OF DIAGNOSIS AFTER PRENATAL MONITORING 
Acid a-1 ,4-Giucosidase activity R . acid Gl 'd Diagnosis in at1o neutral ucos1 ose"" 
neonate or in 
Patient material Muscle Heart Liver in Leucocytes obortjon material 
Bl 4 abortion 1 .2 0 0.4 M. ?ompe 
II No 2 neonaf'e 0.78 Hete~ozygote or normal 
II No 3 abortion 0.9 M. Pompe 
II No 4 neonate 0.93 Heterozygote or normal 
IV Vo 4 abortion 9.32 6.2 23.8 Heterozygote or normal 
v Co 2 neonate 0,98 Heterozygote or normal 
Control subject 4.2-21.4 21.7 - 38.8 0.8 1.3 (n=34) (n=9) (n=4) 
Heterozygotes 0.63 0.97 (n=l2) 
M. Pompe 0 - 1 .6 0 0.1 - 0.5 0.25 0.71 (n= 11) 
(o=16) (n=3) 
a-1,4-glucosidose activities were assayed with maltose as the substrate at pH 4,0 and pH 6.5 and expressed 
as nmoles glucose formed/min/mg protein, 
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in other organs. No biochemical studies were performed and a tentative diag-
nosis of Pompe 1s disease was made. The second child was a healthy girl. In 
the third pregnancy prenatal monitoring was requested. Amniocentesis was 
performed and the acid glucosidase activity in the cultured amniotic fluid 
cells (Ill Nie 3, Table 2) was comparable with that in a control· sample and the 
fetus seemed not affected. The acid glucosidase activity in fibroblasts from 
both parents showed quite high values compared with most other values in 
obligate heterozygotes (Table 2). Later a-glucosidase assays in the leuco-
cytes of the parents were carried out using glycogen as substrate. Activities 
in the control range were observed which made it unlikely that the first 
affected sibling had died from Pompe 1s disease. Unfortunately, no cell material 
of the affected sibling was available for enzyme studies. If biochemical 
assays had been performed or cultured cells had been stored the amniocentesis 
could have been avoided. The third pregnancy resulted in a healthy girl who 
had a normal ratio of acid to neutral a-glucosidase in her leucocytes using 
glycogen as substrate. 
In family IV Vo the first child died at the age of three months and the diag-
nosis of Pompe 1s disease was based on morphologic studies at autopsy. A 
second child was healthy. In the third pregnancy amniocentesis was carried 
out in the 14th week but in vitro growth failed and enzyme assays could 
be performed only on the amniotic fluid supernatant.A normal value was found 
but the parents were informed about the limitations of this assay. They deci-
ded to continue the pregnancy, but an affected child (IV Vo 3) was born 
with cheilopalatoschizis, muscular hypotonia, cardiomegaly,and a deficient 
acid a-glucosidase activity in the leucocytes (Table 1). In the fourth preg-
nancy amniocentesis was periormed in the 15th week and the results of en-
zyme assays on cultured amniotic fluid cells were available two weeks later 
(Table 2, IV Vo 4). The acid a-glucosidase activity was quite low compared 
with the control sample and with prenatal analyses performed earlier. The 
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activity was about 25% of that of the fibroblasts from the heterozygous mother 
and about four times higher than in fibroblasts from the affected sibling. The 
fetus could have been a Pompe patient with a relatively high residual enzyme 
activity or a heterozygote with a very low activity. The parents were in-
formed that the fetus was likely to be affected and the pregnancy was termi-
nated at their request in the 17th week. No deficiency of acid a-glucosi-
dase activity could be demonstrated in various fetal organs. We then specu-
lated that the mistake in diagnosis was due to the fact that short term primary 
cultures of amniotic fluid cells from the pregnancy at risk had been compared 
with later passages from control amniotic fluid cell strains. The acid a-gluco-
sidase activities in various amniotic fluid cell samples were then measu.red at 
different periods of time in primary culture and were compared with the 
enzyme activities in subcultured cells at different intervals after the last 
subculture (Fig. 1). 
o:-glucosidase ocl,vity 
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FIGURE 1 
Relations between acid a-1,4-glucosi-
dase activity and in vitro cultivation 
condi!-ions of amniotic fluid cells. 
Different symbols represent cultures 
from different amniotic fluid samples. 
e= cells from the some amniotic fluid 
sample at -different time intervals in 
primary culture and after subcultivation. 
Acid a-glucosidase activity showed no obvious correlation with time in cul-
ture whereas the specific activity in subcultured cells showed a definite in-
crease with time after subculture. 
In the fifth pregnancyamniocentesis was performed and the enzyme activity in 
a 12-day culture was compared with that of a primary culture of the same 
duration from a control sample. The acid a-glucosidase activity in cells from 
the pregnancy at risk showed normal values and the pregnancy ended at term 
with the birth of o healthy child. 
In family V Co the first child died at 13 months of age with the classical 
symptoms of Pompe•s disease. Biochemical assays on leucocytes revealed an 
acid a-glucosidase deficiency (Table 1). In the second pregnancy enzyme 
assays on cultured amniotic fluid cells could be carried out 10 and 14 days 
after the second amniocentesis in the 17th week. The results in Table 2 
(V Co 2) show that the acid a-glucosidase activity in cells from the preg-
nancy at risk was 104 picomole/min/mg protein, whereas a value of 391 was 
found in the second subculture of these cells. In control amniotic cells an 
activity of 261 was found at 21 days after initiation of a primary culture. 
From these results it was concluded that the fetus was not affected with 
Pompe's disease. The pregnancy was continued and a boy was born at term; 
the acid a-glucosidase activity in his leucocytes was in the range between 
heterozygotes and controls with maltose as substrate (Table 3 ) • 
The results of these analyses indicate that for a reliable pre-natal diagnosis, 
a -glucosidase activities in short term (10 - 20 days) amniotic fluid cell 
cultures from pregnancies at risk should be compared with primary cultures of 
control amniotic fluid samples that have been grown under similar conditions. 
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MICROCHEMICAL ANALYSIS OF a-1 ,4-GLUCOSIDASE IN DISSECTED GROUPS OF FREEZE-DRIED 
AMNIOTIC CELLS FROM A PREGNANCY AT RISK FOR POMPE'S DISEASE (Ill N;e 3) 
Number of dissected cells 160 160 100 120 115 165 200 110 95 
Fluorescence intensity* 11 12 9 15 12 12 20 10 9 
(relative units) 
a -1, 4-Giucosidase Activity 1.0 1.0 1.1 1.8 1.4 1.0 1.5 1 .2 1.0 
(xJo-14 mol/hr/cell) 
Mean activity in pregnancy at risk 1,2 {cell homogenate; 1,3 f< 10-14 mol/hr/cell) 
Mean activity control amniotic fluid cells: 2,2 
Mean activity fibrobl-asts Pompe no detectable activity ( :S: 0,3 x 10-14 mol/hr/ce!l) 
130 
10 
1.0 
*Blank values of 3% (range 2-5%) consisted of 10 empty pieces of plastic foil dissected adjacent to cell groups 
~ 
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2. PRENATAL DIAGNOSIS USING MICROANALYSIS OF ISOLATED CELL 
GROUPS 
In the last three pregnancies at risk (III Nie 3, IV Vo 4, V Co 2) part of 
the amniotic fluid sample was used for microchemical analysis of isolated 
groups of freeze-dried cultured cells. This technique does not require parallel 
protein assays and harvesting can be carried out as soon as small cell clones 
appear. As a consequence prenatal diagnosis can be completed 10- 14 days 
after amniocentesis during the 14th- 15th week of pregnancy. 
Table 4 shows the acid a-1,4-glucosidase activities determined by this 
technique in 10 dissected groups of amniotic fluid cells from a pregnancy at 
risk (III Nie 3), in control amniotic fluid cells and in fibroblasts from a 
patient with Pompe 1 s disease. The fluorescence intensities are well above the 
blank values for all groups of cells from the pregnancy at risk and the mean 
a -glucosidase activity was found to be about half the value of that of con-
trol amniotic fluid cells. No acid a -1 ,4-glucosidase activity was detected 
in dissected groups of fibroblasts from a patient with Pompe•s disease. The 
data obtained indicated either a normal fetus or a heterozygous carrier. The 
mean glucosidase activity found in dissected cells from the pregnancy at risk 
are in good agreement with the enzymatic activity determined in cell homo-
genates from the same sample (Table 4 ) • 
To test the validity of microchemical enzyme analysis on dissected groups of 
cells, the results of such assays on various cell strains have been compared 
with data obtained by analysis on cell homogenates (Table 5). In the latter 
the enzyme activity is expressed as both per milligram of protein and per cell as 
calculated from the cell number of the same before homogenization and from data 
on the protein content of single cultured cells (2 - 3 x 10-lOg) as deter-
mined by interference microscopy. These comparative studies indi cote a good 
agreement between the results of the two methods for primary cultures of 
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COMPARISON OF MICROANALYSIS OF o-1 ,4-GLUCOSIDASE ACTIVITY USING DISSECTED 
GROUPS OF FREEZE-DRIED CELLS AND CELL HOMOGENATES 
ENZYME ACTIVITY CELL HOMOGENATE 
per cell per mg protein 
TYPE OF CELL STRAIN DISSECTED CELL GROUPS' 
X} Q- J4 mol/hour xlo-12 mol/min 
Pregnancies at risk - Ill Nie 3 1.2 1.3 680 
IV Vo 4 0.3 0.2 123 
- v Co 2" 0.4 0 2 and 0.8 104 and 391** 
Control Amniotic Fluid Cells 
primary culture*** 0.3 0.5 261*** 
later subcultures (n = 2) 1.2; 2. J 1.1;1.5 548; 763 
Control Fibroblasts (n = 4) 3.1-5.1 2.9-5.3 1440-2645 
Heterozygous Fibroblasts 1.5 1.0 500 
Pompe's Fibroblasts (n = 3) 0.3 0.03 - 0.05 18-26 
Data are the mean of values from 10-26 groups of cells. 
Freeze-dried cells have been analyzed after 10 days growth, but cell homogenate studies were performed after 
14 days in primary culture and after the 3rd subculture, 
Analysis of freeze-dried control cells after 14 days primary culture, studies on cell homogenate after 21 days 
primary culture, 
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amniotic fluid cells and for later subcultures of normal amniotic fluid cells, 
fibroblasts from control ~ubjects, patients with Pompe•s disease and hetero-
zygous carriers. 
3. ANALYSIS OF a-1,4-GLUCOSIDASE IN AMNIOTIC FLUID SUPERNATANT 
For five pregnancies at risk for Pompe's disease, where enzymatic analysis had 
been carried out on cultured amniotic fluid cells, the activities of acid and 
neutral a-glucosidase have been determined in the amniotic fluid supernatant. 
The results in Table 6 show that there was no correlation between the acid 
glucosidase activity in amniotic fluid supernatant and the status of the fetus. 
Furthermore, it is apparent that the ratio of acid to neutral glucosidase was 
rather constant in all cases tested. 
TABLE 6 
a-1,4-GLUCOSIDASE ACTIVITIES IN AMNIOTIC FLUID SUPERNATANT 
IN PREGNANCIES AT RISK FOR POMPE'S DISEASE 
Patient code and 
time of amniocentesis 
81 4 (14 wk) 
II No 4 (17 wk) 
II No 4 (19 wk) 
Ill Nie 4 (15 wk) 
IV Vo 3 (15 wk) 
v Co 2 (17 wk) 
Control (16 wk) 
a-1,4-Givcosidase activity* 
(x1Q-12 mol/min/mg protein) 
pH 4.0 pH 6.5 
421 1850 
759 3498 
216 1059 
196 823 
445 1899 
359 1465 
227 833 
Ratio acid 
neutral Outcome of Pregnancy 
0.22 Heterozygote 
0.21 
M. Pompe 
0.20 
0.23 Heterozygote or normal 
0.23 Normal 
0.24 Heterozygote or normal 
0.27 Normal 
* In all analyses methylvmbelliferyl- a-D-glvcopyranoside was used as the substrate. 
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DISCUSSION 
11 lt is difficult, to conceive of a diag-
nostic approach which must be made 
under greater 11 blind 11 conditions: 
an opportunity does not exist to check 
the laboratory diagnosis with the phy-
sical examination and clinical course 
of the patient 11 • 
Kirkman, 1972. (20) 
For the prenatal diagnosis of Pompe's disease three potential sources of diag-
nostic material have been proposed: uncultured amniotic fluid cells (31L 
amniotic fluid supernatant (3l),and cultured amniotic fluid cells (6, 30, 31). 
At present it is clear that only cultured fetal cells permit reliable prenatal 
monitoring. The analysis of uncultured amniotic fluid cells is complicated by 
contamination with maternal white blood cells (6), the large proportion of 
dead cells which lose part of their enzymatic activity (7, 32),and contami-
nation with enzymes which may be present in the amniotic fluid supernatant 
(41). The absence of acid a-1,4-glucosidase activity in the amniotic fluid 
supernatant was reported in a pregnancy of a fetus with Pompe's disease (31) 
but later studies (30, 37) could not substantiate a relation between the en-
zyme activity in the fluid supernatant and that in the fetal cells. The reSults 
in the present paper (Table 6) are in agreement with this last finding. 
Neither acid a-1,4-glucosidase activity nor the ratio of acid to neutral gluco-
sidase activity of the supernatant gave any conclusive information. This 
finding contradicts the assumption that acid a-1,4-glucosidase activity in the 
supernatant is mainly derived from fetal cell organelles (38). Another suggested 
source for acid a-1,4-glucosidase activity is an enzyme of renal origin with 
properties differing from the enzyme found in other tissues (37). The function 
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of this enzyme and its rapid disappearance from the amniotic fluid supernatant 
after the 20th week of pregnancy (9, 42, 43) needs further clarification. 
Since fetal urine contributes to amniotic fluid it is difficult to understand why 
Pompe's disease cannot be detected prenatally using amniotic fluid supernatant 
(9) if urine from patients can be used for enzymatic diagnosis after birth (39). 
The only reliable material for prenatal diagnosis of Pompe's disease is cultured 
amniotic fluid cells. Our results (Table 2) showed that microchemical analysis 
of a-glucosidase activity (13) in cell homogenates permits prenatal diagnosis 
14 - 20 days after amniocentesis during the 15th week of pregnancy. 
When microanalyses were carried out on small groups of dissected freeze-dried 
cells (Table 4 and 5) a further reduction to 10 - 12 days was realized. 
Comparable procedures have been developed for the prenatal detection of a 
number of other lysosomal diseases (11,12, 14). The advantage of these micro-
methods is that a prenatal diagnosis can be completed before the mother 
experiences fetal movements and that multiple analyses including karyotyping 
can be performed on a small amount of cell material. In addition assays of 
other 1 non-affected enzymes in the same cui ture can be performed to test 
enzyme preservation in the sample used. 
Although the results of a-1,4-glucosidase analyses on small groups of dis-
sected freeze-dried cells correspond very well with assays on cell homogenates, 
the former method has some limitationsif a conventional fluorometer is used. 
Groups of 100- 300 freeze-dried cells can be accurately analyzed with 
methylumbelliferyl substrates only if the enzyme activity is higher than 0.3 -
1x 1o-14 mol/hr/cell (which corresponds to about 150 pmol/min/mg protein). 
In order to distinguish cells from heterozygous carriers from cells from affected 
patients enzymatic activities higher than this level should be present. 
This is the case for enzymes with relatively high activities in cultured cells 
such as those involved in GM1 and GM2 gangliosidoses. In some instances of 
Fabry's disease (14) and Pompe's disease (see Table 5) the enzymatic activity 
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in cells from heterozygous fetuses may be below the level of detection and 
erroneous interpretation is possible. Mistakes can be avoided either by micro-
analysis on cell homogenates in the case that more cell material is available 
or by the use of more sensitive microfluorometric methods (12, 13). 
A prerequisite for prenatal monitoring should be that the diagnosis of the me-
tabolic disease in the affected sibling is based on the demonstration of the 
enzyme defect in tissues or cultured cells. In two of the presently described 
cases such data were not available and the only possibility remaining is 
carrier detection in both parents. For this purpose the use of glycogen as 
substrate (22) has given the best results so far, although in larger series there 
is some overlap between control and heterozygote values. 
For a reliable distinction between normal, heterozygous, and enzyme-defi-
cient cells the use of appropriate controls is required. The residual activity 
of acid a-glucosidase shows considerable variations in fibroblasts from diffe-
rent affected patients and in different heterozygous carriers (see Table 2). 
Part of this variation might be due to differences in cell cultivation condi-
tions (3-5, 8, 23, 35, 36, 40), but also the residual enzyme activity may 
in part be genetically determined. Therefore, in prenatal diagnosis the en-
zymatic assays of cells from a pregnancy at risk should be compared with 
control amniotic fluid cells and with cultured fibroblasts from heterozygotes 
and an affected patient in that particular family. For this purpose parents 
of a child affected with a metabolic disease which can be detected in utero 
(29) should be informed in time about this possibility and skin biopsies should 
be taken so that cells can be stored until required for prenatal monitoring in 
a subsequent pregnancy. 
Ideally, control amniotic fluid cell cultures should be from the same gesta-
tional period and grown for the same period of time as those from the preg-
nancy at risk. The use of later subcultures of control samples may lead to 
erroneous interpretations such as described for patient IV Vo 3 (see Table 2). 
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The activity of acid a-glucosidase(Fig. 1) and also of several other lysosomal 
enzymes is usually low in primary cui tures and unpredictable variations have 
been observed at different time intervals after initiation of a primary culture. 
In this respect possible differences in enzyme activity between epitheloid and 
fibroblast-like amniotic fluid cells (15, 19) should be further investigated. In 
later subcultures of amniotic fluid cells the activity of acid a-glucosidase 
increases during prolonged cultivation (2 - 3 weeks) after the last subculture. 
A similar effect has been reported by others and in fibroblasts the activity of 
several enzymes was found to increase considerably during growth in confluen-
cy (3, 4, 8, 35, 40). The use of primary cultures of control amniotic fluid 
cells has been facilitated by methods for storing samples of uncultured amnio-
tic fluid cells with maintenance of cell viability (33). 
Of course, therapy of Pompe 1s disease by enzyme substitution would be 
preferable to preventive control by prenatal diagnosis followed by selective 
abortion, but preliminary results of therapeutic approaches (1, 17) warrant 
the conclusion that at present genetic counseling and prenatal diagnosis are 
the only practical means for prevention of this disease. 
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SUMMARY 
1. In order to reduce the time interval between amniocentesis and prenatal 
diagnosis of Pompe•s disease microchemical techniques were used for assay 
of acid a-1 ,4-glucosidase activities in cultured amniotic fluid cells. 
2. Microtechniques used on homogenates of cultured amniotic fluid cells 
enabled the waiting period to be reduced to 2 - 3 weeks. 
3. When dissected lyophilized groups of 200 - 300 cultured cells were 
analyzed, a prenatal diagnosis was possible at about 10 days after 
amniocentesis. 
4. The acid a-1,4-g/ucosidase activity in the amniotic fluid supernatant is 
not informative in prenatal diagnosis of Pompe•s disease. 
5. Conditions of cell cultivation such as length of time in culture were 
found to influence markedly the acid a-1 1.4-glucosidase activity in 
cultured amniotic fluid cells. 
6. For a reliable prenatal diagnosis of metabolic disorders primary cultures 
of control amniotic fluid cells should be used and the analytical results 
from the pregnancy at risk should be compared with primary cultures of 
control amniotic fluid cells and with those in cultured fibroblasts from 
heterozygous carriers, and an affected sibling from the particular family. 
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An example of rapid prenatal 
diagnosis of Fabry's disease using 
microtechniques 
H. GALJAARD, M. F. NIERMELT.ER, N. HAHNEMANN, J. MoHR, AND S. A. S¢RENSEN 
Department of Cell Biology and Genetics, Medical Faculty, Erasmus University, 
Rotterdam, The Netherlands and University Institute of Medical Genetics, 
Copenhagen, Denmark 
In a pregnancy at risk for Fabry's disease, a prenatal diagnosis could be established 11 
days after amniocentesis in the 15th week of pregnancy. This was possible by microche-
mical analysis of the a-galactosidase activity in isolated groups of 100 - 200 freeze-
dried, cultured amniotic fluid cells. The results of this microassay were confirmed by 
(micro)biochemical analysis in cell homogenates from replicate cultures performed in 
two independent laboratories. Some problems in prenatal diagnosis of heterozygotes are 
discussed, as well as the possibilities of microchemical techniques for the more rapid 
prenatal diagnosis of other lysosomal storage diseases. 
Received 21 December 1973, accepted for publication 18 January 1974 
During the last few years it has been shown 
that the specific metabolic defect in more 
than 30 inborn erro;-s of metabolism is 
expressed in cultured skin fibroblasts and 
in amniotic fluid cells, thus enabling their 
prenatal detection (for reviews see Milun-
sky et a!. 1970, Nadler 1971, Milunsky & 
Littlefield 1972). In most instances so far 
r::oported, amniocentesis has been performed 
between the 14th and 20th week of preg-
nancy, and a period of amniotic fluid cell 
culture varying from 4 to 10 weeks was 
necessary to obtain sufficient cell material 
for biochemical analysis (Fratantoni et al. 
1969, Schulman et r.l. 1970, Milunsky et al. 
1970, Nadler i972). A long waiting period 
implies not only psychological stress for 
the parents but termination of a pregnancy 
at a later stage may also involve obstetrical 
problems (Olsen et al. 1970). 
The application of microchemical techni-
qu:!s, enabling biochemical assays on very 
littl:! cell material, offers the possibility of 
reducing the waiting period. The principles 
of such methods for the purpose of histo-
chemical studies on tissue sections have 
been described mainly by Lowry (1953), 
Matschinsky (1971), Lowry & Passoneau 
(1972) and Glick (1961, 1963). The adapta-
tions of some of these methods for the ana-
lysis of small numbers of cells, or even 
single cultured cells, have already been 
briefly described (Mulder & Galjard 1972, 
Galjaard et al. 1972a, Galjaard 1972) and 
the first examples of the application of 
th!!se methods in prenatal diagnosis have 
been reported (Galjaard et a!. 1972b, Gal-
jaard 1973, Galjaard et al. 1973). 
The present paper deals with the appli-
cation of such microtechniques in the sec-
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ond reported case of prenatal monitoring 
for Fabry's disease. After the identification 
of the primary biochemical defect of this 
disease (Brady et a!. 1969), the recognition 
by Kint (1970) that artificial substrates 
could be used for the determination of an 
a-galactosidase deficiency in leucocytes 
greatly simplified the diagnosis of Fabry's 
disease. Romeo & Migeon (1970) demon-
strated the presence of a-galactosidase ac-
tivity in normal cultured fibroblasts, which 
suggested that prenatal detection would be 
feasible. The first example of prenatal diag-
nosis of Fabry's disease was described by 
Brady et al. (1971), who analyzed a-galac-
tosidase activity with p-nitrophenyl sub-
strate in cultured amniotic fluid cells 4 
weeks after amniocentesis at the 17th week 
of pregnancy. 
The prenatal diagnosis to be described 
here was established 11 days after amnio-
centesis in the 15th week of pregnancy, 
using microassays on isolated groups of 
cultured amniotic fluid cells. The data ob-
tained were compared with those of con-
ventional analyses on cell homogenates. 
These results will be discussed together with 
some problems concerning the prenatal de-
tection of female heterozygotes. 
Materials and Methods 
At transabdominal amniocentesis in the 
15th week of pregnancy (as counted from 
the first day of the last menstruation) ap-
proximately 20 ml of amniotic fluid was 
obtained. The fluid was not visibly san-
guine, although some erythrocytes were ob-
served microscopically. The sample was 
divided into two, one aliquot being exa-
mined at the University Institute of Medical 
Genetics, Copenhagen, the second being 
sent to the Department of Cell Biology and 
Genetics, Erasmus University, Rotterdam, to 
be examined by micro-methods. In addi-
tion, this procedure gained the additional 
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reliability given by making diagnostic tests 
in two independent laboratories. 
The first aliquot was cultured and exam-
ined at the University Institute of Medical 
Genetics as follows: centrifugation for 10 
min at 1000 rev/min; resuspension of cell 
pellet in 4 ml Eagle's medium supplemented 
with fetal calf serum (20%); culturing in 
two Leighton tubes and subsequent transfer 
to Falcon flasks, 11 changes of medium 
in 25 d of culturing; for the purpose of 
sex determination by karyotyping, a cell 
sample had been taken out earlier, which 
showed male sex at 12 d after amniocen-
tesis. Fur the purpose of a-galactosidase 
assay, the cells were scraped from the bot-
tom of the Falcon flasks, washed three 
times with physiological saline, resuspended 
in 0.7 ml 0.25 moll! acetate buffer, pH 4.5, 
disintegrated by soni.c vibration and centri-
fuged for 15 min at 15000 rev/min at 4°C. 
The a-galactosidase activity was assayed 
according to Kint (1970) and Brady et al. 
(1971). 2001'1 of substrate (0.05 moll! p-
nitrophenyl-a-D-galactoside in 0.25 moll! 
acetate buffer, pH 4) was added tu 200 ,ul 
of amniotic fluid cell homogenate and the 
mixture incubated at 3rC for 4 h. After 
incubation, 400,ul of 1 mol/! tris, pH 10.5 
was added and the extinction was measured 
at 400nm in a Beckman DB spectrophoto-
meter. The protein content of the reaction 
mixture was measured according to Lowry 
et al. (1951). Three samples of cultured 
amniotic fluid cells from normal pregnan-
cies served as controls (Table 3). Additio-
nally, the enzymatic activities were deter-
mined (3 h incubation) in various fibro-
blast cultures: from the consultant, "L", 
from a normal man, "S", from two hetero-
zygotes, "M" and "0", and from a male 
patient, "P". 
Enzymatic activities were determined in 
leucocytes for the consultant, "L", her nor-
mal half brother, "S", her carrier aunt, 
"0", as well as her Fabry cousin, "P". 
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The procedure was: collection of a 20 ml 
blood sample in heparin, separation of leu-
cocytes, washing three times in physiolo-
gical saline, resuspension of cell pellet, and 
assay as described above for cultured cells. 
The second aliquot of the amniotic fluid 
sample was examined as follows (Dept of 
Cell Biology and Genetics, Erasmus Uni-
versity, Rotterdam): 
a. Microchemical analysis of a-galactosidase 
activity in small clones of freeze-dried cells 
After centrifugation (5 min at 1000 rev/ 
min) of the 10 ml amniotic fluid sample 
(8700 cells per ml) the cell pellet was re-
suspended in 3 ml Ham's FlO medium, 
supplemented with 20% fetal calf serum. 
The sample was divided into three parts 
and cultured in two 35 mm plastic Falcon 
petri dishes and in a "mylar dish" consis-
ting of a glass ring (5 em diam.) and a base 
of thin plastic ("Melinex" polyester film 
type 0, ICI). After 10 d cultivation in the 
mylar dish, a number of clones, mainly 
consisting of epithelial-like cells, were ob-
served. The dish was quickly frozen in a 
mixture of C02 and acetone (-70°C) and 
subsequently freeze-dried overnight in 
vacuo (10-3 mmHg) at -45°C using a 
WKF freeze-drying apparatus (Wetzlar 
instr. B.V.). After raising the t~mperature 
to 20°C the vacuum was released, and small 
pieces of the plastic base of the dish, con-
taining a counted number of freeze-dried 
cells, were dissected out under a stereo-
microscope. About 10-15 pieces of plastic, 
each with 100-250 cells (see Table 1) were 
used for microchemical analysis. 
The dissected pieces of film, containing 
small numbers of cells from various cell 
strains, were incubated in 0.3 - 0.6 1d of 
5 mmol/1 methylumbelliferyl-n-D-galacto-
side in 0.1 mol/! acetate buffer pH 4.5 for 
2 h at 3JDC. Incubation was carried out 
using the "oil well technique" (Matschin-
sky 1971) in which small volumes of sub-
strate are introduced into wells in a teflon 
rack and covered with a mixture of hexa-
decane and paraffin oil (40%:60% v/v) 
to prevent evaporation. The microvolumes 
are transferred under microscopic control 
with specially constructed constriction mi-
cropipettes (Lowry & Passonneau 1972). 
After incubation, the reaction velum~ was 
pipetted into microcuvettes containing 500 
,ul 0.5 moVI carbonate buffer pH 10.7. The 
fluorescence of the methylumbelliferone 
formed was read in a Perkin Elmer fluoro-
meter (extinction 365 nm and fluorescence 
448 nm). The data were compared with 
those from methylumbelliferone standards 
(1 - 8.10-12 mol dissolved in substrate) and 
pieces of plastic film without any cells were 
used as a blank. The a-galactosidase activi-
ties were expressed per cell by dividing the 
fluorescence values by the counted number 
of cells on each incubated piece of film. 
During the same period, control amniotic 
fluid cells from the same stage of a normal 
pregnancy, and fibroblasts from a control 
individual, from a patient with Fabry's dis-
ease (the latter cells obtained from, and 
diagnosis established by Prof. H. Loel!i and 
Dr. E. Vamos, Dept. of Prediatrics, Hospital 
St. Pierre, Bruxelles), and from a hetero-
zygous carrier were cultured and prepared 
under the same conditions. 
b. Microchemical analysis of a-galactosidase 
activity in cell homogenates 
Parallel amniotic fluid cell cultures and 
control cells were prepared for conventional 
assays on cell homogenates. Cells were 
grown on Falcon dishes in Ham's FlO 
medium, supplemented with 15% fetal calf 
serum for the fibroblast cultures and with 
20% for the amniotic fluid cells. After 14 
d, sufficient cells were available for har-
vesting for microassays for protein and 
a-galactosidase activity. After trypsinization 
(0.25% trypsin), the cell number was coun-
ted in a haemocytometer. After washing 
and suspension in 0.01% bovine albumine 
solution (to a concentration of about 106 
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cells per ml) homogenization was carried 
out by sonic vibration. Subsequently, 1 ,ul 
samples of cell homogenate were incubated 
with 2 Jll methylumbelliferyl substrate using 
the same "oil well technique" and identical 
conditions as mentioned above. After 2 h 
incubation at Jrc the reagent was trans-
ferred to 500 ,ul carbonate buffer and the 
fluorescence was read. 
From each cell homogenate 5 Jll samples 
were used for a protein assay according to 
Lowry (1953) adapted to a final volume 
of 60 pl. The extinctions were read in 20 ,ul 
microcuvettes which fitted a commercial 
Zeiss spectrophotometer. The a-galactosi-
+54 
Fig. 1. Kindred of the consultant (L) 
111 Fabry's hemizygote 
141 Fabry's heterozygote 
Embryo 
m Information inadequate 
dase activities were expressed per mg pro-
tein and also per cell, based on the cell 
counting after trypsinization. 
Case Report and Kindred 
The consultant, "L", born 11th March, 
1951, sought genetic counselling in 1969, 
at the University Institute of Medical Gen-
etics, Copenhagen. Her father, "K" and 
four other male relatives, "I", "P", "A", 
and "B" had been diagnosed as having 
Fabry's disease (Fig. 1), according to 
Christensen Lou (1972). The consultant 
appeared to be clinically healthy, but was 
31~ 
/' 
[<] Relatives less than 10 years old, so far no 
symptoms or signs of Fabry's disease 
1"3a Dead at the age of 38 years 
30y 30 years old at the last examination 
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an obligate heterozygote, since the disease 
is X-linked and her father had been affec-
ted. This was confirmed by a slit lamp 
examination performed at Rigshospital, Co-
penhagen, 1969, which revealed the charac-
teristic corneal opacities. The consultant 
gave a history of a few instances of buzz-
ing paraesthesias in the fingers, accom-
panied by a temperature rise to about 
38°C, as well as diffuse headache since the 
age of 5 years, and loss of consciousness 
for a few seconds on a single occasion 
(Christensen Lou 1972). 
The consultant's father, born 1914, had 
died in 1968 at the age of 54 years. From 
the age of 5 years he showed episodes of 
fever, or pain and/or paraesthesias of the 
extremities, provoked by fever or overheat-
ing; from the age of 15 years a slowly 
progressive rash of dust- or grain-sized, 
elevated eruptions on the trunk and geni-
tals; from the age of 25 years proteinuria 
and low back pain; from the age of 35 
years episodes of paraesthesias spreading to 
most areas of the arms and to the face in 
the course of about 10 min, followed by 
throbbing, often one-sided, frontal head-
ache. From the age of 44 years symptoms 
of functional loss in the central nervous 
system occurred, followed by deteriorating 
sight and death at 54 years from a cardiac 
insufficiency which had progressed gradu-
ally since the age of 39 years. The. clinical 
features of the four remaining male rela-
tives of the consultant were largely in 
agreement with this picture, "A" and "I" 
had died at the ages of 3_3 and 38 years, 
respectively, while "P" and "B'' at the time 
of the examination (1969) were 17 and 33 
years old, respectively, and seriously affec-
ted (Christensen Lou 1972). 
The consultant had eight female carrier 
relatives, "Q", "J", "0", "H", "M", "E", 
"G" and "F" (Fig. 1), of whom "J" and 
"Q" had died at ages 48 and 64 years, 
from cardiac failure and mammary carci-
noma, respectively. The remaining six car-
rier relatives, "0", "H", "M", "G" and "F" 
showed, at the time of the last clinical 
examination (at ages 49, 57, 30, 31 and 29 
years, respectively), some symptoms of the 
disease such as episodes of pain in the ex-
tremities (all six), "Fabry rash" (four), 
corneal opacities. (three), proteinuria (three), 
and cardiomegaly (two). 
These findings confirm observations from 
other families that the Fabry carrier state 
may not be considered as clinically harm-
less, although the symptoms generally occur 
later, and are milder than in male patients 
(Christensen Lou 1972, Sweeley ct a!. 
1972). 
At the first counselling in 1969, only 
prenatal sex determination could be offered 
to prevent the birth of affected males. In 
consideration of the rapid development in 
this field, the consultant was informed that 
a technique for biochemical prenatal diag-
nosis might become available in the near 
future. When she became pregnant in 1972, 
a prenatal diagnosis was possible assaying 
the a-galactosidase activity in cultured am-
niotic fluid cells (Kint 1970, Brady et al. 
1971 ). In the meantime, microtechniques 
had been adapted for the analysis of cul-
tured fluid cells (Mulder & Galjaard 1972, 
Galjaard et al. 1972a, b) which enable a 
prenatal diagnosis at an earlier stage of 
pregnancy than is possible with conventio-
nal techniques. 
Results 
The first results of u-galactosidase activity 
in cultured amniotic fluid cells from the 
pregnancy at risk were obtained by the 
microassays performed in the Dept. of Cell 
Biology and Genetics at Rotterdam. Anal-
yses on dissected groups of small numbers 
of freeze·dried cells (1 00 - 300 cells) (see 
Table 1) showed that the fluorescence in-
tensities were well above the blank values. 
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Table 1 
Microchemical analysis of a-galactosidase in clones of freeze-dried amniotic fluid 
cells from a pregnancy at risk for Fabry's disease 
Cell number per sample 
250 240 190 150 250 200 120 215 145 110 
Fluorescence intensity' 
(relative units) 31 42 31 30 23 31 23 33 19 16 
,-Galactosidase activity 
(x10-" mol /h/cell) 1.16 1.71 1.60 i .91 0.90 1.51 1.87 1.50 1.29 1.43 
E'P I' Exp. II' 
Pregnancy at risk X = 1.49 ± 0.31 (n = 10) X " 1.88 
'" 
" 
6) 
Control amniotic fluid cells X = 2-76 ± 0.46 {n "" 16) X " 2.19 
'" 
" 
B) 
Control fibroblasts X = 2.60 ± 0.60 (n = 20) X = 2.20 
'" 
"" 15) 
Fabry's fibroblasts X = O.?Ol 
'" 
" 
21) X = 0.70 
'" 
= 15) 
' The blank values were 2-4~/~ (empty pieces of plastic film dissected adjacent to cell groups}. 
2 In a number of clones (10) no activity could be detected, hence calculation of the standard deviation did 
not seem informative. 
3 Mean activities ± s.d. 
The enzyme activity, expressed per cell, 
showed a considerable variation between 
the various cell groups dissected. The same 
was found for all other cell strains tested, 
as is indicated by the standard deviations. 
The mean a-galactosidase activity for the 
pregnancy at risk was found to be 1.49 X 
10 14 mol/h/cell. An independent experi-
ment (exp. II in Table 1) performed the 
next day on cells from the same culture 
dish showed a somewhat higher activity 
(1.88 X 10 14 mol/hi cell). These values are 
very close to those found for control am-
niotic fluid cells and for control fibroblasts. 
The enzymatic activity in fibroblasts from 
a patient with Fabry's disease was much 
lower, although a residual activity of about 
30% was present. 
Microchemical analyses Of a-galactosi-
dase activity in cell homogenates, perfor-
med a few days later (Table 2), also showed 
similar values for the pregnancy at risk 
and for control cell strains. The activity 
in fibroblasts from a heterozygous carrier 
was somewhat lower, and that in fibro-
blasts from a patient with Fabry's disease 
again showed a residual activity of about 
30%. When these data on cell homogenates 
Table 2 
Microchemical analysis of a-galactosidase in homogenates from various 
amniotic fluid cell and fibroblast strains 
Protein content ,-galactosidase activity (mol/h) 
(xtQ·6 g/ml) protein per cell* 
Amniotic fluid cells pregnancy at risk 325 62 X iO·' 1.9 X 
Control amniotic fluid cells 330 65 X to·•. 1.7 X 
Control fibroblasts 340 52 X to·• 1.6 X 
Heterozygote Fabry fibroblasts 270 34 
' 
to·• 1.3 X 
Fabry fibroblasts 360 18 X to·• 0.6 X 
per mg 
tQ-H 
iQ-" 
1Q-" 
to-·" 
10·" 
• Enzyme activities per cell are based on counts of c:.tltured cells after harvesting (these counts involve an 
error of 10--15%). 
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were expressed per cell (based on cell coun-
ting after trypsinization) a remarkable 
agreement exists with the analytical data 
as obtained by microassays on isolated 
groups of freeze-dried cells (compare last 
column Table 2 with Table 1). 
A chromosome preparation from amniotic 
fluid cells grown in a Falcon dish at the 
tenth day after amniocentesis showed male 
sex, thus excluding the possibility of a 
heterozygous carrier. Hence, it could be 
concluded that the expected child would 
be a boy free from Fabry's disease. This 
diagnosis was available the eleventh day 
after amniocentesis. 
The a-galactosidase activities of the cul-
tured amniotic fluid cells from the preg-
nancy at risk, from control samples and of 
fibroblasts from the consultant, relatives 
and control individuals, as determined at 
the University Institute of Medical Gene-
tics, Copenhagen, are shown in Table 3. 
The a-galactosidase activity in cells from 
the pregnancy at risk appeared to be the 
same as those in the three control samples. 
It could be concluded on the 25th day 
after amniocentesis i.e. in the 18th - 19th 
week o.f pregnancy, that the fetus was a 
male not suffering from Fabry's disease, 
which was in agreement with the analytical 
results obtained earlier. Using p-nitrophenyl 
substrate again, the a-galactosidase activity 
in normal amniotic fluid cells was compar-
able to that in control fibroblasts. The ac-
tivities in the three heterozygotes, although 
showing considerable differences, were all 
lower than the controls. In the patient with 
Fabry's disease the a-galactosidase in fibro-
blasts showed a residual activity of 15 -
20% whereas in leucocytes no activity was 
found at all. The range of a-galactosidase 
activities in the different cell strains using 
p-nitrophenyl substrate was about two ti-
mes lower than that with methylumbelli-
feryl substrate. 
A male child was born after an unevent-
ful pregnancy and delivery. Assay of a-
galactosidase activity in a leucocyte prepa-
ration from peripheral blood showed a 
normal value (130.0 X 10-9 moilhour/mg 
protein) confirming the prenatal diagnosis. 
Table 3 
a-galactosidase activities as determined by conventional techniques using 
p-nitrophenyl substrate 
Cell type 
Cultured amniotic fluid cells 
Fibroblasts 
Leucocytes 
Individuals 
(see Fig. 1) 
Pregnancy at risk 
Control no. 476 
Control no. 474 
Control "Goteborg·• 
"L" consultant 
"S" normal male 
"M" heterozygote 
"'0" heterozygote 
"P"' male Fabry patient 
"L" consultant 
"S'' normal male 
"P" Fabry male 
"0" heterozygote 
"-galactosidase activity* 
x 10·• mol/h/mg protein 
30.6 
29.8 
21.7 
22.3 
18.0 
31.4 
15.1 
09.9 
04.6 
37.4 
149.6 
00.0 
28.4 
* The quantity of available material was sufficient for only one reading, therefore, standard deviations could 
not be assessed. 
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Discussion 
Microtechniqucs compared with 
conventional methods 
The results illustrate the feasibility of using 
microchemical analysis for a more rapid 
prenatal diagnosis than is possible with 
conventional analytical methods. In the pre-
5cnt case, analysis could be carried out 
11 d after amniocentesis using microtech-
niques, the prenatal diagnosis being avail-
able before the 17th week of pregnancy, 
while with conventional techniques it was 
available 2 weeks later. Confirmation of 
the prenatal diagnosis was obtained by 
a-galactosidase activity studies in leucocytes 
of the male child after birth. 
The same principles may be applied to 
the monitoring of other metabolic defects 
when these involve spectrophotometric or 
fluorometric assays (Galjaard et a!. 1972a, 
b, Galjaard 1973). Although in enzyme 
studies the activity for artificial substrates 
is usually less than for natural substrates, 
the simplicity of assays using artificial sub-
strates gives an important advantage in 
microchemical analysis. In both spectro-
photometry and fluorometry, Jess cell ma-
terial is required for analysis when incu-
bation and final volumes are reduced (Gal-
jaard et al. 1972b, 1973 ). The extent to 
which the reaction volumes should be re-
duced depends on the activity of the en-
zyme to be analyzed and on the kind of 
assay. It may be deduced from the results 
for (!-galactosidase shown in Table 1, that 
for enzyme activities in the order of 10 -H 
mol/h/cell, incubation volumes between 0.5 
- I /II result in fluorescence values which 
arc well above the blank values. 
Reliability of micromethods 
The values for a-galactosidase activities m 
various cell strains, as measured in cell ho-
mogenatcs (Table 2), correspond remark-
ably well with data obtained by other war-
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kers using the same methylumbelliferyl sub-
strate (Wood & Nadler 1972, Ho et al. 
1972). When expressed per cell, the data are 
also in fair agreement with the enzyme ana-
lyses on isolated freeze-dried groups of am-
nio-tic fluid cells, although the latter values 
are somewhat h_igher. This difference might 
be due to errors in cell counting and/or 
the fact that the accessibility of the en-
zyme for the Substrate is generally better 
when freeze-dried material is incubated, 
as compared with other precedures (Boo-
ting & Rosenthal 1960). 
The variation in a-galactosidase activity 
per cell between the various dissected cell 
groups (Table 1) cannot yet be completely 
explained. The experimental errors in cell 
counting and the micro-assay procedure are 
relatively small (Galjaard et al. 1973), and 
it is likely that the cell density and the 
proportion of proliferative versus non-pro~ 
liferative cells are mainly responsible for the 
variation observed. In comparing enzymatic 
activities of different cell strains, these fac-
tors, as well as the phase in the growth 
curve of the culture, should be considered. 
In normal fibroblast cultures the activity of 
a-galactosidase has been found to increase 
by a factor of 1 0 from 2 to 30 d after 
subculture (Heukels-Dully et a!. to be pub-
lished). The considerable variation between 
individuals shown in Table 3, may also be 
partly due to these factors. 
Distinction between hemizygotes, hetero-
zygotes, and normal homozygotes 
Prenatal diagnosis of Fabry's disease and 
some other lysosomal storage disorders now 
seems possible within a relatively short pe-
riod after amniocentesis, using the micro-
methods described. However, the reliability 
and usefulness of prenatal diagnosis of 
metabo-lic defects, both by means of mi-
crochemical assays and conventional anal-
ysis on cell homogenates, depend decisively 
on the ability to distinguish clearly between 
RAPID DIAGNOSIS OF FABRY'S DISEASE 
cells from a homozygous (or hemizygous) 
patient, a heterozygous carrier and a nor-
mal control. In the case of Fabry's disease 
this may be difficult for three reasons. 
Firstly, a relatively high residual a-galacto-
sidase activity (10 - 30%) is present in 
cells from Fabry's patients (Romeo & Mi-
geon 1970, Brady et a!. 1971, Romeo et al. 
1972, Ho et at. 1972). Secondly, there may 
be genetic heterogeneity within the group 
of Fabry's patients (Clarke et al. 1971, 
Wood & Nadler 1972, Romeo et al. 1972). 
Thirdly, within the same culture of amnio-
tic fluid cells from a heterozygous female 
fetus, two cell populations (deficient and 
normal cells) are present (Romeo & Mi-
geon 1970), and a difference in growth be-
tween these two cell types might lead to 
erroneous interpretations. Such growth dif-
ferences have been observed in fibroblast 
cultures from a heterozygous carrier for 
another X-linked disease, glucose-6-phos-
phate dehydrogenase deficiency (Galjaard 
1972). However, in prenatal diagnosis the 
problem of distinction between hemizygotes 
and heterozygous carriers can be avoided 
by combining the biochemical assay af a-
galactosidase with karyotyping of the am-
niotic fluid cells. When a female karyotype 
is found, microchemical analysis of single 
cells, or different clones of cultured amnio-
tic fluid cells, should enable prenatal diag-
nosis of the heterozygous state (Galjaard 
1972). 
When sufficient knowledge is available 
about the residual enzyme activity in cells 
from patients from the particular family 
involved, and when proper controls, (i.e. 
primary cultures of control amniotic fluid 
cells at the same stage of pregnancy) are 
culture(\ under standardized conditions, re-
liable prenatal diagnosis of Fabry's disease 
is possible. When microtechniques are being 
used the diagnosis can be completed 10 -
14 d after amniocentesis at the 14th to 15th 
week of pregnancy. 
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1. Summary 
The similarity between cultured amniotic fluid cells and cultured fibroblasts indicates 
that prenatal diagnosis of those lysosomal storage diseases is possible when the enzymatic 
or metabolic defect is expressed in in vitro cultured cells from patients affected with the 
lysosomal disease involved. The application of microtechniques in the study of cultured amnio-
tic fluid cells enabled the establishing of a diagnosis in 12-22 days after amniocentesis in 
five pregnancies at risk for Fompe's disease, in 16-18 days in two pregnancies at risk for 
metachromatic leukodystrophy and 11 days '1n a case for Fabry's disease. Hunter's dheose 
could be excluded within 4 weeks after amniocentesis, Contribution of microtechniques to 
a more rapid prenatal diagnosis are discussed. Control of conditions of cell culture and 
knowledge of possible variations in enzymatic activity of cultured amniotic fluid c~ls is 
essential for the interpretation of data in prenatal diagnosis. 
2. Introduction 
Amniocentesis in early pregnancy and the subsequent cultivation and biochemical 
analysis of amniotic fluid cells is a new and important tool in the precise genetic 
counseling of families at risk for a lysosomal storage disease 1• Potentially all lysosomal 
diseases where the metabolic defect is expressed in cultured fibroblasts from affected 
patients, are amenable to prenata[ diagnosis. 
A number of lysosomal storage dioseases 
. I d .. fl.d 11 2-IO us1ng cu ture amn1ot1c u1 ce s 
have already been detected in early pregnancy 
However, the cultivation period between amnia-
centesis and the diagnostic assay by conventional biochemical procedures required 4-8 
weeks. Such long waiting periods could theoretically be avoided by tbe use of uncultured 
amniotic fluid cells. This is complicated by contam'1noting maternal white blood cells11 
the 
12, 
Iorge proportion of 
13 h . I and t e poss1b e 
dead fetal cells which may loose port of their enzymatic activity 
admixture with enzymes from the amniotic fluid supernatant 14 
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The use of the cell free amniotic fluid supernatant seems another alternative. However, this 
. 15-19 
approach proved to be unreliable for glycogenesis type II and mucopolysacchandoses 
Hexosaminidase A activity in amniotic fluid seems to be related with the fetal status for 
GM 2 gangliosidosis type
6
' 
20
' 
21
, but contamination of the sample with blood may limit 
. d" . 21 F GM 1· "d . 122 I II d" 23 d h . 1ts 1agnoshc use • or 1 gang IOSI os1s type , ce aseose an metac romat1c 
leukodystrophl\nalysis of amniotic fluid indicated the fetal condition for these diseases. 
More data are needed before the value of this approach can be established. 
Since cultured amniotic fluid cells are preferentially used in prenatal diagnosis of 
lysosomal storage diseases, we have tried to reduce the number of cells required for 
b h I. . f . h . I h . 25• 26 Th" h · enzyme assays y t e app 1cat1on o m1croc em1ca tee mques • 1s approac 1n 
principle enables the prenatal diagnosis of various lysosomal storage diseases within 10-12 
days after amniocentesis in the 14-16th week of pregnancy, i.e. before the mother 
. f I 27, expen ences eta movements 28 I h" 1· . . I d" . f • n t 1s paper 1rst expenences 1n prenata 1agnos1s o 
Pompe's disease, metachromatic leukodystrophy, Hunter's syndrome ond Fabry's disease are 
described. 
3. Materials and Methods 
After transabdominal amniocentesis in the 14th-16th week of pregnancy amniotic 
fluid cell cultures were performed as described25, 26 . Microchemical assay techniques for 
acid c<.-1.4-glucosidase and o(-galactosidase were performed with methylumbelliferyl 
substrates according to methods describei5- 27 . Homogenates of cultured amniotic fluid 
cells or groups of a counted number of lyophillized cells grown on a transparent thin 
plastic film were incubated in small volumes of substrate, using the oilwell technique29 
For the assay of arylsuphatase A activity 5 J .. d of cell homogenate was incubated with 25 
)JI of substrate, consisting of 0.01 M p. nitrocatecholsulphate, 0.0005 M sodium pyrophos-
phate and 1.7 M sodiumchloride in 0,5 M sodiumacetate buffer at pH 5.0. The reaction 
was stopped after 1 hour incubation at 37°C with 25 J-ll 1 N sodiumhydroxide. Extinction 
was read in microcuvettes in a Zeiss PM Q II spectrophotometer. The assay for stored 
30 
mucopolysaccharides was carried out according to Fratantoni et al . Cells were grown 
to confluency in 35 mm Falcon Petri dishes in tagle's MEM medium (Difco) supplemented 
with 10% fetal calf serum and 5 m M sodium bicarbonate and organic buffers31 Cultures 
were kept during 5 days in medium containing 2, 5 Jl Ci/m I H2 
35so 4 (Amersham) (spec. 
activity 4 mCi/mmol); on day 5 cultures were washed and trypsinized; half of the cell 
pellet was used for the study of uptake of labelled sulphate, the other half was cultured 
for 2 days in cold medium for a chase experiment. The cell pellets were extracted in 
80% ethanol, dissolved in 1 ml lN NoOH and processed for scintillation counting and a 
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32 protein assay according to lowry Karyotyping of cultured amniotic fluid cells in preg-
nancies at risk for Hunter's syndrome and Fabry's disease was performed on a coverslip 
culture of an aliquot of amniotic fluid cells using atebrine staining. 
4, Results 
Five pregnancies at risk were monitored for Pompe's disease. Detailed results will be 
published elsewher/8 . The cultivation period ranged from 12 to 22 days, one affected 
fetus (Table 1, pregnancy I) was detected and analysis of acid o<-1.4-glucosidase in 
fetal organs obtained from the saline induced abortion confirmed the prenatal diagnosis. 
Table 1 
Prenatal diagnosis in five pregnancies at risk for Pompe's disease 
acid r:i.-1.4-glucosidase activity 
(xl0-12 m.ole/min/mg .protein) 
cultivation cells from fibroblasts 
period pregnancy control amniotic Pompe's 
Pregnancy (days) at risk fluid cells disease outcome of pregnancy 
20 26 381 28 Pompe 1s disease (A8) 
II 17 501 1049 59 unaffected 
Ill 22 680 715 unaffected 
IV 14 112 614 27 unaffected (A8) 
v 12 104 261* 25 unaffected 
AB = saline induced abortion after !'renatal prediction of Pompe's disease. 
*Primary culture of control amniotic fluid cells, all others were later confluent subcultures 
of control amnin+ic fluid cells. 
In pregnancy IV a low en7ymatic activity in an amniotic fluid cell culture analy~ed 2 
weeks after amniocentesis was erroneously interpreted as indicative for Pompe 1s disease. 
Analysis of fetal organs obtained at abortion showed normal acid d...-1.4-glucosidase 
activities. Later it was found that primary cultures of amniotic fluid cells may show lower 
enzymatic activities compared to later subcultures of amnintic fluid cells that have been 
grown into confluency. Comparison of cultured cell~ from pregnancy V with a primary 
culture of control amniotic fluid cells showed little difference in enzymatic activity. In 
this case it was concluded that the fetus was unaffected and the pregnancy resulted in a 
child with normal acid d.....-1.4-glucosidase activity in its leukocytes. 
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Analysis of acid o(-1 .4-glucosidase activity in the amniotic fluid supernatant in 
these 5 pregnancies showed no relation with the fetal condition, 
II 
Table 2 
Pregnancies at risk for metachromatic leukodystrophy (MLD) 
ary!su!phatase A activity (xl0-9 mole/PNC/min/mg protein) 
amniotic fluid cells fibroblasts 
pregnancy 
at risk* control** MLD heterozygotes 
1.0 (16 days/ 2.2 - 5.0 0.2 3.4 
1.6 (27 day•) 4.2 
1.8 (18 day•) 2.7- 3.54 0.0 2.7 
*Duration of cell culture after amniocentesis 1s indicated between brackets. 
control 
10.8 
**Data are the extreme values of assays on 2 - 5 cell strains. In case I later subcultures 
were used as control and in case II primary cultures. 
Table 2 presents results on two prenatal diagnosis in pregnancies at risks for metachro-
matic leukodystrophy. In family I a previous child showed a deficient a~ylsulphatase A 
activity in cultured fibroblasts (0.2). Cultured amniotic fluid cells from pregnancy I were 
analyzed 16 and 27 days after amniocentesis and on both occasions a clear 01ylsulphatase 
A activity was found, the second culture showing a higher specific activity. This preg-
nancy resulted in a female child with arylsulpho~ase A activity in the leukocytes in the 
range between controls and heterozygotes. In pregnancy II the previous affected child died 
before enzymatic confirmation of the diagnosis could be made and the diagnosis was based 
on the histology of the brain. Fibroblasts of an unrelated patient with MLD had b be used 
as a control. Cultured amniotic fluid cells analyzed 18 days after amniocentesis showed an 
mylsulphatase A activity slightly lower than two control cultures grown for the same period. 
This pregnancy is continuing. 
Prenatal analyses in 2 pregnancies at risk for Hunter's syndrome as presented in table 
3 indicated that in pregnancy I, where a male sex was detected, the cultured amniotic 
fluid cells incorporated nearly twice as much labelled sulphate as control fibroblasts. 
However, the residual radiactivity after 2 days of chose was nonnal and in agreement 
with that obtained by Dr. Dorfman in Chicago. In pregnancy II (where a female sex was 
35 
detected on karyotyping of cultured amniotic fluid cells) the uptake of so4 was found 
to be in the control range and a no1Tl1ol rate of degradati'on was observed. These studies 
were performed 22 days after amniocentesis. Analysis of acid-mucopolysaccharides in the 
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amniotic fluid supernatant in pregnancy II showed a normal pattern for the period of 
gestation (Dr. M.A.H. Giesberts, leiden). 
Table 3 
Results of two prenatal analyses for Hunter's disease 
3550 . . 
1 1ncorporat1on of er 5 days % residual radioactivity 
C.p.m ./mg. protein after 2 days "chase" 
pregnancy I ("F") 1448 0 
(sex: ~) 
Hunter fibroblasts 3380 100 
control fibroblast I 393 16 
2 668 21 
pregnancy II ("V") 470 0 
(sex: ~) 
Hunter fibroblasts 4159 61 
control fibroblast I 662 8 
2 245 18 
In a pregnancy at risk for Fabry's disease (table 4) prenatal diagnosis was performed 
by microchemical assay of the ~-galactosidase activity in small groups (50-200) of lyo-
philized cultured cells isolated from the amniotic fluid cell culture 11 days after amnio-
centesis. Results as described in detail elsewhere27, were compared with studies on a cell 
homogenate prepared from a parallel culture and enzyme activities expressed per cell 
showed a good corrleation between both techniques. A male karyotype was found on 
atebrine staining of a chromosome preparation of cultured amniotic fluid cells. A boy was 
born at term, showing normal o(-galactosidase activity in a leukocyte preparation. 
Table 4 
Prenatal diagnosis of Fabry's disease using microchemical techniques 
co·ntrol amniotic fluid cells 
pregnancy at risk (male sex) 
o(-galactosidase activity 
(x lo-14 mole/he/cell) 
microanalysis on 
groups of 50 - 200 
freeze-dried cells 
2.76 + 0.46* 
1.49 + 0.31 
analysis on cell homogenate 
and enzyme activity 
expressed per cell 
1.70 
1.96 
*The mean activity of 10-16 groups of 50 -200 cells. s.d. standard deviation. 
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5. Discussion 
Our first experiences with microchemical techniques in the prenatal diagnosis of a 
number of lysosomal enzyme deficiencies showed that enzyme assays on small numbers of 
cultured amniotic fluid cells could be established within 11-22 days after amniocentesis in 
the 14-16th week of pregnancy. The period required for obtaining sufficient cultured cells 
for biochemical analysis, which ranged from 4- 8 weeks3' 9 ' 33-35, is shortened and 
such a reduction in the waiting time is not only of psychological advantage for the parents 
but also an interruption of pregnancy is likely to cause less problems than after the 5-7th 
month of pregnancy. 
The use of primary cultures of control amniotic fluid cells from the same gestational 
age is required for a correct interpretation of the analytical data on cells from a pregnan-
cy at risk. As was noted in this study (Table 1) and in other reports 28 ' 36, 37 the 
specific activity of some lysosomal enzymes m<:Jy be considerably lower in primary cultures 
than in later subcultures of the same amniotic fluid sample. If later subcultures of normal 
amniotic fluid cells are used as a control erroneous interpretations can be made especially 
if low enzyme activities are observed in cells from a pregnancy at risk (see Table 1, case 
IV). In this respect it should be noted that for add o<,_-1.4-glycoside the mean activity in 
primary cultures of normal amniotic fluid cells was found to be less than 10 percent of that 
in normal fibroblasts. The enzyme activities in cells from heterozygotes will show even 
lower values. Since amniotic fluid samples can be stored with the maintenance of cell 
viability38 primary cultures of control samples can be available for prenatal diagnoses at 
any desired time. 
The examples of prenatal diagnosis given in the present paper all involve incubati-on 
in microliter volumes followed by measurements in final volumes between 50 and 500 }JI 
using microcuvettes adapted to commercially available spectrofluommeters. For five cases 
of prenatal diagnosis of Pompe's disease this enabled an enzyme assay after 12 - 22 days 
of in vitro growth of the amniotic fluid cells, for Fqbry's disease after 11 days and for 
metachromatic leucodystrophy after 16 - 18 days. A further reduction in the number of 
cells required and hence in the waiting time can be accomplished by performing the 
extinction or fluorescence measurements in microdroplets (1-5 }Jl) using a microspectro-
fluorometer design. Such methods can be used for the assay of about ten lysosomal enzyme 
defl6en6e, where ar@dal 'ub.trate' can be u,ei9 ' 40 
If biochemical assays are to be performed with radioactive labelled substrates there 
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is less scope for increasing the sensitivity of the measurement except by using radioisotopes 
with high specific activity. In our examples of prenatal diagnosis for Hunter's disease 
liquid scintillation counting of 35so4 incorporation could be carried out within 4 weeks 
after amniocentesis, and the use of adapted culture techniques41 might enable some 
additional reduction in this period. In the near future analysis of the specific enzyme 
defects in mucopolysacchoridoses are likely to replace the assay for the stored products. 
So far the number of cells required for the assay of one of these enzymes ( c<.. -iduronidase) 
has been reported to be the same as for 35so 4 incorporation studies
42
• However, by 
simply scaling doen of the incubation and final volumes also for this enzYme assay the 
number of cells might be reduced 100 - 1000 fold 26• 39• 40 
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SUMMARY 
350 Pregnancies were monitored by transabdominal amniocentesis in the 14th-
16th week of gestation followed by karyotyping or biochemical assays of cul-
tured amniotic fluid cells and analysis of alpha-fetoprotein in the amniotic 
fluid supernatant. The pregnancy was interrupted in 36 cases (10%) either 
because of a fetal abnormality or the presence of a male fetus in pregnancies 
at risk for an X-linked disease. 
Four chromosomal aberrations were found in 87 pregnancies tested because of 
advanced maternal age. In 101 pregnancies with a recurrence risk of Down's 
syndrome, 2 fetuses with an abnormal karyotype were detected. In 11 cases, 
in which one parent was a carrier of a balanced translocation, 2 unbalanced 
fetal karyotypes were found. Fetal chromosome studies in 43 pregnancies at 
risk for an X-linked disease indicated the presence of a male fetus in 21 
cases. 
Prenatal diagnosis of 11 different metabolic diseases was performed in a total 
of 34 cases. Microchemical technigues were used to allow completion of the 
diagnosis of seven different enzyme deficiencies within 9 - 22 days after am-
niocentesis. 
Alpha-fetoprotein assay in the amniotic fluid supernatant of 47 pregnancies at 
risk for an open neural tube defect resulted in the detection of 3 anencepha-
lic fetuses during the second half of pregnancy. 
The safety and reliability of amniocentesis and the possible effects on the out-
come of pregnancy are evaluated. Prenatal diagnosis offers a promising alter-
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native for parents who are at risk of having a child with a genetic disease 
which can be detected in amniotic fluid or in cultured amniotic fluid cells. 
INTRODUCTION 
Since the first reports of fetal karyotyping (Steele & Breg, 1966; Jacobson & 
Barter 1967) and biochemical assays (Nadler, 1968; 1969) after amniocentesis 
in early pregnancy, an increasing number of centers have gained experience 
on prenatal diagnosis of genetic disease. Recent reviews (Milunsky, 1973; 
Hsu & Hirschhorn, 1974) demonstrate how the application of prenatal diagnosis 
in genetic counseling has already enabled many parents at risk for genetic 
disease to have non-affected children. Prenatal chromosome analysis has be-
come routine and the number of inborn errors of metabolism which can be de-
tected in cultured amniotic fluid cells has steadily increased (Milunsky & 
Littlefield, 1972; Burton et al., 1974). Although theoretically over 40 meta-
bolic disorders are now detectable in cultured amniotic fluid cells, only limi-
ted experience with each of these diseases has been gained. A few small se-
ries have been accumulated: for GM2 gangliosidosis type l (Toy-Sachs' disease) 
(O'Brien et al., 1970; Navon & Padeh, 1971; Ellis et al., 1973), glycogeno-
sis type II (Pompe•s disease) and the mucopolysaccharidoses (Milunsky, 1973; 
Niermei jer et al., . 1974). Conventional biochemical analysis requires relatively 
large cell numbers, which sometimes resulted in rather long waiting periods 
for the parents (4- 8 weeks). The development of microchemical techniques 
enabled enzyme assays on small numbers of cultured amniotic fluid cells and 
a reduction in the time required for prenatal diagnosis (Galjaard et al., 1973; 
a b 1974 ; 1974 ; Wendel et a!., 1973). 
A recent and important contribution to the field of prenatal diagnosis was the 
finding by Brock & Sutcliffe (1972), that the alpha-fetoprotein level in am-
niotic fluid is increased when the fetus has an open defect of the neural tube. 
When relatively new techniques like those of prenatal diagnosis are used full 
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assesment of the scope and risks of the various procedures is possible only 
when sufficiently large series of diagnoses for different groups of genetic di-
seases can be analysed, including follow-up studies on children born after 
amniocentesis. The present report describes 350 prenatal diagnoses performed 
in pregnancies at risk for a chromosomal aberration, X-linked disease, neural 
tube defect or one of 11 different metabolic diseases. 
METHODS AND MATERIALS 
1. Clinical methods 
The actual genetic risk was estimated in each woman referred for prenatal 
diagnosis by taking the family history. Additional diagnostic tests on previous 
affected children, parents or relatives {karyotyping, enzymatic studies, etc.) 
were performed when necessary in order to make sure that amniocentesis was 
justified. A risk higher than 1% for a disease amenable to prenatal diagnosis 
was taken as an indication for amniocentesis (table 1). The indication for 
advanced maternal age was accordingly limited to women 38 years and older. 
The procedure of amniocentesis and its related risks were explained to the 
patients. 
Transabdominal amniocentesis (Queenan, 1970) was performed under local 
anesthesia in the 14th - 16th week after the last menstrual period. Ultrasound 
examination was carried out to localize the placenta, measure the fetal bi-
parietal diameter, estimate the volume of amniotic fluid and to exclude the 
presence of twins. 10 - 15 ml of amniotic fluid was aspirated into a silico-
nised glass syringe. 
Selective abortion was performed when indicated by intraamniotic injection of 
hypertonic saline or by intra- or extraovular infusion of prostaglandin F2-alpha. 
Follow-up studies on children born after amniocentesis were performed using a 
schedule modified from the British Medical Research Council 11Working Party on 
Amniocentesis 11 • 
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The vast majo~ity of amniocenteses and different analyses were performed by 
our own group. Samples referred by other centers were transported in silico-
nised glass flasks. Amr1iotic fluid samples from normal pregnancies were kindly 
provided by Dr. K.L. Garver, Magee Womens Hospital, Pittsburgh (U.S.A.) 
and stored until use as controls in biochemical studies according to a proce-
dure described earlier (Niermeijer et al., 1973). 
2. Cell culture methods for amniotic fluid cells 
After counting the cells with a hemocytometer the amniotic fluid was centri-
fuged for 5 min. at 80 x g. and the supernatant was centrifuged for another 
10 min. at 1500 x g. and stored at -70°C until needed. The collected cells 
were cultured according to different techniques, especially during the initial 
phase of this study. The procedure used in the last 300 cases is described 
here. 
The cell pellets were resuspended in Ham's FlO medium supplemented with 
25% v/v of fetal calf serum (Flow Company), penicillin (50 U/ml) and strep-
tomycin (50 llg/ml). For chromosome analysis cells were seeded on 22 x 22 mm 
coverslips in different 35 mm Falcon plastic Petri dishes. Aliquots of 0.75 ml, 
containing 50,000- 100,000 cells, were gently pipetted on the top of the 
coverslips and left overnight in a fully humidified incubator with 5% C02 in 
air as the gaseous phase, before additional medium was added up to 2 ml. 
The medium was changed after 5 days and subsequently every second day unti I 
sufficient mitotic cells for harvesting were present. Some bloody samples of 
amniotic fluid were processed according to lee et al., (1970)i since this did 
not give significant improvement in cell growth, the method was omitted. 
Culture methods for biochemical analysis were similar. Cells cultured in the 
Petri dishes were used to provide cell homogenates. In addition cells were 
seeded in Mylar dishes with a thin plastic bottom to enable microchemical 
studies on groups of 100- 300 dissected cells (Galjaard et al., 1973; 1974~. 
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For each prenatal diagnosis amniotic fluid cell samples from a comparable 
gestational period cultivated under similar conditions (medium, pH, cell num-
ber seeded,period of cell cultivation after subculture) were used as controls. 
Amniotic fluid cell cultures received from outside centers were grown in Ham•s 
Fl 0 medium for at least 24 hours before harvesting. 
3. Chromosome analysis of cultured amniotic fluid cells 
When sufficient mitotic cells were observed in a culture, colchicine (0.02 Jlg/ 
ml) was added to the medium for 3.5 - 4 hours. A procedure adapted from 
Htssli (personal communication) was used for in situ spreading and gradual 
fixation to avoid loss of mitotic cells. Q banding was performed with a 0.5% 
solution of atebrin (Caspersson et al., 1971). Metaphases were studied with 
a Leitz fluorescence microscope equipped with a vertical illuminator and fil-
ter combinations as described by Van der Ploeg and Ploem (1973). 
A minimum of 16 metaphases was analysed from at least two different cultures 
and a minimum of 3 metaphases was karyotyped (Paris Conference, 1971). 
Polyploid metaphases were not included. A complete fetal chromosome analy-
sis was used for prenatal sex determination in pregnancies at risk for an X-
I inked disease. 
4. Microchemical analysis of cultured amniotic fluid cells 
Cell homogenates or dissected groups of 100 - 300 freeze-dried cultured cells 
were prepared as described (Galjaard et al., 1973; 1974b). The procedures 
for the microchemical assay of a-galactosidase (Gaiiaard et al., 1974a), 
acid a-1 ,4-glucosidase (Galjaard et al., 1973), acid p-galactosidase (Gal-
jaard et al., 1974c), p-D-N-acetylglucosaminidase (Galjaard et al., 1974d) 
and arylsulfatase A (Niermeijer et al., 1974) have been described. a -L-Idu-
ronidase was measured according to Hall & Neufeld (1973) using a final 
volume of 30 ill. p-Giucosidase was assayed using a procedure modified from 
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Beutler et al. (1971). 
Electrophoresis of p-D-N-acetylglucosaminidase was performed as described 
(Galjaard et al., 1974d) and heat inactivation studies of p-D-N-acetylglu-
cosaminidase isoenzymes in amniotic fluid supernatant were performed accor-
ding to O'Brien et al.(1970). 
The results of assays on cell homogenates were expressed per mg protein as 
determined according to Lowry et al. (1951) using a final volume of 60 ~1. 
When possible the activity of a second, non-related enzyme localized in the 
same subcellular compartment was measured as a test for the preservation of 
enzymatic activity during preparation of the sample. 
The enzymatic activities were expressed per cell in microchemical assays on 
dissected groups of freeze dried cells. 
Cultured cells from control amniotic fluids and fibroblasts from a previous af-
fected child and heterozygous carriers were analyzed at the same time as the 
cells for diagnosis, whenever these specific fibroblast strains were available. 
35 Studies on the uptake and release of SO 
4
-sulphate in cultured amniotic 
fluid cells from pregnancies at risk for mucopolysaccharidoses type I and II 
were performed according to Fratantoni et al.(l969) as modified by Neufeld 
(personal communication). 
Branched chain ketoacid decarboxylase was assayed in cultured amniotic fluid 
cells using a microassay described by Wendel et a1.(1973). 
Cultured cells from a pregnancy at risk for Krabbe's di~ease were assayed for 
p-galactocerebrosidase activity using the natural substrate by Dr. A.D. Patrick, 
Institute of Child Health, London. 
5. Determination of a -fetoprotein (AFP) in amniotic fluid 
The single radial immunodiffusion technique using Partigen plates (Behring-
werke) was used and duplicate samples from pregnancies with a recurrence 
risk for a neural tube defect were analysed by Dr. D.J. Brock, Dept. Human 
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Genetics, Edinburgh, with rocket immunoelectrophoresis. This test has only 
been used since January, 1974, and in addition to pregnancies at risk for a 
neural tube defect all other amniotic fluids were routinely tested. In pregnan-
cies at risk for a neural tube defect a chromosome analysis was performed as 
well to exclude the presence of a fetus with a chromosome aberration. 
6. Confirmational studies after selective abortion 
Fetal autopsies were performed by Dr. J.L.J. Gaillard, Dept. Pathology. 
Cell cultures were initiated from fetal skin. Fetal organs or fetal cells were 
used for biochemical assays by Dr. J.F. Koster (Dept. of Biochemistry) in the 
case of metabolic diseases. 
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TABLE I 
PREGNANCIES MONITORED BY AMNIOTIC FLUID (CELL-) ANALYSIS 
INDICATION 
CHROMOSOMAL ABERRATIONS 
-recur. risk Down's syndrome 
-advanced maternal age 
-Down's syndr. in relatives 
-inherited translocations 
-miscellaneous 
X-LINKED DISEASES 
-Duchenne's muse. dystrophy 
-Haemophi!io 
-others 
METABOLIC DISEASES 
-Glycogenesis type II 
-GM2 gangliosidosis (Toy-Sachs) 
-GM2 gangliosidosis (Sandhoff) 
-GM1 gangliosidosis 
-Fabry's disease 
-Metachromatic leukodystrophy 
-Krabbe's disease* 
-Hurler's disease 
-Hunter's disease 
-Gaucher's disease 
-Maple syrup urine disease 
NEURAL TUBE DEFECTS 
-recur. risk neural tube defects 
-hydramnios after 20 weeks 
226 
43 
34 
47 
350 
N 
tested 
101 
87 
B 
11 
19 
18 
16 
9 
13 
3 
3 
2 
3 
3 
3 
28 
19 
* Assay performed by Or. A.D. Patrick, london 
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N 
selective 
abortions 
10 
20 
3 
3 
36 
2 
4 
2 
2 
10 
7 
3 
3 
3 
PRENATAL DIAGNOSIS 
trisomy 21;1 7/21 transloc, 
3 trisomy 21;1 47 XXY 
13/22 unba1.;1 G/G unbal, 
trisomy 18; 1 47 XYY 
11 d fetuses (1 XO/XY mosaic) 
7 d fetuses 
3 d fetuses 
2 affected; 1 misdiagnosed 
3 anencephalies 
RESULTS 
l. PRENATAL CHROMOSOME STUDIES 
The results of 350 pregnancies monitored for a variety of genetic risks are 
listed in table I. The period between amniocentesis and diagnosis in 269 pre-
natal chromosome analyses was 6 - 14 days in 47%, 15 - 21 days in 40% 
and 22 - 28 days in 13% of the cases. Most cultures had colonies with vary-
ing morphology (epitheloid, fibroblast-like and intermediate). No 46 XX/46 XY 
mosaicism was observed, which might indicate admixture with maternal cells, 
nor was a male child diagnosed as female. 
In 101 pregnancies with a recurrence risk of Down's syndrome 60 mothers had 
a previous child with cytogenetic evidence of trisomy 21 and 2 had a child 
with a sporadic translocation. The diagnosis of Down•s syndrome in the other 
children had been made because of the clinical features. In one case of fetal 
trisomy 21, the mother had had a previous child with the same aberration. 
Lymphocyte and fibroblast studies on the parents showed no evidence for 
mosaicism. A second abnormal karyotype found in the group with recurrence 
risk of Down•s syndrome was a sporadic translocation 46 XY, t (7p-,2lq+) 
(figure 1). The previous child had hod Down's syndrome caused by o 46 XY/ 
47 XY + 21 mosaicism; the parents• karyotypes were normal (Dr. W.L. Gouw, 
Dept. Anthropogeneti cs, Groningen). The parents were informed about the 
possible consequences of this type of chromosomal aberration and they asked 
for interruption of the pregnancy. Chromosome studies on fetal cord blood 
gave similar results as the prenatal karyotype, however the fetus showed no 
macroscopical abnormalities. 
In 87 cases tested because of advanced maternal age 4 non-disjunctions were 
detected (table I). These 4 cases occurred in 68 mothers of 40 years and ol-
der. The chromosome abnormalities were confirmed after elective abortion. 
Eight patients were referred because one of the sibs of the parents had Down•s 
syndrome. No abnormalities were detected. 
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Figure 1. 
Prenatal karyotype (Q-banding) 46 XY, t(7p-, 21q+) from a pregnancy with a· recurrence 
risk of trisomy 21 . 
Figure 2. 
Prenatal karyotype (Q-banding) 46 XY, D-, t{22-13)+ showing partial trisomy 22. 
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In 11 cases one of the parents carried a balanced chromosomal translocation. 
The type of translocation and the result of prenatal testing are listed in table 
II. Two unbalanced karyotypes were observed. After interruption of the preg-
nancy the prenatal diagnosis was confirmed in case 4. Case 2 was referred in 
the 23th week of pregnancy ond the mother was found to be a 22/13 translo-
cation carrier. A 46 XY,D-,t (22-13) +karyotype was found in the fetus 
(figure 2) in the 27th week of pregnancy. A male child weighing 1950 gm 
was born in the 37th week and died on the second day of life. The following 
malformations were observed: cleft palate, antimongoloid eye slant, bilateral 
iris colobomata, broad nasal bridge, dextrocardia, ventricular septal defect, 
transposition of the aorta, anal atresia with rectourethral fistula, hypospadia 
and undescended testes and a small cystic left kidney. This pattern of malfor-
mations resembled the cases of trisomy 22 as described by Punnett Gt al. (1973) 
ond Hirschhorn et al. (1973). 
In case 3 {table II) spontaneous abortion occurred 4 weeks after amniocentesis; 
there had been previous signs of imminent abortion. The amniotic fluid cells 
TABLE II 
PREGNANCIES AT RISK FOR AN INHERITED TRANSLOCATION 
type of 
case 
translocation . 1 carrier-parent karyotype of amniotic fluid cells 
14 - 21 M 46 XY 
2 13 - 22 M 46 XY, t(13q;22q) 
3 14- 21 M spont. abortion 4 weeks after amniocentesis 
4 21 - 22 M 46 XY, t(21q;22q); selective abortion 
5 14- 21 M 45 XY, t(14q;21 q) 
6 14 - 21 M 45 XY, t(14q;21q) 
7 14- 21 F 45 XY, t(14q;21q) 
8 6 - 13 (p23; q22-31) M 46 XX 
9 t(4;10)-(q21; q11) M 46 XX, 1(4; 10)(q21 ;q 11) 
10 14 - 21 F 45 XX, t(14q;21q) 
1. M = mother, F = father 
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-METHODS OF DIAGNOSIS IN PREVIOUS AFFECTED CHILDREN IN PREGNANCIES AT RISK FOR METABOLIC DISEASES 
N diagnosis of index-patient by studies on (l) 
pregnancies 
fibroblosts( 2) 
clinical 
studied leukocytes urine autopsy features pedigree 
---
--------- --·· 
GLYCOGENOSIS TYPE II 13 II II 
GM2 GANGLIOSIDOSIS (Tay-Sach•) 3 2 
GM2 GANGLIOSIDOSIS (Sandhaff) 3 3 
GM1 GANGLIOSIDOSIS 2 
FABRY'S DISEASE 
METACHROMATIC LEUKODYSTROPHY 3 
KRABBE'S DISEASE 
HURLER'S Dl SEASE 3 2 
HUNTER'S DISEASE 3 3 + 3 
GAUCHER'S DISEASE 
MAPLE SYRUP URINE DISEASE 
- -
- - - -
34 19 16 2 4 3 + 3 
{1) Data as obtained from centers referring amniotic fluid or amniotic fluid cell cultures for prenatal diagnosis, 
(2} Fibroblasts from index case studied simultaneously with amniotic fluid celts. 
failed to grow. Unfortunately, the abortion material was not available for 
chromosome analysis. Miscellaneous indications for cytogenetic studies in 19 
cases included the recurrence risk of the 5p- and 18q- syndromes, maternal 
mosaicism, multiple abortions and severe intrauterine growth retardation in the 
second half of pregnancy. A trisomy 18 was found in the 35th week of ges-
tation in the last case. The child was delivered stillborn. A 47 XYY fetus 
was detected in a pregnancy from a mother who had two previous spontaneous 
abortions; a number of her relatives were mentally retarded. The parents re-
quested interruption of the pregnancy. 
In 34 of the 43 cases in the group at risk for X-linked recessive diseases the 
mother was a proven or possible carrier of either Duchenne's muscular dystro-
phy or hemophilia. Other indications for prenatal sex determination were risks 
for X-linked mental retardation, oculocerebrorenal (Lowe's) syndrome and X-
linked agammaglobulinemia. These parents wanted to limit their offspring to 
non-affected females, knowing that a male would have a 50% chance of be-
ing affected. One couple at risk for Duchenne's muscular dystrophy choose to 
continue their pregnancy after the prenatal test showed that a male child 
would be born. In one culture obtained from the 15th week of a pregnancy 
at risk for Duchenne's muscular dystrophy a 45 X0/46 XY mosaicism was found. 
Cultures initiated from amniotic fluid obtained at termination of the pregnan-
cy all showed 46 XY metaphases. The fetus had a male phenotype and male 
internal genitals; cells from fetal tissues could not be grown. 
2. PRENATAL DIAGNOSIS OF METABOLIC DISEASES 
34 Pregnancies were monitored for 11 different metabolic diseases (table 1). 
Some of these results have been presented in detail elsewhere (Niermeijer et 
al., 1974; 1975; Galjaard et al., 1974°). 
The diagnosis in a previous affected child was made according to the methods 
listed in table Ill and it is apparent that the enzyme defect had been identi-
137 
fied in the maiority of cases by studies on leukocytes and fibroblasts. When 
only autopsy studies were available, the parents were i nfonned that prenatal 
diagnosis in their cases had certain restrictions. 
In the first two pregnancies tested for Pompe•s disease insufficient cell growth 
was obtained and the activity of acid a-1,4-glucosidase in the amniotic fluid 
supernatant was normal. At that time (1969) such a test was still considered as 
reliable (Nadler & Messi no, 1969). Unfortunately, one of these children 
proved to be affected with Pompe 1s disease. In all 11 subsequent cases prena-
tal diagnosis was based on assays on cultured cells. In two cases very low ac-
tivities of acid a -1 ,4-gl ucosidase were observed; after interruption of these 
pregnancies in the 18th week enzyme assays on fetal tissues (liver, muscle, 
heart, brain and kidney) confirmed the diagnosis. In one instance a low acti-
vity of acid a-1 ,4-glucosidase in an early primary amniotic fluid cell culture 
was erroneously interpreted as compatible with Pompe•s disease in the fetus and 
the pregnancy was terminated. Later it was observed, that the enzymatic ac-
tivities in later subcultures of control amniotic fluid cells might be considerably 
higher than those in early primary cultures. Since then we have used control 
cells which have been cultured under similar conditions and for the same 
period as those from the pregnancy at risk (Niermeijer et al., 1975). In 8 
cases the activities of acid a-1 ,4-glucosidase were found to be in the range 
of controls or heterozygotes and all children born were found to be normal. 
These prenatal diagnoses were completed in 14 - 22 days after amniocentesis. 
Three pregnancies were tested for Toy-Sachs• disease. In one case a rtormal 
hexosaminidase A activity was detected on electrophoresis of cultured amniotic 
fluid cells. A normal electrophoretic pattern in amniotic fluid supernatant was 
found in the other two cases; this result was confirmed by analysis of cultured 
cells in other laboratories. 
Three amniotic fluid cell cultures were monitored for SandhofPs disease and 
all showed the presence of both hexosaminidase A and B by electrophoresis 
and a normal total hexosaminidase activity. One of these children has been 
138 
TABLE IV 
PRENATAL DIAGNOSIS FOR GM1-GANGLIOSIDOSIS 
USING DIFFERENT MICROTECHNIQUES 
A. STUDIES ON GROUPS OF 10-20 FREEZE-DRIED CELLS1 
Amniotic fluid cells 
pregnancy at risk (Mrs. E) 
control 
Fibroblasts 
GM1-gangliosidosis 
B. STUDIES ON CELL HOMOGENATES2 
Amniotic fluid cells 
pregnancy at risk (Mrs. E) 
control 
control 2 
control 3 
Fi bra blasts 
control 
GM1 patient E 
1. performed 9 days after amniocentesis. 
2. performed 12 days after amniocentesis. 
pgalactosidose 
nmol/h/mg P 
690 
520 
710 
1500 
780 
63 
p -galactosidase 
activity 
x10- 13 mol/h/cell 
2.5 
3.6 
0.08 
p-0-N-acetyl-
glucosomi nidase 
nmol/h/mg P 
5400 
5100 
4100 
11200 
11300 
12500 
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born and has serum hexosaminidase activity in the normal range. 
Microchemical assays of p-galactosidase were performed on dissected groups of 
10 - 20 freeze-dried cultured cells from two pregnancies at risk for GM
1
-
gangliosidosis. The diagnoses were completed 9 and 15 days after amniocente-
sis and showed normal values (table IV). p-galactosidase activities obtained 
from freeze-dried cells showed a good correspondence with values obtained in 
analyses on cell homogenates prepared from replicate cultures. Activities are 
expressed per mg protein in cell homogenates but can be calculated per cell 
by using the factor 1 mg protein=3.106 cells (Galjaard et al., 1974b). 
Microchemical analyses were also done on freeze-dried cells cultured from a 
pregnancy at risk for Fabry•s disease. The result was available ll days after 
amniocentesis. Cell homogenates from replicate cultures were also analyzed, 
both in our laboratory and in the Institute of Medical Genetics, Copenhagen. 
Normal a-galactosidase activities and a normal male karyotype were found. 
A normal boy was born (Galiaard et al., 
In three cases at risk for Hurler's disease 
1974a). 
3550 . . 
4-1ncorporahon and chase stu-
dies suggested normal muc·opolysaccharide metabolism in the fetus. In one case 
however, a-L-iduronidase activity fell in the same range found in fibroblasts 
from Hurler patients. According to the suggestion by Hall & Neufeld (1973), 
35 
who observed a similar phenomenon, we relied upon the results of SO 4-stu-
dies and the pregnancy was continued~ 
In three pregnancies at risk for Hunter's syndrome chromosome analyses were 
performed along with 35so 4 incorporation studies. Three female fetuses were 
detected and all showed normal mucopolysaccharide degradation, as expected. 
Microchemical assays of arylsulfatase A activity in three pregnancies at risk 
for metachromatic leukodystrophy were performed 16 and 18 days after amnio-
centesis and indicated the presence of unaffected fetuses. 
In a pregnancy at risk for Krabbe's disease the assay of p-galactocerebrosidase 
(performed by Dr.A.D. Patrick, London) on a homogenate of cultured cells 
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showed a normal activity. 
A p-glucosidase activity half of control amniotic fluid samples but clearly 
higher than that found in a previous pregnancy was found in cultured amniotic 
fluid cells from a pregnancy at risk for Gaucher•s disease. 
The assay of branched-chain ketoacid decarboxylase activity was completed 11 
days after amniocentesis in a pregnancy at risk for Maple Syrup Urine Disease. 
A normal activity was found. 
In children born after prenatal testing for metabolic defects biochemical assays 
on leukocytes or fibroblasts were performed whenever possible and in 25 cases 
confirmation of the prenatal diagnosis has been obtained. The other pregnan-
cies were not completed at the moment of this report. 
3. PRENATAL DIAGNOSIS OF NEURAL TUBE DEFECTS 
Cl-Fetoprotein levels were elevated (90 ~g/ml in week 27; 13 in week 29 and 
90 in week 22, respectively) in 3 of 19 cases where hydramnios developed in 
the second half of pregnancy. Ultrasound examination showed anencephalic 
fetuses in these three cases. No abnormal elevated levels were found in 28 
pregnancies tested for the recurrence risk of a neural tube defect. 
In a pregnancy tested for the recurrence risk of trisomy 21 during the 16th 
week an AFP level of 70 ~g/ml was found; this sample however showed ad-
mixture with fetal red blood cells and a second sample obtained at the 19th 
week of the pregnancy showed a normal AF P I eve I • 
4. COMPLICATIONS OF AMNIOCENTESIS 
No serious maternal complications were observed. Two patients experienced a 
transient vaginal leakage of amniotic fluid for a few days after amniocentesis. 
Spontaneous abortions within one month after amniocentesis were observed in 
3 pregnancies: 
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case 1: Spontaneous abortion within two weeks after transvaginal amniocentesis, 
which was performed because the placenta was localized over the com-
plete anterior uterine wall. Fetal tissues showed signs of amnionitis 
and the transvaginal route has since never been repeated. 
case 2: Pregnancy at risk for Pompe•s disease; spontaneous abortion 3 weeks 
after amniocentesis. Analysis of fetal tissues showed a deficiency of 
acid a-1,4-glucosidase activity. 
case: 3: Balanced carrier of a 14/21 translocation. Spontaneous abortion occur-
red 4 weeks after amniocentesis. Amniotic fluid cells failed to grow. 
Fetal tissues were not avai !able for study. 
5. FAILURES OF AMNIOCENTESIS AND AMNIOTIC FLUID CELL CULTIVATION 
In 14 of 350 cases (4%) attempts to obtain amniotic fluid failed at the first 
puncture. In every case a repeat puncture was succesfully carried out 10-14 
days later. 
In the whole series of 350 pregnancies monitored "no result" (no prenatal di-
agnosis established) was obtained in 9 cases (2.5%); in 18 cases (5%) a re-
peat amniocentesis was indicated because of failure in cell cultivation. 
However, in the 198 consecutive cases srudied in 1974 the figure for 11 no 
result" was 2/198 or 1%. In both failures (cases at risk for Down•s syndrome) 
either the repeat amniocentesis failed to obtain sufficient amniotic fluid or 
cell growth was insufficient for karyotyping. The figure for failure in cell cul-
tivation in 1974 dropped to 2.5%. The reasons for these failures were: trans-
port failures (2 cases), insufficient amniotic fluid obtained at the first punc-
ture (1) and insufficient growth in the first sample (2). In one of these latter 
cases multiple chromosomal breaks were observed in the first sample obtained; 
in the repeat culh.lre a normal karyotype was found. 
At present the failure rate due to insufficient growth of amniotic fluid cells 
may be estimated as 2/198 or 1%. 
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6. FOLLOW-UP OF CHILDREN BORN AFTER PRENATAL DIAGNOSIS 
The outcome of pregnancy is known in ~ 300 cases. No increase in complica-
tions of pregnancy and delivery was found6 Children were seen for follow-up 
studies at different ages by one of the authors (M.J.). No serious damage or 
malformations were seen which could be related to amniocentesis. Detailed 
results on the follow-up studies wi II be presented elsewhere. 
DISCUSSION 
Evaluation of amniocentesis and amniotic fluid cell culture 
Prenatal diagnosis may be evaluated according to several different criteria. 
The risk of amniocentesis to the mother may be estimated as negligible; the 
risk to the fetus as measured as the rate of spontaneous abortion after amnio-
centesis differs from one study to the other: l : 155 (Nadler & Gerbie,l970), 
4 : 73 (Doran et ol., 1974), 3 : 100 (Golbus et ol., 1974), 1 : 50 (Prescott 
et al., 1973), 10 128 (Robinson et al., 1973) and 7: 477 (Milunsky & At-
kins, 1974). These variations may be caused by differences in techniques and 
by different criteria during the follow-up period. For an abortion to be caused 
by amniocentesis, a time relationship between these two events should exist 
(Wahlstrtsm et al., 1974). For the period of one month after amniocentesis 
three spontaneous abortions occurred in our series of 350 pregnancies (about 1 %)i 
in one of these amniocentesis was clearly causal to the fetal loss. The average 
risk of about 1% is not significantly different from the risk of spontaneous 
abortion in the second trimester, which was estimated in the U.S.A. as 1.2% 
(Javert, 1957i Shapiro et al., 1962) and as 1 - 3% in Sweden (Petterson, 
1968). 32% Of the total fetal loss occurred in the 12 - 19th weeks of ges-
tation, and 12% at 20 weeks or more in a study on spontaneous abortion 
(Shapiro et al., 1962). 
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Follow-up studies on the children born after prenatal diagnosis failed to de-
tect either an increase in congenital malformations or a specific malformation 
pattern associated with the puncture. Hsu & Hirschhorn (1974), Golbus et al. 
(1974) and Allen et al. (1974) observed similar results. 
We failed to obtain amniotic fluid at the first amniocentesis in 4% of the 
cases in the present series; failure rates of 1% (Nadler & Gerbie, 1970), 6% 
(Golbus et al., 1974; Prescott et al., 1973; Robinson et al., 1973; Wahl-
str~m et al., 1974), 8.5% (Doran et al., 1974) and 10% (Milunsky & Atkins, 
1974) have been reported. 
The failure rate of amniotic fluid cell culture in the present study is l%; 
others reported either similar data (Nadler & Gerbie, 1970) or higher figures: 
10% (Milunsky & Atkins, 1974; Allen et al., 1974) and 30% (Robinson et 
al., 1973). The length of the waiting period between amniocentesis (in the 
14th - 16th week) and the eventual diagnosis is another criterium for evalu-
ating prenatal diagnosis. This period should not exceed 2 to 3 weeks so that 
if necessary abortion can be performed before the mother experiences fetal 
movements (Ferguson-Smith et al., 1971; Golbus et al., 1974).1n the present 
study the result of prenatal chromosome analysis was available within 3 weeks 
in 87% of the cases (47% of the parents knew the result within 2 weeks). 
These data are similar to those from Nadler & Gerbie (1970), Therkelsen et 
al.(1972)and Milunsky & Atkins (1974); Prescott et al. (1973) and Golbus et 
al.(1974) used longer periods. 
Indications and problems in prenatal chromosome analysis 
Prenatal monitoring has become a routine for pregnancies at advanced maternal 
age and for cases with a recurrence risk of trisomy 21 {Down 1s syndrome). The 
recurrence risk of trisomy 21 was found to be 1% in a series of prenatal diag-
noses collected by Milunsky (1973) and a similar risk was observed in the 
present series. In the group of pregnancies at advanced maternal age the risk 
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for chromosomal aberrations {determined from several series of prenatal diag-
nosis) is 1.5% in mothers between 35 and 39 years and about 3% in the 
group of 40 years and older (Hsu & Hirschhorn, 1974). In the present series 
4 non-disjunctions we.-e found in 68 pregnancies in mothers 40 years and ol-
der. These risk figures are higher than those generally given in genetic coun-
seling to older mothers. The risk for a child with a chromosomal aberration is 
much higher when one of the parents is a carrier of a balanced translocation 
{table II). Following the detection of the familial nature of a translocation in 
a family with one child affected with Down's syndrome (table !1, case 1), 
several relatives were karyotyped. In this way another high-risk pregnancy 
was identified in time to give the parents the possibility to request prenatal 
diagnosis {table II, case 5). Timely identification of translocation carriers is 
one of the important tasks of a genetic counseling service. 
A number of the technical problems in chromosome analysis on cultured am-
niotic fluid cells has been discussed recently, including chromosomal mosai-
cism (Kardon et al., 1972; Hsu et al., 1973; Cox et al., 1974) and structu-
ral aberrations arising in vitro by contamination with mycoplasma (Schneider 
et al., 1974). One case of a 45 X0/46 XY mosaicism in the present study 
is comparable with the observation of Kardon et al. (1972) and this mosaicism 
probably arose in vitro; however 1 cytogenetic studies on the fetus were not 
possible. In one case inconsistent structural aberrations were detected; meta-
phases from a repeat culture (obtained after a second amniocentesis)were nor-
mal. The role of mycoplasma in this series is difficult to evaluate. Although 
all tests were negative, mycoplasma testing was performed only periodically. 
Nadler (1972) estimated that maternal cells would be growing in 0.5% of am-
niotic fluid cell cultures and this would accordingly lead to a number of false 
diagnoses. Philip et al. (1974) reported 2 false sex predictions in 93 cases 
and they advocate the comparative study of Q-banded maternal and fetal ka-
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ryotypes, since in most cases differences in fluorescent markers might enable a 
distinction between mother and fetus. In the present series no sex chromosome 
mosaicism was observed and comparative studies of maternal and fetal cells 
were not done. 
Hsu & Hirschhorn {1974) discuss the problem of counseling parents when an 
apparent balanced reciprocal translocation is found. This rearrangement may 
be an aneusomy by recombination, although true cases should be detectable 
by banding techniques (Boue & Baue, 1973). In sporadic balanced reciprocal 
translocations, which occur in about one of every 3000 newborns (Jacobs et 
al., 1974), small deletions, not discernable with present techniques, or a po-
sition effect may be present (Skovby & Niebuhr, 1974). In addition, de novo 
balanced structural autosomal rearrangements might be associated or causal to 
severe mental retardation (Jacobs, 1974). Our finding of an apparently balan-
ced de novo 7 - 21 translocation is an example of this problem, when the 
prenatal karyptype leaves doubts ov'er the eventual phenotype. 
Another couseling problem arises upon the finding of a numerical abnormality 
of the sex chromosomes. An XYY karyotype may be expected in 0.09% of 
newborns, an XXY in 0.1% (Jacobs et al., 1974). Even after extensive stu-
dies ·on the clinical aspects of the XYY genotype (see for reviews: Hook, 1973; 
Borgaonkar & Shah, 1974) the number of unanswered questions warrants coun-
seling of the parents to inform them that the definite risk is not known. The 
final decision rests with the parents. 
Prenatal diagnosis of metabolic disease 
The prenatal diagnosis of metabolic defects formerly required a period of 4-8 
weeks after amniocentesis and parents had to be warned about waiting periods 
of up to 6 weeks, when prenatal diagnosis is discussed (Milunsky et al., 1972). 
Microtechniques facilitated the enzymatic analysis of fewer numbers of cells, 
either small groups of freeze-dried cultured amniotic fluid cells or homogenates 
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of a few thousands cells. Prenatal analysis for Pompe's disease was completed 
in 11 - 22 days (Niermeijer et al., 1975), for Fabry's disease in 11 days 
(Galjaard et al., 1974a) and for GM1-gangliosidosis in 9 and 12 days. In 
previous reports on prenatal diagnosis of GM1-gangliosidosis the result became 
available after 18 days (Lowden et al., 1973) and 4 weeks (Kaback et al., 
1973; Booth et al., 1973). The prenatal monitoring for metachromatic leuko-
dystrophy has required 3-4 weeks (Leroy et al., 1973; Van der Hagen et al., 1973); 
in the present study diagnosis was performec;l in 16 and 18 days in two preg-
nancies studied. A further reduction in this waiting period may be achieved 
by decreasing the final volume of the enzymatic reaction to 1 - 5 Ill and 
measuring the extinction in a microspectrophotometer (Galjaard et al., 1974~. 
Testing for Maple Syrup Urine disease using a radioactive substrate was com-
pleted in 11 days in this study; others have used periods of up to 8 weeks. 
(Eisas et al., 1974; Hoo et al., 1974). 
Using the methods described, the interval between amniocentesis and diagnosis 
for a number of metabolic diseases is comparable to the period required for 
prenatal chromosome analysis. 
The basic requirements for reliable prenatal diagnosis of metabolic diseases 
were reviewed by Burton et a1.(1974) and Hsu & Hirschhorn (1974). The pre-
sent experience indicates that the following points should be considered: 
1. The expression of the metabolic defect should be characterized in fibro-
blasts from a previous affected child or relative from the family under study 
and the level of residual enzymatic activity should be studied, since ge-
netic heterogeneity exists within apparently identical metabolic diseases. 
From table Ill one may note, that these data were not available in all 
cases studied. Many parents will not seek genetic counseling until after 
the death of an affected child; fibroblast cultures from affected children 
can be stored in a cell bank to provide control material for a future pre-
natal diagnosis. 
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2. A number of variables may influence enzymatic activities in cultured cells 
and sufficient experience with these factors is essential. The type of tis-
sue culture media (Ryan et al., 1972; Butterworth et al., 1974), its pH 
(Eagle, 1973; Lie et al., 1973), differences in cell types in amniotic fluid 
cell cultures (Gerbie et al., 1972) and the effect of growth to confluen-
cy (Okada et al., 1971; Russell et al., 1971; Galjaard et al., 1974e) 
may all affect enzymatic activities. The activity of some lysosomal hydro-
lases may show considerable variations in primary cultures of amniotic fluid 
cells; in later subcultures the activities increased during prolonged culti-
vation (Niermeijer et al., 1975). Amniotic fluid cell cultures used as con-
trols in prenatal diagnosis should therefore be carefully matched for their 
growth stage and passage. Since fibroblast cultures and amniotic fluid cul-
tures have important enzymatic differences, fibroblasts should not be used 
as the sole controls (Kaback et al., 1971). 
Prena_tal diagnosis of neural tube defects 
The prenatal diagnosis of open neural tube defects by elevated levels of 
a-fetoprotein in the amniotic fluid (Brock & Sutcliffe, 1972) offers new 
perspectives in genetic counseling. The risk of open neural tube defects will 
become a common indication for prenatal diagnosis, since neural tube defects 
and Down's syndrome have a comparable frequency. Closed lesions or smaller 
open defects possibly remain undetectable by AFP levels, and the parents 
should be so informed, however, the clinical effects of these lesions may be 
milder in some cases (Laurence et aL, 1973; Harris et ol., 1974). The relia-
bility of the method has been proven in different centers (Allan et al., 1973; 
Milunsky & Alpert, 1974; Brock et al., 1975). Aspecific elevations in second 
trimester amniotic fluids may be caused by admixture with fetal blood, which 
has a high AFP concentration (Field et al., 1974; Ward & Stewart, 1974) .In 
the case observed in this study the amniotic fluid AFP level returned to nor-
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mal levels in 10 days. In our laboratory bloody amniotic fluids were tested 
for fetal Hb in cases with a recurrence risk for neural tube defects. 
In our series of 350 pregnancies, selective abortion was performed as a result 
of the prenatal diagnosis in 36 cases. In 90% of the cases the pregnancies 
were continuated knowing that the risk of a particular genetic disease was 
eliminated. Ferguson-Smith (1974) stated: 11unfortunately, many parents at risk 
do not know that the option of prenatal diagnosis is available to them, and 
a very few are actively discouraged from seeking it by their medical advisers, 
who may feel that the risks of foetal abnormality are too small to justify the 
risk of the procedure 11 • Results in the present series again show that these lat-
ter fears are unjustified. Improvement of communications between genetic 
counselors and family doctors might contribute to a better application of pre-
sent knowledge. 
CONCLUSIONS 
1. Transabdominal amniocentesis in the 14th - 16th week is harmless to the 
mother and carries a risk for abortion which is as yet unknown but may be 
estimated as + l%. 
2. There is· a 5% chance that a second amniocentesis after 10- 14 days will 
be necessary (4% because of a first ''dry tap" and 1% for culture failure). 
The chance that no diagnosis will be obtained after a repeat amniocentesis 
is about 1%. 
3. When sufficient experience in celf cultivation and chromosome identifica-
tion techniques are available, prenatal chromosome analysis may be con-
sidered a routine technique. The same applies to AFP analysis for open 
neural tube defects. 
4. Prenatal diagnosis of metabolic disorders should be carried out only in cen-
ters which have sufficient experience with biochemical analysis of cultured 
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human cells. Experience with the biochemistry of the metabolic diseases 
studied is a prerequisite as is the availability of the proper control material 
in a cell bank. Microchemical techniques have the advantage of reducing 
the waiting periods for the parents and should be available in the diagnos-
tic center. 
Collaboration between different centers is required because of the relative 
infrequency of most metabolic diseases and the facilities and know-how re-
quired. 
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